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Summary 
Platelets are small, megakaryocyte-derived cell fragments that play a key role in 
haemostasis. Platelet receptors, in particular integrins, contain high numbers of 
reactive cysteines making them prime targets for thiol modifications. The 
plasma redox environment is controlled by low-molecular-weight thiol couples 
along with reactive oxygen/nitrogen species (RONS) and their respective 
scavengers. ‘Stress’ arises when an imbalance occurs within this tightly 
regulated redox system. The aim of this thesis is to investigate the role of thiol 
signalling in platelet function and examine the modulation of this signalling by 
the external redox environment. Previous work in our laboratory has 
demonstrated thiol/disulphide exchange to be critical to integrin IIb3 function.  
 
In this study, a significant increase in purified integrin IIb3 free thiols was 
observed upon activation. Integrin activation was inhibited in a reducing redox 
environment. Subsequently, it was found that platelet surface thiol population 
was increased upon stimulation with collagen only. Platelet activation by 
collagen was exclusively inhibited by a reducing external redox environment, 
with a concomitant modulation of the platelet surface thiol population. These 
results pointed to an exquisitely redox sensitive element of the collagen 
activation pathway, namely integrin 21. Furthermore, the phosphorylation 
state of VASP (vasodilator-stimulated phosphoprotein), a protein found 
downstream of integrin 21, was found to be affected by an external reducing 
redox environment in collagen stimulated platelets only. These results indicate 
modification of the receptor by the external environment can also impact on 
downstream, intra-platelet signalling events. These findings suggest a potential 
 v 
novel therapeutic target for diseases with a characteristic imbalanced redox 
environment in which thromboembolic events are common, such an 
inflammatory bowel disease.  
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1.1 Haemostasis and platelets 
Haemostasis is a complex biological process which stops bleeding caused by 
injury or damage to blood vessels. It is a term that essentially encompasses all 
the processes through which a clot is formed. This includes events involving the 
coagulation cascade along with platelet plug formation, the eventual removal of 
this clot, through fibrinolysis, and vascular remodelling. Platelets are cell 
fragments, derived from megakaryocytes in the bone marrow, which play a key 
role in haemostasis. They are small in size, approximately 3.0 m x 0.5 m, 
with a mean volume of 7 – 11 fL and are anucleated (Watson, 2005). Platelets 
form through the rearrangement of the cytoskeleton of mature megakaryocytes 
leading to the development of long, thin cytoplasmic extensions called 
proplatelets (De Botton et al, 2002). The platelets are subsequently released 
into the blood stream and the megakaryocytes undergo cell death by apoptosis. 
 
Under normal conditions, discoid shaped platelets circulate in blood in a 
quiescent or unactivated state, and are only activated in response to endothelial 
damage. The average lifespan of a platelet is 7 - 10 days and the normal 
concentration of platelets in blood is approximately 1.5 – 4.0 X 108/ml. When an 
injury to a blood vessel occurs, endothelial cells lining the vessel are damaged 
leading to the exposure of the platelet activating agent collagen in the 
subendothelium. Von Willebrand factor (vWF) is a large multimeric glycoprotein 
found circulating in the plasma that becomes immobilised by binding to collagen 
through its A3 domain. VWF then assists in capturing and tethering platelets to 
the site of vascular injury under high shear rates (> 600 s-1). The interaction of 
platelets with these agents is via receptors on the platelet surface. GP Ib-IX-V 
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complex along with integrin IIb3 interact with vWF, while glycoprotein VI 
(GPVI) and integrin 21 interact with collagen. These interactions promote the 
adhesion of platelets to the site of injury. Platelets subsequently undergo major 
morphological changes with dramatic spreading and the development of 
filopodia. This, in turn, results in the activation of signalling and secretion 
pathways within the platelet. These events lead to recruitment of additional 
platelets and, ultimately, the formation of platelet aggregates via the cross-
linking of platelets through the interaction of the plasma protein fibrinogen with 
its receptor integrin IIb3 on the platelet surface. All of these processes work 
together in association with the blood coagulation cascade. Ultimately, a blood 
clot or thrombus is formed. This prevents further blood loss from the damaged 
blood vessel by ‘plugging’ the damaged endothelium (Zucker & Nachmias, 
1985). 
1.2 General platelet biology 
1.2.1 Platelet structure  
Unactivated platelets circulate in the blood as small discs. Their surface is 
smooth and predominantly featureless except for some membrane 
invaginations or pits. These invaginations are entrances into the open 
canalicular system (OCS), a complex system of internal membranes organised 
into a network of tubules which run through the platelet (Hartwig & DeSisto, 
1991). The OCS provides a large surface area for the platelets and becomes 
exposed when the platelets spread during the activation process. The 
invaginations allow the entry of some small particles but restrict the entry of 
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larger particles, i.e. they are semi-selective. They also facilitate the discharge of 
granule contents during secretion (White & Escolar, 1991).  
 
A multifaceted cytoskeletal system is present in unactivated platelets which aids 
in maintaining their discoid shape when they encounter high shear stress whilst 
in circulation. The cytoskeletal system consists of three components: a 
spectrin-based cytoskeleton, a microtubule coil and a rigid actin network. The 
cytoplasmic space of platelets is predominantly filled by the rigid actin network. 
Actin is the most abundant platelet protein with approximately 2 million copies 
per platelet (Nachmias, 1988). Around 30 - 40 % of actin in unactivated platelets 
is in the form of filaments (F-actin). This number increases greatly with 
activation (Hartwig & DeSisto, 1991). These filaments are assembled to form 
linear actin polymers, interconnecting at various points to form the rigid actin 
cytoplasmic network. This is evident from the presence of high concentrations 
of actin-crosslinking proteins such as filamin and -actinin (Rosenberg & 
Stracher, 1982; Rosenberg et al, 1981a; Rosenberg et al, 1981b) 
 
The cytoplasm of platelets contains secretory organelles such as alpha () and 
dense granules, lysosomes, mitochondria and a dense membrane system. 
There may also be some other organelles or structures such as glycosomes, 
electron-dense chains and clusters or tubular inclusions (White, 1999; White, 
2002; White, 2004). The secretory granules contain proteins and other 
substances which are released upon platelet activation. 
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1.2.2 Platelet activation 
1.2.2.1 Platelet adhesion 
Adhesion is the first event to occur physiologically when platelets come in 
contact with the site of injury in the blood vessel wall. Adhesion is a complex 
process mediated by the platelet surface glycoprotein (GP) Ib-IX-V complex 
which binds von Willebrand factor (vWF). Members of the integrin family also 
play a role in the process, particularly integrin 21, which binds collagen.  
When platelets come in contact with damaged endothelium they initially bind to 
vWF, through the receptor GP Ib, initiating platelet adhesion. The A1-domain 
of vWF interacts with GP Ib (Ruggeri & Ware, 1993) reducing the velocity of 
platelets in contact with the surface under high flow conditions, thereby 
prolonging the time available for the occurrence of other interactions (Savage et 
al, 1996). This binding also generates a signal which causes activation of 
integrin IIb3, which in turn leads to stability of adhesion, platelet spreading and 
further platelets being recruited to the site forming aggregates via the interaction 
of fibrinogen with integrin IIb3 (Ikeda et al, 1991). 
1.2.2.2 Platelet shape change 
Upon activation, platelets undergo significant structural changes. The processes 
by which shape change occurs are complex in nature. Platelet activation leads 
to increased levels of intracellular calcium. This triggers membrane 
reorganisation, with phosphatidylserine (PS) exposure, and rearrangement of 
the platelet’s cytoskeleton. The development of new actin filaments is 
necessary for cytoskeletal restructuring. A number of proteins are involved in 
the control of the actin architecture and dynamics during activation. Proteins 
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involved in the regulation of the actin polymerisation and rearrangement include 
heat shock protein 27 (HSP27), talin-1, kindlin-2, kindlin-3 and vasodilator-
stimulated phosphoprotein (VASP) (Butt et al, 2001; Montanez et al, 2008; 
Moser et al, 2008). 
 
The first change in the structure of platelets upon activation is they become 
more spherical and lose their discoid shape. Finger-like projections, known as 
filopodia, develop and grow from the cells periphery (Figure 1.1). The platelets 
become flattened and all the organelles are forced into the centre of the 
platelets giving them a distinct ‘fried-egg-like’ appearance (Figure 1.2). 
Membrane ruffles begin to form and retract inwards and novel filopodia are 
extended from the centre of the platelet and rotate around the cell periphery. 
New actin filaments are formed and fill the space created by the spreading of 
the cells (Figure 1.3).  
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Figure 1.1 A platelet in the early stage of spreading. Finger-like projections known 
as filopodia develop. The central body of the platelet is still visible but is flattening out 
and gradually disappearing as the cytoplasm spreads and fills the spaces between the 
filopodia. Image is taken by a scanning-electron microscope (SEM), magnification X 
11,000 (White, 2007)). 
 
 
Figure 1.2 A fully spread platelet. The platelet has lost its discoid shape and become 
flattened. The organelles have been forced into the centre of the platelet, giving it a 
distinct ‘fried-egg-like’ appearance. Image is taken by scanning-electron microscope 
(SEM), magnification X 9,000 (White, 2007). 
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Figure 1.3 Actin rearrangement and formation in spreading platelets. When 
platelets are activated, they are transformed from a disc shape to a spread form, a 
process which involves remodelling of the cytoskeleton. Initially, as the platelet 
changes from a disc to a more spherical shape, long actin filaments are severed into 
many short filaments. In order to spread, new filaments are then formed from the 
barbed end of these short filaments (Hartwig, 2007) 
 
 
1.2.2.3 Platelet secretion 
Platelets contain three types of secretory organelles: lysosomes, alpha () 
granules and dense granules. Secretion, or degranulation, is a process that 
occurs when platelets are activated and involves granules releasing their 
contents extracellularly. -granules are the most abundant granules present in 
platelets, with approximately 40 - 80 per platelet (Sixma et al, 1989). They are 
oval in shape and measure approximately 200 - 500 nm in diameter. The 
interior is divided into a number of zones: the submembrane, peripheral and 
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central zones. The submembrane zone contains vWF arranged into tube-like 
structures (White, 1968). The peripheral zone contains many proteins, including 
coagulation factor V, thrombospondin, P-selectin, and vWF in addition to 
proteins synthesised in other cells and taken up by platelets, such as fibrinogen. 
The central zone is similar in composition to the peripheral zone but is denser in 
nature.  
 
Dense granules are fewer in number, with only approximately 3 - 8 per platelet 
(Israels et al, 1990; White, 1969). They are small in size and relatively opaque 
in appearance. Dense granules are rich in adenine nucleotides such as 
adenosine triphosphate (ATP) and adenosine diphosphate (ADP). They also 
contain serotonin, pyrophosphate, calcium and magnesium.  
 
Platelets contain a small number of lysosomes. There can be up to three while 
some platelets may not possess any. Lysosomes are spherical organelles and 
are slightly smaller than -granules. They contain approximately 13 acid 
hydrolases. The process by which lysosomes secrete their contents is 
uncertain, but it is known that they require a much stronger stimulus than the - 
or dense granules. The functional role of lysosomes in platelets is not fully 
understood but the fact that platelets do not exhibit phagocytic behaviour like 
other cells which contain lysosomes indicates that they may not have a 
significant role in platelet function (White, 2005).  
 
Secretion occurs through a process known as exocytosis. Exocytosis involves 
the rearrangement of the actin cytoskeleton, movement of the granules to the 
 10 
membrane surface, fusion of the granules to the membrane and eventually, due 
to an increase in intracellular calcium, a release of the intracellular contents 
from the platelet into the extracellular space (Flaumenhaft et al, 2005; White, 
1974). It is a SNARE-dependent mechanism. SNARES (SNAp (Soluble NSF 
(N-ethylmaleimide sensitive factor) Attachment Protein) Receptors) are a group 
of structurally similar proteins. Platelets contain the SNARE proteins syntaxin 2, 
syntaxin 4, SNAP-23, SNAP-25, SNAP-29, VAMP 3, and VAMP 8. SNAREs 
form tight, stable trans complexes, through a motif of approximately 60 amino 
acids, which are sufficient to catalyse membrane fusion (Weber et al, 1998).  
1.2.2.4 Platelet aggregation 
Platelet aggregation is an event which occurs following the adhesion and 
activation of platelets at the site of injury. It involves the recruitment of more 
platelets to the site. Platelet aggregation is mediated by the integrin IIb3, a 
platelet specific receptor.  It is also known as glycoprotein (GP) IIbIIIa (Plow & 
Byzova, 1999). Integrin IIb3 is a member of the integrin family, a large group of 
adhesive and signalling molecules present on most cell types. They mediate 
cell-cell and cell-extracellular matrix (ECM) adhesions, acting as bi-directional 
signalling molecules that provide a link between the ECM and cytoskeleton of a 
cell.  
 
Integrin IIb3 is the major integral plasma membrane protein on platelets. It can 
bind several adhesive glycoproteins including vWF, fibronectin and vitronectin, 
all RGD-containing ligands. Fibrinogen is the main ligand of integrin IIb3. In 
unactivated platelets, integrin IIb3 is found in an inactive conformation which 
has low affinity for its ligands. This allows platelets to circulate freely in the 
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blood without interacting with these ligands. When platelet agonists activate 
platelets through their specific receptors, intracellular pathways are stimulated, 
leading to the generation of inside-out signals through the integrins’ cytoplasmic 
tails. Inside-out signalling leads to a change in the conformation of integrin IIb3 
and this ‘switch’ mechanism is essential for the integrins cellular function (Yan & 
Smith, 2001). The integrin is converted from a bent-over conformation to a 
straightened, extended conformation upon activation (Humphries et al, 2003).  
Inside-out signalling also causes clustering of integrins into oligomers within the 
plane of the membrane, which has been shown to enhance platelet adhesion 
(Bazzoni & Hemler, 1998). These conformational changes in the integrin, 
convert it to an ‘active’ state and cause increased binding affinity for its ligand 
fibrinogen. Human fibrinogen exists as a dimer with each half molecule 
composed of three different polypeptide chains (A, B and ) (Blomback, 
2001). It is this dimeric conformation that leads to the cross-linkage of platelets, 
resulting in platelet aggregation. Fibrinogen binding to the ectodomains of 
integrin IIb3  initiates outside-in signalling (Leisner et al, 1999). This outside-in 
signalling induces further conformational changes in the receptor and although 
not fully understood, may lead to cytoskeletal reorganisation and further 
receptor clustering. The complementary functions of inside-out and outside-in 
signalling, i.e. bi-directional transmembrane signalling, in integrin IIb3 are 
crucial for platelet adhesion, aggregation and, ultimately, thrombus formation. 
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1.2.3 Platelet receptors  
A number of receptors are found on the platelet surface, which regulate platelet 
function through complex interactions with their respective ligands. A defect or 
lack of a specific receptor can lead to loss of platelet function and, ultimately, a 
disorder or disease state in the subject. Glanzmann’s thrombasthenia, which is 
characterised by the absence or dysfunction of integrin IIb3 on platelets, is an 
example of such a bleeding disorder. Platelet receptors are critical to a platelets 
identity and normal function and, therefore, a huge amount of research has 
been dedicated to platelet receptors, their ligands and their role in platelet 
function.  
1.2.3.1 Integrins 
Integrins are a large family of transmembrane receptors that mediate cell 
adhesion and signalling between intracellular and extracellular environments 
(Humphries, 2000). They consist of heterodimers of alpha (-) and beta (-) 
subunits, associated in a 1:1 ratio. Both - and -subunits are non-covalently 
associated, type I transmembrane proteins with large extracellular domains 
(700 - 1100 residues) and short cytoplasmic tails (30 - 50 residues) (Humphries, 
2000). Integrins exist in a number of forms; ranging from a bent low affinity state 
to an extended high affinity ligand binding state which is formed following 
cytoplasmic signalling at the tails of the subunits (Hynes, 2002) (Figure 1.5). 
Eighteen -subunits and eight -subunits have been identified to date, forming 
at least twenty-four heterodimers (Bennett et al, 2009; Shimaoka & Springer, 
2003). Platelets possess three families of integrins (1, 2 and 3) and have six 
different integrins in total: 21, 51, 61, L2, V3 and IIb3. In all 
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-subunits the N-terminal contains seven tandem repeats with internal 
homology that can be folded into a seven-bladed -propeller structure 
(Springer, 1997). The -propeller contains three to four calcium co-ordination 
sites. Some -subunits also contain an inserted I-domain. The I-domain folds 
into five parallel and one antiparallel -strand surrounded by seven -helices 
including a metal coordination site. In the -subunit the N-terminal domain has a 
sequence that is similar to I-domains and metal-ion dependent adhesion sites 
(MIDAS) and is thought to be folded into a related structure.  
 
 
 
Figure 1.4 Ribbon diagrams of the extracellular segment of integrin. (A) A bent-
over (unactivated) conformation. (B) A straightened, extended (active) 
conformation. The pink colour represents the -subunit, while the blue colour 
represents the -subunit. The model of the extended conformation was created by 
breaking the bent form at the junction between the thigh and calf-1 domains in  and 
I-EGF1 and 2 in  (dashed line) into the headpiece and tailpiece, and moving the 
headpiece relative to the tailpiece. Illustration is a model of V3 but is representative of 
general integrin conformational changes as a result of activation (Takagi et al, 2002).  
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Integrin 51 (fibronectin receptor) and 61 (laminin receptor) are minor 
integrins on platelets and their functions are not fully understood. It is thought 
they have supplementary roles in platelet adhesion (Piotrowicz et al, 1988). 
Similarly, little is known about integrin V3 in platelet function. Only several 
hundred copies are found on platelets. It is found on many other cell types, 
including endothelial cells (Cheresh, 1992), where it is a receptor for vitronectin, 
an adhesive protein that can also bind to integrin IIb3. There is also limited 
knowledge about integrin L2 on platelets. It is found only on the surface of 
activated platelets, which suggests it may be expressed on platelet granule 
membranes (Philippeaux et al, 1996).  
 
Integrin 21, also known as GPIa-IIa, is the second most abundant integrin on 
platelets, with around 2000 – 4000 copies per platelet.  It is the main receptor 
for collagen on platelets. Similar to other integrins, the -subunit contains a 
seven-bladed -propeller structure containing three to four calcium binding sites 
and, unlike integrin IIb3, an inserted (I)-domain. The I-domain consists of 
around 200 amino acids folded into five parallel and one antiparallel -strands, 
surrounded by seven -helices and a conserved cation binding site, a metal 
ion-dependent adhesion site (MIDAS), for magnesium cations (Mg2+). It is this 
I-domain that controls collagen binding (Depraetere et al, 1997). Integrin 21 
can bind GFOGER (glycine-phenylalanine-hydroxyproline-glycine-glutamate-
arginine) peptides, a collagen derived sequence, with high affinity (Knight et al, 
2000). Additionally, studies have shown that binding of the GFOGER peptide to 
the 2 I-domain was mediated by Mg
2+, suggesting collagen may bind the 
integrin in a similar Mg2+ dependent manner (Emsley et al, 2000). In addition, 
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calcium binding outside the I-domain, is another requirement for integrin 21 
function (Onley et al, 2000). The -subunit of 21 contains a sequence similar 
to a MIDAS, called an I-like domain, at its N-terminal. As with other integrins, 
21 works through both outside-in signalling and inside-out signalling. Collagen 
interacting with the extracellular domains of integrin 21 can lead to 
conformation changes in the integrin and trigger inside-out signalling. This 
inside-out signalling occurs through the binding of cytoskeletal proteins, such as 
talin-1 (Nieswandt et al, 2007), kindlin-2 (Montanez et al, 2008) and kindlin-3 
(Moser et al, 2008), to the cytoplasmic tails of the -subunit. Further 
conformational changes in the integrin are induced by this binding and more 
collagen binding sites exposed. Intracellular signalling and cross-talk may lead 
to inside-out signalling to integrin IIb3 also, subsequently resulting in platelet 
aggregation.  
 
Integrin IIb3 is the most abundant integrin on platelets. It makes up 3 % of the 
total protein in platelets and there are approximately 80,000 - 100,000 copies 
per platelet (Wagner et al, 1996). Both subunits of integrin IIb3 are 
synthesised as single glycosylated polypeptide chains. The IIb-subunit is 
cleaved proteolytically to form a heavy and a light chain which are connected by 
a disulphide bond. The IIb-subunit is composed of 1008 amino acids while the 
3-subunit is composed of 762 amino acids (Poncz et al, 1987; Zimrin et al, 
1990). Unlike other -subunits, the IIb-subunit does not contain an I-domain 
(Humphries, 2000). Integrin IIb3 is calcium-dependent, with calcium binding 
sites in both the - and -subunits. There are a number of ligands for integrin 
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IIb3, including fibronectin, vitronectin, thrombospondin-1 and vWF. However, 
fibrinogen is the main ligand and the key player in platelet aggregation though 
integrin IIb3. All of these ligands contain an RGD sequence which acts as a 
recognition motif for integrin IIb3 and other integrins. Fibrinogen also contains 
a second binding site, a dodecapeptide (HHLGGAKQAGDV) found on the 
C-terminus of the -chain which binds to integrin IIb3 (Kloczewiak et al, 1984). 
In fact, this site may primarily mediate fibrinogen binding integrin IIb3, rather 
than either of its two RGD sequences in its A-chain. To date, two major ligand 
binding sites have been identified within integrin IIb3: the putative -propeller 
site within the IIb-subunit and the I-like domain within the 3-subunit. There are 
two types of signalling which are associated with integrin IIb3 activation, 
namely inside-out and outside-in signalling. It is these signalling pathways that 
determine the conformational state and ligand binding ability of integrins. Inside-
out signalling is initiated upon stimulation of platelets by agonists such as 
collagen or vWF. These agonists interact with their respective receptors, 
triggering downstream intracellular signalling, culminating in an elevated 
calcium level. The cytoplasmic tails play a significant role in the conversion of 
integrin to an activated conformation through inside-out signalling, though the 
exact mechanism remains unclear. It is known, however, that a number of 
proteins are implicated in the process. Talin, a cytoskeletal protein that binds to 
the 3 cytoplasmic tails, is thought to be one of the main players in the event 
and a final common pathway in the integrin activation process (Tadokoro et al, 
2003). Both kindlin-2 and kindlin-3 are also implicated in the process (Montanez 
et al, 2008; Moser et al, 2008). When the cytoplasmic tails of the integrin are 
converted into the activated form, parallel conformational changes in the 
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extracellular domain of the integrin occur. These conformational changes and 
subsequent clustering of the subunits are necessary for full outside-in signalling 
to occur. When the extracellular domain is in the activated conformation, ligands 
can then bind to the integrin, initially reversibly, then progressively irreversible. 
This promotes further clustering of integrins and also further conformational 
changes that are transmitted to the cytoplasmic tails (Shatill, 2004). Interactions 
between the cytoplasmic tails and intracellular proteins trigger signalling 
cascades which are responsible for major platelet responses such as 
aggregation and secretion. 
1.2.3.2 Glycoprotein Ib-IX-V 
Glycoprotein Ib-IX-V, a receptor exclusively expressed in megakaryocytes and 
platelets, is the second most abundant receptor on platelets with approximately 
50,000 copies per platelet. It is a receptor complex composed of four membrane 
spanning polypeptides: GPIb, GPIb, GPIX and GPV (Lopez et al, 1992; 
Modderman et al, 1992). The complex is formed through the non-covalent 
linkage of GPIb- GPIb (disulphide bonded to each other) to GPIX and GPV 
(Andrews et al, 1997; Berndt et al, 2001). Owing to its vast array of ligands, 
GPIb-IX-V is involved in a range of platelet functions. The first to be uncovered 
and the main ligand for GPIb-IX-V is the adhesive ligand vWF (von Willebrand 
Factor). While vWF is found circulating in plasma, it can also be secreted from 
-granules in activated platelets, and released from damaged endothelial cells. 
vWF binds to GPIb-IX-V and plays a key role in the initial adhesion of platelets 
to the site of injury under shear. VWF binds to GPIb through its A1-domain 
and collagen through its A3-domain, thereby indirectly implicating GPIb-IX-V in 
collagen adhesion (Nieswandt, 2003).  It has been long assumed that the main 
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function of the interaction between vWF and GPIb was to slow down platelets 
and enable the interaction of collagen with its platelet receptors, eventually 
leading to activation of integrin IIb3 and platelet aggregation. More recent 
studies, have suggested that activation of GPIb-IX-V may induce intracellular 
signalling that is capable of activating integrin IIb3 and inducing platelet 
aggregation alone (Ozaki et al, 2005). However, this intracellular signalling 
pathway, involving Src family kinases activating phospholipase C 2 (PLC2), 
has yet to be fully elucidated.  
1.2.3.3 Glycoprotein VI (GPVI) 
Glycoprotein VI (GPVI) is another collagen receptor, in addition to integrin 21, 
found on platelets. GPVI is a 62 kDa glycoprotein, and a member of the 
immunoglobulin (Ig) super family. It is found in a complex with the Fc receptor 
(FcR) -chain, consisting of two GPVI molecules and one FcR -chain dimer 
(Moroi & Jung, 2004). The FcR -chain contains an immunoreceptor tyrosine-
based activation motif (ITAM) which becomes phosphorylated upon platelet 
activation by collagen. SH2 domains of another protein, Syk, bind to the 
phosphorylated tyrosine residues in the ITAM, which in turn leads to activation 
of Syk and the production of activation signals to other proteins. These 
intracellular, or inside-out signals, then activate and convert integrins into their 
high affinity conformation. These intracellular signals also induce the release of 
second-wave platelet agonists such as ADP and thromboxane A2 (TxA2). The 
integrins 21 and IIb3, through ligation by vWF, then initiate firm adhesion, 
which strengthens the GPVI-collagen interaction and leads to further signalling 
and activation of the platelet (Nieswandt et al, 2001a; Nieswandt, 2003). Others 
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still argue that the primary interaction with collagen is through integrin 21, 
inducing intracellular signalling leading to activation of GPVI, a lower affinity 
co-receptor, which then triggers its cascade of downstream signalling events 
(Barnes et al, 1998; Santoro, 1999).  
 
1.2.3.4 Protease activated receptors (PARs) 
Protease activated receptors (PARs) have seven transmembrane domains and 
are G protein-coupled receptors (GPCRs) activated by a proteolytic cleavage at 
a specific site in the N-terminal extracellular domain. This is unlike most other 
GPCRs which signal through a standard ligand/receptor interaction. To date, 
there are four known PARs, numbered 1-4. PAR-2 is expressed in a number of 
human tissues including the gastrointestinal tract, neurons and astrocytes in the 
central nervous system (CNS) and also in the skin  but is not found on platelets 
(D'Andrea et al, 1998). PAR-1 and PAR-4 are expressed on human platelets. A 
third PAR, the PAR-3 receptor, was identified by Ishihara et al (Ishihara et al, 
1997). However, a study by Kahn et al suggests PAR-3 plays little or no role in 
human platelets (Kahn et al, 1999). This conclusion is confounded by the fact 
that PAR-3 is present on human platelets in very small numbers, 150 - 200 
(Cupit et al, 1999), compared to approximately 1500 - 2000 copies of PAR-1 
(Brass et al, 1992; Norton et al, 1993). The coagulation protein -thrombin, also 
known as coagulation factor II, is the ligand for PARs on platelets. Thrombin, a 
trypsin-like serine protease, cleaves the peptide bond in PARs between 
receptor residues Arg 41 and Ser 42. This unmasks a new N-terminus, 
beginning with the sequence SFLLRN that functions as a tethered ligand, 
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docking intramolecularly with the body of the receptor to effect transmembrane 
signalling (Coughlin, 2000).  
 
Thrombin is a potent platelet activator and plays a critical role in promoting 
thrombus formation (McNicol & Gerrard, 1993). It initiates platelet 
degranulation, aggregation and indirectly activates the integrin IIb3 through the 
activation of a number of signalling cascades. Thrombin also plays a role in the 
shape change of platelets during activation. Activation of platelets with thrombin 
leads to the complexing of gelsolin to actin within seconds (Kurth & Bryan, 
1984; Lind et al, 1982). Gelsolin is a calcium-dependent protein associated with 
remodelling of the cytoskeleton during activation. Thrombin is also involved in 
the coagulation cascade where it converts soluble fibrinogen into insoluble 
fibrin. It also catalyses and potentiates many other reactions by activating 
Factors V, VIII, XI and XIII. 
 
In humans, PAR-1 is necessary for responses to both high (30 nM) and low 
concentrations (1 nM) of thrombin, but it plays a particularly important role in 
platelet activation at low concentrations of thrombin. PAR-4 appears to mediate 
platelet responses at high concentrations of thrombin only. Interestingly, a 
PAR-1 antagonist only becomes effective at blocking platelet activation by high 
concentrations of thrombin when PAR-4 is blocked simultaneously (Kahn et al, 
1999). This also suggests some crosstalk between PAR-1 and PAR-4, with 
PAR-1 being the primary mediator and PAR-4 taking on a ‘back-up’ role. 
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1.2.3.5 P2-purinergic receptors 
Three P2-purinergic receptors are found on platelets. P2Y1 and P2Y12 are the 
receptors for ADP on platelets (Jin et al, 1998; Savi et al, 2001). ADP is a weak, 
but important, primary platelet agonist. It also plays a key role in enhancing 
platelet activation levels and recruiting further platelets when secreted from 
dense granules upon platelet activation by other agonists (Packham & Mustard, 
2005). Both P2Y1 and P2Y12 are seven transmembrane G-protein-coupled 
receptors.  The ATP receptor, P2X1, is a ligand-gated ion channel, activation of 
which leads to a short-lived influx of calcium insufficient to induce platelet 
activation alone but it may work in synergy with the ADP receptors  (Rolf & 
Mahaut-Smith, 2002; Vial et al, 2002).  
1.2.3.6 Other platelet receptors 
There are a number of other receptors present on the surface of platelets, not 
addressed in detail in this thesis but which are equally important in terms of 
normal platelet function. The prostaglandin receptors found on platelets include 
the thromboxane TXA2/PGH2, prostacyclin (PGI2), PGD2 and PGE2 receptors. 
Receptors for serotonin (5-HT2A), dopamine (D3, D5), epinephrine (2-
adrenergic receptor), adenosine (A2a-adenosine receptor), vasopressin (V1a 
receptor), platelet activating factor (PAF receptor), along with toll-like receptors 
are also found on platelets and are involved in various activating and inhibitory 
processes.  
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1.3 Redox and thiol signalling in platelets 
1.3.1 Thiols and disulphides 
Sulphur is a vital element for living organisms. It is present in cells in a number 
of forms, namely sulphide, sulphate or as sulphydryl (thiol) (-SH) and disulphide 
(SS) groups. Thiols undergo many chemical reactions and are therefore of great 
interest in biological processes. Thiols can be readily converted to disulphide 
groups and vice versa in the chemical reactions reduction, oxidation and 
thiol/disulphide exchange. Figure 1.5 illustrates the reactions involving thiol and 
disulphide groups, and their respective reducing and oxidising agents, in 
proteins.  
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Figure 1.5 The formation of thiol/disulphide bonds in proteins. 1. Reduction: 
Disulphide bonds (SS) are reduced to form 2 thiol groups (-SH) in the presence of a 
reducing agent (RSH), resulting in the reducing agent itself becoming oxidised (RSSR). 
2. Oxidation: In the presence of an oxidising agent (RSSR), thiols (-SH) become 
oxidised resulting in the formation of a disulphide bond (SS), the oxidising agent is itself 
reduced. 3. Thiol/disulphide exchange: A thiolate anion (S-), formed from the 
deprotonation of a thiol, attacks a disulphide bond, displacing one of the sulphur atoms. 
This leads to the formation of a mixed-disulphide bond. The remaining thiolate anion 
then attacks and resolves the mixed-disulphide bond. The end result of the 
thiol/disulphide exchange mechanism is the reduction of the original disulphide bond 
and oxidation of the original free thiol groups. (Exchange mechanism adapted from 
(Sevier & Kaiser, 2002)). 
 
 
A number of free thiol containing proteins have been identified to be associated 
with platelets (Essex & Li, 2006). Some known thiol containing platelet proteins 
include: protein disulphide isomerase (PDI), glycoprotein Ib (GPIb)  
(Burgess, 2000) and P2Y12, the ADP receptor (Ding, 2003). Thiol/disulphide 
groups have also been found to be a crucial component of the platelet 
integrins IIb3 (O'Neill et al, 2000; Yan & Smith, 2000) and 21 (Gofer-Dadosh, 
1997). 
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Thiol and disulphide groups play a critical role in integrin function, owing to the 
large number of cysteine residues present in their structure. The IIb-subunit of 
integrin IIb3 contains 18 cysteine residues, while there are 56 cysteine 
residues found in the -subunit, which are highly conserved across all integrin 
-subunits. Studies examining the effects of the reducing agent dithiothreitol 
(DTT) on platelet function found DTT caused platelet aggregation in the 
presence of fibrinogen, (MacIntyre, 1974; Zucker & Masiello, 1984). These 
studies suggested that disruption of disulphide bonds in integrin IIb3 by a 
reducing agent modulated the activity of the integrin and thereby induced 
platelet aggregation. Studies by Yan and Smith uncovered a redox site involved 
in integrin IIb3 activation (Yan & Smith, 2000). They found integrin IIb3 in the 
unactivated conformation contained 2 - 3 free thiols, with an increase to 4 - 5 
free thiols in the activated conformation, an overall net reduction of one 
disulphide bond upon activation. They suggest that while DTT may not be 
capable of recapitulating all of the steps involved in physiological activation of 
the integrin, it does cause re-shuffling of disulphide bonds which may be an 
element of the physiological activation mechanism. They further explored the 
mechanism of integrin activation and observed that DTT reduces two disulphide 
bonds within the cysteine-rich domain of integrin IIb3, leading to global 
conformational changes in both subunits and thereby exposing the fibrinogen 
binding sites (Yan & Smith, 2001). More recent investigations have confirmed 
that DTT induces platelet aggregation and suggest that these results may be 
caused not only by reduction of disulphide bonds in integrin IIb3 but also in a 
series of other surface proteins including P2Y12 and GPVI (Margaritis, 2011). It 
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has also been revealed that vicinal (closely spaced thiols that interconvert 
between thiol and disulphide) thiols in integrin IIb3 may be a contributing factor 
in its redox sensitivity (Manickam et al, 2011). A number of studies show thiol 
blocking agents, such as N-ethylmaleimide (NEM), para-chloro-mercuriphenyl 
sulphonate acid (pCMPS) and para-chloromercuribenzene sulphonate 
(pCMBS), decrease platelet aggregation responses, again underlining the 
importance of thiol groups in normal platelet function (Lahav et al, 2000; 
Manickam et al, 2008; Margaritis, 2011). 
 
Previous work carried out in our laboratory uncovered a role for thiol/disulphide 
exchange in integrin IIb3 activity along with endogenous thiol isomerase 
activity (O'Neill et al, 2000; Walsh et al, 2004). The reactivity of thiol groups, and 
the importance of this feature in integrin function, has also been demonstrated 
by our laboratory using Raman spectroscopy, to examine the S-nitrosylation of 
thiols present in purified integrin IIb3 (Walsh et al, 2007).  
 
While not as well established as integrin IIb3, redox sensitivity and a role for 
thiol/disulphide groups have also been demonstrated in integrin 21. 
Gofer-Dadosh et al have shown that binding of collagen to integrin 21 results 
in the increased affinity of the receptor for its ligand with a suggestion of the 
presence of intra-receptor disulphide bond linkages in integrin 21. The 
suggestion was supported by the fact that type I collagen does not contain any 
cysteines within its structure. Therefore, the linkage between collagen and 
integrin 21 was mediated through a conformational change in the integrin 
rather than a direct physical interaction with the collagen (Gofer-Dadosh, 1997). 
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Furthermore, it has been shown that blocking protein disulphide isomerase 
activity on platelets inhibits adhesion to collagen (Lahav et al, 2000). In addition 
adhesion to the 21-specific peptide, GFOGER, is disulphide-exchange 
dependent and protein-disulphide isomerase mediated (Lahav et al, 2003).  
 
1.3.2 Redox environments: Cysteine and glutathione 
One of the major pathways for signalling in cells involves modifications of the 
thiol status of proteins induced by alterations in the redox environment. The 
redox environment of a cell, biological fluid or tissue is a reflection of the state of 
the redox couples present (Schafer & Buettner, 2001). The redox state of a 
couple refers to the ratio of absolute concentrations of reduced to oxidised 
forms of the couple. Some examples of redox couples are NAD+/NADH, and 
NADP+/NADPH. Glutathione (GSH/GSSG) and cysteine (Cys/CySS) are the 
major low-molecular-weight redox couples present in human plasma. The redox 
state of a couple may be quantified by its redox potential, which measures the 
reducing capacity of the couple. Redox potential (Eh) is calculated using the 
Nernst equation and is expressed in terms of millivolts (mV) (Schafer & 
Buettner, 2001). A negative redox potential is indicative of a reducing 
environment whereas a positive value indicates an oxidising environment. A 
study of the redox environment of human plasma in 740 subjects analysed over 
2 years found the redox potential  in plasma for glutathione (GSH/GSSG) 
ranges from -198.8 to -55.1 mV and cysteine (Cys/CySS) ranges between 
-112.4 and -24.2 mV (Go & Jones, 2005). In addition, changes in the redox 
state of the cysteine couple do not impact on the redox state of the glutathione 
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couple, i.e. the redox couples are maintained independently (Go & Jones, 2005; 
Jones et al, 2004).  
 
Cysteine (Cys), along with its disulphide form cystine (CySS), is the major redox 
couple in human plasma (Jones et al, 2000). In fact, due to its abundance, the 
redox potential of the plasma is largely dependent on that of the Cys/CySS 
couple. Cysteine can undergo rapid auto-oxidisation to form cystine. Likewise, 
cystine can be reduced back to cysteine. However, the oxidation process is 
more likely to occur. The conversion between cysteine and cystine is shown in 
the half cell reactions: 
 
2Cys → CySS + 2e- + 2H+ 
CySS + 2e- + 2H+ → 2Cys 
 
Cysteine is a semi-essential amino acid, indicating that it can be synthesised in 
the body. However, the majority of cysteine is derived from the diet and through 
protein degradation within the body (Lu, 2009). Cysteine biosynthesis occurs in 
the liver through methionine metabolism. This metabolic pathway is referred to 
as the trans-sulfuration or cystathione pathway and was first described by 
Tarver and Schmidt (Tarver & Schmidt, 1939). There are a number of enzymes 
involved in the conversion of methionine to cysteine, two of which are unique to 
the trans-sulfuration pathway, namely cystathionine--synthase and 
cystathionase (Finkelstein & Martin, 2000). Methionine is initially converted to 
S-adenosylmethionine (SAMe) in a rapid reaction catalysed by methionine 
adenosyltransferase. S-adenosylhomocysteine (SAH) is then generated as a 
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result of trans-methylation of SAMe, in a reaction catalysed by 
methyltransferases. Hydrolysis of SAH, catalysed by SAH hydrolase, leads to 
the formation of homocysteine (Hcy) and adenosine. At this stage Hcy can 
either be remethylated and recycled, or it can be converted to cysteine. The 
conversion to cysteine is a two-step process in which Hcy is converted to 
cystathionine, catalysed by cystathionine--synthase, and finally cysteine is 
formed from cystathionine in a reaction catalysed by -cystathionase 
(Finkelstein, 1990; Finkelstein & Martin, 2000; Lu, 2009). Both 
cystathione--synthase and -cystathionase require vitamin B6 as a cofactor. 
The synthesis of cysteine through the trans-sulfuration pathway is illustrated in 
Figure 1.6. The resulting free cysteine is used in the synthesis of glutathione 
(GSH).  
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Figure 1.6 The biosynthesis of cysteine through methionine metabolism. The 
biosynthesis of cysteine occurs in the hepatic cells in the body. Methionine is 
catabolised to S-adenosylmethionine (SAMe), in a reaction catalysed by methionine 
adenosyltransferase. SAMe is subsequently transmethylated to form 
S-adenosylhomocysteine, which is in turn converted to homocysteine (Hcy), catalysed 
be adenosylcysteinase. Hcy may at this stage be remethylated and converted back to 
methionine or broken down into cysteine in a two-step process. Hcy is firstly converted 
to cystathione, catalsysed by cystathione--synthase, and finally cystathione is 
converted to cysteine, a process catalysed by -cystathionase. Cysteine may then be 
utilised in the synthesis of glutathione. (The cysteine synthesis pathway is adapted 
from (Finkelstein & Martin, 2000; Lu, 2009)). 
 
 
Glutathione (GSH) is one of the most abundant non-protein cellular thiols 
present in the body. GSH molecules can readily react together to form the 
oxidised, disulphide form of glutathione: GSSG. The conversion between 
reduced and oxidised glutathione is shown in the half cell reactions: 
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2GSH → GSSG + 2e- + 2H+ 
GSSG + 2e- + 2H+ → 2GSH 
 
GSH is a tripeptide composed of the three amino acids: glutamic acid (Glu), 
cysteine (Cys) and glycine (Gly). The structure of glutathione is illustrated in 
Figure 1.7. Glutathione is synthesised in all mammalian cells and its synthesis 
is of particular importance in organs, such as the liver, where there is increased 
exposure to toxins (Kretzschmar, 1996). Decreased circulating GSH, including 
supply to plasma, has been shown to occur in hepatic cirrhosis, due to 
decreased hepatic function (Chawla et al, 1984).  
 
 
 
Figure 1.7 The chemical structure of glutathione (GSH).  Glutathione (GSH) is a 
tripeptide composed of the three amino acids: glutamic acid, cysteine and glycine. 
Glutamic acid and cysteine are bonded via an unusual -carboxyl linkage between the 
amine group of cysteine and the carboxyl group of glutamic acid. Cysteine and glycine 
are linked through a normal peptide linkage. (GSH structure adapted from (Lu, 2009)). 
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Approximately 85 % of GSH is synthesised in the cytosol of cells, with a small 
percentage also produced by the mitochondria and the endoplasmic reticulum 
(Hwang et al, 1992; Meredith & Reed, 1982).  
 
The synthesis of GSH is a two-step process catalysed by two ATP-dependent 
enzymes as follows:  
 
The synthesis is preceded by the trans-sulfuration pathway in which cysteine is 
produced as described in Figure 1.6. Cysteine is one of the limiting factors in 
the synthesis of glutathione. In the initial step, glutamic acid (Glu) and cysteine 
(Cys) are converted to -glutamyl-L-cysteine (-GluCys), in a reaction catalysed 
by glutamate cysteine ligase (GCL, formerly known as -glutamylcysteine 
synthetase (-GCS)). This is then converted to GSH by glutathione synthase 
(GS) (Griffith, 1999; Griffith & Mulcahy, 1999). GCL is the rate limiting enzyme 
for GSH synthesis, with the regulation and expression of the enzyme playing a 
key role in maintaining GSH homeostasis. The synthesis is also regulated, not 
only by the availability of cysteine, but also by the concentration of GSH itself, 
which works through a negative feedback mechanism to inhibit GCL activity (Lu, 
2009). GSH can also be regenerated from GSSG by a flavoenzyme, glutathione 
reductase (Gred), using NADPH as a reductant (Argyrou & Blanchard, 2004). 
GSH is metabolised, only extracellularly, by -glutamyltranspeptidases (GGTs), 
which catalyse the cleavage of the -glutamyl amide bond to Cys and transfer 
 32 
the Glu residue to another amino acid. CysGly and -Glu-CySS (-Glu-cystine) 
are the resulting products of this reaction. CysGly is then broken down into Cys 
and Gly by extracellular dipeptidases and transported back into the cell, while 
-Glu-CySS is also transported back to the cell where it is reduced to -GluCys. 
It may then be converted back to GSH again. It is this cycle which maintains a 
balanced GSH pool, both intra- and extra-cellularly. This cycle also serves as a 
continuous source of cysteine, which by its nature is extremely unstable and is 
rapidly auto-oxidised to cystine (Meister, 1988). The biologically active site of 
glutathione corresponds to the thiol group of the cysteine residue within its 
structure. It is the high nucleophilicity of this thiol group that provides glutathione 
with its characteristic antioxidant properties. Glutathione can directly scavenge 
free radicals, along with assisting in the regeneration of other antioxidants and 
acting as a cofactor for glutathione peroxidase (GPx) and glutathione 
S-transferase (GST) in the degradation of hydrogen peroxide (H2O2) and other 
toxic peroxides. These functions of GSH are critical in the defence against 
oxidative stress. 
 
1.3.3 Oxidative and reductive stress 
Oxidative stress has attracted much attention in recent years and is well 
documented to be a major factor contributing to the process of aging (Beckman 
& Ames, 1998). It has also been implicated in the development and progression 
of a wide range of diseases such as diabetes (Baynes & Thorpe, 1999; Ceriello, 
2000), neurodegenerative diseases (Coyle & Puttfarcken, 1993), various 
cancers (Reuter et al, 2010; Toyokuni et al, 1995) and CVD such as stroke and 
atherosclerosis (Bennett, 2001; Harrison et al, 2003). Oxidative stress can be 
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brought about by exposure of biological macromolecules to reactive oxygen 
(ROS) or nitrogen species (RNS) resulting in alterations of their fundamental 
physical and chemical properties. Oxidative stress induces conformational 
modifications, through the targeting of critical cysteine thiols, ultimately, leading 
to a change or loss of function of the macromolecule in question. RONS is a 
term encompassing both ROS and RNS. RONS can cause a broad spectrum of 
damage through attacking lipids, proteins and DNA, inducing membrane 
damage, enzyme deactivation and DNA disruption.   
 
A free radical is defined as a cluster of atoms with one or more unpaired 
electrons in the outer shell. This is an extremely unstable conformation and is 
the basis for the radical’s high reactivity status. ROS refers collectively to 
oxygen radicals and certain non-radical oxidising agents that can be readily 
converted to radicals (Halliwell, 1989). ROS are generated during the process 
of aerobic energy metabolism. The metabolites of molecular oxygen (O2), an 
essential component of the process, are referred to as ROS. Aerobic cellular 
metabolism involves a process in which the oxidoreduction energy of 
mitochondrial electron transport is converted to the high-energy phosphate 
bond of ATP. O2 acts as the final electron acceptor for cytochrome-c-oxidase, 
an enzyme which catalyses the four-electron reduction of O2 to H2O. This 
reaction leads to the formation of partially reduced and highly reactive 
metabolites such as superoxide (O2
•-), hydroxyl (OH•) (a radical formed in the 
presence of transition metals (Fe/Cu)), peroxyl (RO2
•), and hydroperoxyl (HO2
•) 
(Thannickal & Fanburg, 2000) radicals. Additionally, other non-radical 
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substances may be formed namely hydrogen peroxide (H202), hypochlorous 
acid (HOCl) and ozone (O3) (Table 1.1). 
 
Similar to ROS, RNS are physiologically necessary but also potentially toxic and 
destructive. RNS are reactive species derived primarily from nitric oxide (NO). 
NO, originally recognised as a vaso-relaxing agent, is also now well described 
as an important cell-signalling and antioxidant molecule. Nitric oxide itself is 
formed through the enzymatic action of nitric oxide synthases: neuronal NO 
synthase (nNOS), endothelial NO synthase (eNOS) and inducible NO synthase 
(iNOS). A by-product of this enzymatic reaction can be O2
•-. A rapid reaction 
occurs between NO and O2
•- leading to the formation of peroxynitrite (ONOO•-). 
ONOO•- has the potential to react with all major biological molecules thereby 
rendering it capable of mediating cytotoxicity independently of both NO and O2
•-. 
Other NO-derived radicals are listed in Table 1.1. The most potent effects of 
RNS appear to be thiol modifications that may affect the function of signalling 
systems or result in the production of tissue-derived donors of NO. RNS readily 
react with GSH and protein thiols resulting in their oxidation or formation of 
nitrosylated thiols (Dalle-Donne et al, 2005). Indeed, studies in our laboratory 
have shown the S-nitrosylation of free thiols in platelet integrin IIb3 impacts on 
the integrin’s activity (Walsh et al, 2007).  
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Table 1.1 Reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
known collectively as RONS. These radicals are produced during normal metabolism 
in cells and tissues of the body and but can be potentially destructive (adapted from 
(Dalle-Donne et al, 2005)). 
 
 
 
As RONS are produced during normal metabolism, they play a role in a number 
of normal biological processes, including enzymatic reactions, mitochondrial 
electron transport, signal transduction and gene expression (Bayir, 2005). The 
redox environment and the levels of RONS are tightly regulated by the action of 
antioxidants and RONS scavengers such as superoxide dismutase (SOD), 
catalase, glutathione peroxidase (GPx), glutathione, ascorbic acid (vitamin C), 
-tocopherol (vitamin E) and thioredoxin. All of these substances display 
protective properties. Problems arise when the level of RONS exceeds that of 
the antioxidants, i.e. the redox balance is upset.  
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Oxidative stress can also arise as a result of an imbalance in low-molecular-
weight thiol couples GSH/GSSG and Cys/CySS. If the concentration of the 
oxidised form (GSSG/CySS) of the couple increases, this leads to a more 
positive redox potential and an oxidising redox environment. A number of 
studies have analysed the redox potentials of these couples in plasma in order 
to establish a link between a change in plasma redox potentials and an onset of 
a disease state within the body. It has been determined that the redox state of 
plasma is more oxidised in smokers and patients with type 2 diabetes or 
cardiovascular disease (Duman et al, 2003; Harrison et al, 2003; Moriarty et al, 
2003). Variations in these values may be an indication of the onset of 
atherosclerosis (Go & Jones, 2005). Additionally, more recent studies have 
shown that oxidised Cys/CySS redox potentials are associated with not only 
increasing age and smoking but also obesity and alcohol abuse, all of which are 
high risk factors for cardiovascular events (Go & Jones, 2011).  
 
While oxidative stress is the most commonly known type of ‘stress’ related to an 
imbalance in redox couples, reductive stress can also occur if the balance is 
tipped in favour of the reducing form. An increase in the reducing element (GSH 
or Cys) of the couple, results in a more negative redox potential and 
subsequently a reducing redox environment. Reductive stress may indeed be 
as common and clinically significant as oxidative stress (Ghyczy & Boros, 
2001). Reductive stress has been linked to corruption of growth factor signalling 
leading to abrogated coronary collateral growth, an adaptation of the 
myocardium to minimise the effects of ischemia within an area of the heart 
(Rocic et al, 2007). A study in mice also has found that reductive stress caused 
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by elevated levels of GSH may be implicated in cardiomyopathies (Rajasekaran 
& al., 2007). Additionally, the mice in this study were found to have increased 
expression of heat shock proteins. Further studies have shown that over 
expression of heat shock protein 27 (HSP27) in transgenic mice resulted in an 
increased GSH/GSSG ratio along with decreased levels of ROS. These mice 
were found to suffer from cardiac hypertrophy, dysfunction and reduced life 
span (Zhang et al, 2010). 
 
In recent years, research focussing on redox states and their regulatory role on 
various different cell types has become increasingly popular. Yet, the amount of 
work carried out to examine the interaction between platelets and redox is 
limited. As mentioned in section 1.2.3.1, platelet receptors and in particular 
integrins, contain high numbers of cysteines within their structure. These 
cysteines are potentially prime targets for thiol modifications either by oxidation 
or reduction of their intramolecular bonds by the redox couples or alternatively 
through S-glutathionylation or S-cysteinylation of these free thiols. Such 
interactions could potentially result in compromised function of the platelet 
receptors and, ultimately, impact on platelet activity.  
 
1.4 Platelets and inflammation 
The primary function of platelets is in the complex processes of haemostasis 
and thrombosis. The significance of platelets appears to have been 
underestimated in the past, mainly due to the notable absence of a nucleus in 
platelets. However, an expanding body of evidence shows platelets are involved 
in a number of other biological responses including inflammation. 
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Atherosclerosis and rheumatoid arthritis are prime examples of inflammatory 
conditions in which inflammation and the coagulation cascade are intricately 
linked. The involvement of platelets in the inflammation process stems from the 
interaction between platelets and endothelial cells at a site of injury. As 
mentioned previously, platelets tether and adhere to the exposed 
subendothelium, leading to platelet activation, recruitment of further platelets 
and eventually the formation of a platelet plug. Upon platelet activation, 
signalling cascades within the platelet are initiated inducing the release not only 
of secondary platelet activators but also pro-inflammatory cytokines such as 
CD40 ligand (CD40L) (Henn et al, 1998) and interleukin-1 (IL-1) (Lindemann 
et al, 2001). CD40L is a transmembrane protein related to the cytokine TNF-, 
and becomes expressed on the surface of platelets within seconds of activation 
(Henn et al, 1998). CD40L induces the secretion of chemokines from 
endothelial cells, which are involved in the recruitment of leukocytes to the site 
of injury. Lindemann et al have shown that platelets are capable of synthesising 
IL-1 from messenger RNA (mRNA) located within the platelet and production 
of IL-1 is regulated by engagement of 3 integrins. Activated platelets also 
secrete the chemokines CCL5 (RANTES) and CXCL4 (platelet factor 4) (von 
Hundelshausen et al, 2001). These pro-inflammatory chemokines are deposited 
on the microvasculature, aortic endothelium and monocytes. This in turn may 
lead to activation of monocytes and integrins with further recruitment of 
monocytes to the site of injury. The promotion of leukocyte adhesion and 
activation induces firm attachment of the leukocytes to the vessel wall and may 
eventually lead to transmigration of these leukocytes into the subendothelial 
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tissue. These examples of platelet derived chemokines demonstrate platelets 
as key players in mediating the inflammatory response at a site of injury.  
 
Inflammatory bowel disease (IBD) is another example of a clinical inflammatory 
condition in which a role for platelets has been implicated, yet the mechanism of 
this interaction remains to be fully understood (Yoshida & Granger, 2009). 
Subclinical thrombosis is common in IBD and is a major source of morbidity in 
approximately 25% of IBD deaths (Tabibian & Roth, 2009). Furthermore, 
thromboembolic events are 3-fold more likely in IBD patients compared to 
controls, with a particularly high risk of thromboembolic events during active 
disease states (Zitomersky et al, 2011). Circulating platelets in IBD patients 
have been found to be in an active-like state with an increased expression of 
activation-dependent surface antigens such as P-selectin and GP53 (Collins et 
al, 1994). Plasma levels of CD40L and platelet factor 4 are increased in patients 
with IBD (Collins & Rampton, 1997; Danese et al, 2003b).  Additionally, in vitro 
studies of platelets from patients suffering with both active and quiescent IBD 
display hypersensitivity to stimulation of platelets with collagen and ADP along 
with spontaneous platelet aggregation (Mori et al, 1980; Webberley et al, 1993). 
Although the etiology of IBD remains poorly understood, immunoregulatory 
factors are hypothesised to be the main dysfunctional players in the process. 
The redox environment is thought to be one such dysfunctional 
immunoregulatory system. An abnormally high level of ROS production has 
been associated with IBD patients (Rezaie et al, 2007). Interestingly, a number 
of studies have also shown not only an increase in ROS, but also a dramatic 
change in the levels of antioxidants present in these IBD patients. A study of 
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knockout mice lacking glutathione peroxidase genes found these mice 
developed a destructive colitis similar to ulcerative colitis (UC) as early as 11 
days old (Esworthy et al, 2001). Further studies investigating the redox status of 
glutathione in human IBD cases found not only a significant increase in the 
oxidised form of glutathione (GSSG) in the colonic mucosa, which was 
positively correlated to the disease severity (Holmes et al, 1998), but also a 
concomitant decrease in reduced glutathione (GSH) levels leading to an overall 
oxidising environment (Tsunada et al, 2003). There exists an ongoing argument 
as to whether oxidative stress is a cause or a consequence of IBD. Due to the 
phenomenon of oxidising agents inducing IBD like symptoms (Bilotta & Waye, 
1989; Meyer et al, 1981) and mice lacking the antioxidant Gpx developing colitis 
with a pathology similar to that seen in IBD, it seems oxidative stress may 
indeed be a cause.  
 
1.5 Aims 
The mechanisms of platelet activation remain to be fully elucidated despite in-
depth research. Integrins, in particular, play a major role in the process of 
platelet activation and are, therefore, a major focus of current platelet research. 
There is overwhelming evidence to suggest cysteine residues and 
thiol/disulphide bonds are critical players in the complex conformational 
changes associated with integrin activation. However, the precise role of thiols 
in these molecular mechanisms, whereby integrins are converted from an 
unactivated state to an active, ligand-binding state, remains to be indentified. 
Similarly, it has been suggested thiols are an important structural component of 
other platelet receptors. The principle aim of this thesis, therefore, is to examine 
 41 
changes in the surface thiol population of platelets in various activating 
scenarios in conjunction with alterations of integrin thiols.  
 
The external redox environment of platelets is tightly controlled by the balance 
of the major low-molecular-weight redox couples, glutathione and cysteine. 
Alterations in the balance of this redox environment may result in the 
development of oxidative or reductive stress. Oxidative stress, in particular, has 
been implicated in a range of disease states, which interestingly, are associated 
with an increased risk of thromboembolic events. The effects of redox-related 
stress are mainly brought about by thiol modifications of proteins leading to 
conformational changes in proteins resulting in the alteration or loss of protein 
function. The presence of thiol-containing proteins on platelets makes them 
potential prime targets for post-translational redox modifications. I will 
investigate the effects of an altered external redox environment on the platelet 
surface thiol population. Additionally, I will examine the impact of the 
modification of platelet surface thiols on downstream, intra-platelet signalling 
events and, ultimately, the effects of such modifications on platelet function.
  
 
Chapter 2 
Materials and Methods 
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2.1 Materials 
 
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB); glutathione (free acid), reduced and 
oxidised, were obtained from Merck Chemicals Ltd., Nottingham, UK. 
 
Alexa Fluor® 488 Phalloidin was obtained from Invitrogen Corporation, 
Carlsbad, CA, USA. 
 
Chinese hamster ovarian-K1 (CHO-K1) cells expressing integrin IIb3 were a 
kind gift from Professor Niamh Moran, RCSI, and were kindly cultured and 
passaged by Dr. Roisin Moriarty, DCU. 
 
Collagen related peptide (CRP) was a kind gift from Professor Richard 
Farndale, Department of Biochemistry, Cambridge University, UK. 
 
Collagen, lyophilised preparation of soluble calf skin (type 1) and siliconised, 
flat-bottom aggregation tubes (7.25 X 55 mm) were obtained from Bio/Data 
Corporation, Horsham, PA, USA.  
 
CD62P-PE, CD41a-FITC and PAC-1-FITC, antibodies and Falcon™ tubes, 
(polystyrene, round bottom), were obtained from Becton-Dickinson, Oxford, UK. 
 
Convulxin, lyophilised, ≥ 90 % (SDS-PAGE), (50 g), was obtained from Enzo 
Life Sciences (UK) Ltd., Exeter, UK. 
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Econo-Pac chromatography columns, Protein DC assay kit and P6 spin 
columns were obtained from Bio-Rad Laboratories Ltd., Hertfordshire, UK. 
 
Flat bottom, 96-well microplates (clear) and Immulon 2HB, flat bottom, 96-well 
plates were obtained from Fisher Scientific Ireland, Ballycoolin, Dublin, Ireland. 
 
Fluorescent mounting medium was obtained from Dako, CA, USA.  
 
Platelet membrane GPIIbIIIa (integrin IIb3) (isolated from human platelets), 
and Amicon® Ultra centrifugal filters (0.5 ml, 30K MWCO) were obtained from 
Merck Millipore, Billerica, MA, USA. 
 
Poly-L-lysine adhesion slides, and glass cover slips (rectangular: 22 X 50 mm, 
round: diameter (Ø) 16 mm) were obtained from VWR International Ltd., 
Ballycoolin, Dublin, Ireland. 
 
Sepharose® 2B-300, prostaglandin E1 (minimum 98 % (HPLC) synthetic) 
(PGE1), thrombin from bovine plasma: lyophilised powder, 600 - 2,000 NIH 
units/mg protein (biuret); manganese chloride tetrahydrate (MnCl2.4H2O); 
DL-Dithiothreitol (DTT); tris(2-carboxyethyl)phosphine (TCEP), hydrochloride 
salt; L-cysteine and L-cystine, non-animal source; collagen from calf skin 
(Bornstein and Traub Type I); fibrinogen from human plasma (50 - 70% protein 
(≥ 80 % of protein is clottable)), albumin from bovine serum (≥ 98 % (agarose 
gel electrophoresis), lyophilised powder); calcium chloride; glycine; Hepes; 
potassium chloride; magnesium chloride; potassium phosphate; sodium 
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bicarbonate; sodium chloride; sodium citrate, sodium dodecyl sulphate (SDS), 
for electrophoresis, > 98.5% (GC); 30 % bis-acrylamide, 0.2 m filtered; 
ammonium persulfate (APS) for electrophoresis, >=98 %; 
tetramethylethylenediamine (TEMED), approximately 90 %; bromophenol blue; 
sodium fluoride; sodium pyrophosphate; sodium orthovanadate; Triton-X-100; 
trizma-base, > 99.9 % titration; dextrose (D-glucose); citric acid; Tween-20; 
polyvinyl difluoride (PVDF) membrane; Ponceau S, practical grade; acetic acid; 
Brilliant Blue G250 (Coomassie); hydrochloric acid (HCl); dimethyl sulfoxide 
(DMSO), puriss.,absolute, over molecular sieves; methanol; ethanol, 
deoxycholic acid (DCA), sodium taurodeoxycholate hydrate (taurodeoxycholic 
acid (TDCA)) and Atto 655-maleimide were obtained from Sigma Aldrich Ltd, 
Tallaght, Dublin, Ireland. 
 
Supersignal® West Pico chemiluminescent substrate; Halt protease inhibitor 
(100X), and pNPP (p-Nitrophenyl phosphate) were obtained from Thermo 
Fisher Scientific, Rockford, IL, USA. 
 
Thiostar, thiol detection substrate, was obtained from BioQuote Ltd., York, UK. 
 
Ursodeoxycholic acid (sodium salt) was obtained from Santa Cruz 
Biotechnology, Leopardstown, Dublin, Ireland. 
 
VASP (A290), phospho-VASP (Ser157) and phospho-VASP (Ser239) were 
obtained from Cell Signaling Technology, Beverly, MA, USA. 
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2.2 Methods 
2.2.1 Isolation of platelets from whole blood 
Venous whole blood was drawn from healthy volunteers, free from aspirin and 
other drugs that may affect platelet function for 7 - 10 days. Blood was drawn 
from the antecubital vein using a Butterfly® 19 gauge needle by a qualified 
phlebotomist. Ethical approval was granted by Royal College of Surgeons in 
Ireland Research Ethics Committee. Blood was anti-coagulated with 15 % (v/v) 
Acid-Citrate-Dextrose (ACD) (38 mM Citric Acid (Anhydrous), 75 mM Sodium 
Citrate, 124 mM Dextrose) (stored at 4 ºC and brought to room temperature 
before use) i.e. 4.5 ml of ACD drawn into a syringe and blood drawn to the 30 
ml mark, with gentle mixing. Blood was divided into 5 ml aliquots in 15 ml tubes 
and centrifuged for 12 minutes at 150 x g (no brake) at room temperature (RT). 
This centrifugation step separated whole blood into two fractions. The top two 
thirds of the top fraction, referred to as platelet rich plasma (PRP), were 
carefully transferred to a 50 ml tube with a plastic transfer pipette. The 
remaining blood portion was discarded. The pH of the PRP was adjusted to pH 
6.5 using ACD. Prostaglandin E1 (PGE1) was added at a final concentration of 1 
µM. The PRP was centrifuged for 10 minutes at 720 x g (no brake) at RT to 
pellet platelets. The supernatant was carefully removed and the platelets were 
resuspended in 1 ml (per 30 ml blood, i.e. resuspend platelets in 2 ml platelet 
buffer if 60 ml of blood was drawn) of a modified Hepes platelet buffer (MHPB) 
(6 mM Dextrose, 130 mM NaCl, 9 mM NaHCO3, 10 mM Sodium Citrate, 10 mM 
Hepes, 3 mM KCl, 0.81 mM KH2PO4, 0.9 mM MgCl2.6H2O, pH 7.35). 
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2.2.1.1 Preparation of gel-filtered platelets 
Gel-filtration is an example of size-exclusion chromatography. It is a method 
commonly used to separate particles in an aqueous solution based on the 
particle size. The concept on which the technique is based is one in which 
beads of a specific size are packed together in a column to form a matrix with 
specific spacing between the beads and a solution is placed on top. The smaller 
particles in the solution can pass into the beads, while the larger particles do 
not. The end result is that the larger particles, therefore, pass through the matrix 
quickly, whereas the smaller particles pass through at a slower rate and can be 
collected at a later time point. In this case, gel-filtration was employed to ensure 
platelets used in the study were in a purified system, with all plasma proteins 
and other cells and cellular fragments removed. 
 
The column for gel-filtration of platelets was prepared by rinsing a plastic 
column (height 15 cm, diameter 1.5 cm) with deionised water. A dilute slurry of 
sepharose 2B-300 beads was prepared with deionised water using 10 ml 
sepharose 2B-300 with 10 ml deionised water. The sepharose 2B-300 slurry 
was layered into the plastic column and allowed to pack without drying out. The 
packed column height was directly related to the volume of suspended platelets 
to be filtered, namely 5 – 6ml packed sepharose 2B per 1 ml of platelets.  The 
sepharose column was rinsed with deionised water, using 10 - 20 times column 
volume. The rinsed column was equilibrated with 3 - 4 times column volume of 
platelet buffer (MHPB).  Once equilibrated, all platelet buffer was allowed to 
pass into the gel column before layering the platelets onto it. When all platelets 
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had passed into the column, approximately 1 ml platelet buffer (MHPB) was 
layered onto the top of the column. Gel-filtered platelets were collected in 0.5 ml 
fractions, platelets were counted using a Sysmex KX-21 haematology analyser 
and the most concentrated fractions were pooled together. The final platelet 
count was adjusted to a count of 2.5 – 3.0 × 108/ml, which is within the normal 
physiological range, by addition of platelet buffer (MHPB). Platelets were 
allowed to rest for approximately 30 minutes. CaCl2 was added at a final 
concentration of 1.8 mM immediately prior to platelets being used in 
experiments. 
2.2.1.2 Preparation of washed platelets 
Following the removal of PRP after the second centrifugation step in section 
2.2.1, 0.5 ml platelet buffer (MHPB) was gently added on top of the platelet 
pellet, whilst ensuring the pellet was not disturbed. This platelet buffer was then 
removed. This step was repeated twice. While the washed platelet preparation 
is not as rigorous as the gel-filtered platelet preparation, this step ensured that 
the majority of plasma proteins were removed. The platelet pellet was then 
resuspended in 1 ml platelet buffer (MHPB) (per 30 ml blood, i.e. resuspended 
in 2 ml platelet buffer if 60 ml blood was used) and the platelets were counted 
using the Sysmex KX-21 haematology analyser. The platelet count was 
adjusted to 2.5 – 3.0 × 108/ml by addition of platelet buffer (MHPB). Platelets 
were allowed to rest for approximately 30 minutes. CaCl2 was added at a final 
concentration of 1.8 mM immediately prior to platelets being used in 
experiments. In the case of washed platelets being used in the platelet 
adhesion assays, platelets were supplemented with 2 mM MgCl2 as an 
alternative to CaCl2. This is due to the dependency of the collagen receptor 
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integrin 21 on Mg
2+ ions. This step is particularly important due to the 
presence of the chelating agent, sodium citrate, in the anticoagulant (ACD) into 
which the blood is originally drawn. It has been shown that in the absence of 
Mg2+ ions, receptors other than integrin 21, such as integrin IIb3 or GPVI 
may become involved in the adhesion of platelets to collagen (de Groot & 
Sixma, 1997). 
 
2.2.2 Platelet aggregation studies 
Percentage platelet aggregation is determined by the percentage of light 
transmission through a sample of platelets in solution. As platelet aggregates 
are formed, they fall to the bottom of the tube thereby increasing the level of 
light transmission through the sample (Figure 2.1). A 100 % percentage 
aggregation baseline is set in the aggregometer by measuring the level of light 
transmission through a platelet poor sample. In the case of gel-filtered platelets 
this baseline is acquired using the platelet buffer (MHPB). This technique is 
based on the principles and technique first described by Born (Born, 1962). 
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Figure 2.1 A schematic illustrating platelet aggregometry. Unactivated platelets in 
solution form a cloudy suspension allowing little or no light to pass through. Upon 
stimulation with a platelet agonist, the platelets aggregate and the resulting platelet 
aggregates fall to the bottom of the tube. This results in a greater amount of light 
passing through the sample, i.e. the percentage light transmission through the sample 
is directly proportional to the level of platelet aggregation. 
 
2.2.2.1 Assessing the levels of platelet aggregation induced by 
manganese chloride (MnCl2), dithiothreitol (DTT) and thrombin 
Gel-filtered platelets were prepared as described in section 2.2.1.1. The platelet 
count was adjusted to 2.5 – 3.0 × 108/ml. Platelets were stimulated with either 1 
mM, 3 mM or 5 mM manganese chloride (MnCl2) or dithiothreitol (DTT) or 1U/ml 
thrombin in a BioData Corporation PAP4 aggregometer at 37 °C with constant 
stirring at 1100 revolutions per minute (rpm) for 10 minutes. The levels of 
platelet aggregation were observed at 0, 5 and an endpoint of 10 minutes after 
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addition of the activator to determine incubation times that would be useful in 
subsequent experiments.  
2.2.2.2 Assessing the effects of an altered external redox environment on 
platelet aggregation 
Gel-filtered platelets were prepared as described in section 2.2.1.1. Platelets 
were activated with 0.1U/ml thrombin, 50 ng/ml convulxin and 38 g/ml 
collagen, in the presence of a reducing or oxidising external environment. A 
reducing environment was generated with 45 M reduced glutathione (GSH), 
tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT). An oxidising 
environment was generated with 45 M oxidised glutathione (GSSG), cystine 
(CySS) or 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). Platelet aggregations 
were carried out in a Biodata Corporation PAP4 aggregometer at 37 °C with 
constant stirring at 1100 rpm. Aggregations were followed for 10 minutes. 
2.2.2.3 Assessing the effects of bile acids on platelet aggregation 
Gel-filtered platelets were prepared as described in section 2.2.1.1. Platelets 
were incubated with ursodeoxycholic acid (UDCA), deoxycholic acid (DCA) or 
taurodeoxycholic acid (TDCA) at concentrations of 10 M, 100 M or 500 M 
for 10 minutes at 37 °C with constant stirring at 1100 rpm. Platelets were left 
unactivated or were activated with either 0.1U/ml thrombin, 50 ng/ml convulxin 
or 38 g/ml collagen. Platelet aggregations were followed for 10 minutes at 
37 °C with constant stirring at 1100 rpm in a Biodata Corporation PAP4 
aggregometer. 
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2.2.2.4 Assessing the effects of protein kinase inhibitors on platelet 
aggregation 
Gel-filtered platelets were prepared as described in section 2.2.1.1. Platelets 
were incubated with either 5 M BAY 61-3606 or 25 M PP2 for 10 or 
15 minutes, respectively, at 37 °C with constant stirring at 1100 rpm. Platelets 
were left unactivated or were activated with either 0.1U/ml thrombin, 50 ng/ml 
convulxin or 38 g/ml collagen. Platelet aggregations were followed for 10 
minutes at 37 °C with constant stirring at 1100 rpm in a Biodata Corporation 
PAP4 aggregometer. 
 
2.2.3 Measurement of the level of activation of the platelet specific 
integrin IIb3 
Flow cytometry is a technique that can be used to analyse particles, usually 
cells, based on their physical characteristics, namely particle size and relative 
granularity. These properties are measured when the injected sample is formed 
into a stream of single cells, which pass through the path of a laser beam. As 
the cells pass through the laser beam, they deflect the light resulting in light 
scattering. The physical properties of the cells can be determined by analysing 
the scattered light. There are two types of scattered light: forward scatter (FSC) 
and side scatter (SSC). Forward scatter is proportional to cell size while side 
scatter is proportional to the granularity or internal complexity of the cell (Figure 
2.2 (a)). The two types of scattered light are collected by their respective 
detectors and translated into electrical signals (voltages), which are detected by 
photodetectors. The voltages are amplified and assigned a digital value by the 
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Analog-to-Digital Convertor (ADC), which converts a voltage pulse to a channel 
value. This signal is transmitted to a computer where the light signal is 
displayed on a data plot, represented as either a contour plot or a dot plot 
(Figure 2.2 (b)).  
 
In addition to measuring scattered light, flow cytometry can also measure 
fluorescence. A cell surface marker can be specifically targeted with a probe 
such as an antibody conjugated to a fluorophore. When this fluorophore passes 
through the laser beam, it absorbs light energy causing its electrons to move to 
a higher energy state. The electrons are highly unstable in this excited state and 
quickly return to ground state, causing the release of excess energy in the form 
of a photon of light. This released energy is referred to as fluorescence. This 
fluorescence can be collected by detectors, which sort it according to the 
emission wavelength (Figure 2.3 (a)). For example, the FITC fluorophore has 
peak emission fluorescence at 525 nm and is detected by the FL-1 detector in 
the flow cytometer. A change in fluorescence associated with a sample 
population is displayed in a histogram. An increase or decrease in the level of 
fluorescence detected is illustrated as a shift in the histogram along the x-axis to 
the right or left, respectively (Figure 2.3 (b)). 
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Figure 2.2 (a) A schematic illustrating the principle of light scattering by cells in 
flow cytometry. (A) The sample containing the cells to be analysed is injected into the 
flow cytometer and focussed into a stream of single cells in sheath fluid through a 
pressurised flow system. (B) A laser beam is focussed across the path of the cells. As 
the cells intercept the path of the laser beam, a scattering of light occurs. Light that is 
scattered along the same axis as the laser is referred to as forward scatter (FSC) and 
is detected by a forward scatter detector. FSC is proportional to cell size. Light that is 
scattered at 90° to the axis of the laser is referred to as side scatter (SSC) and is 
detected by a side scatter detector. Side scatter is a measure of the cells granularity or 
internal complexity. 
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Figure 2.2 (b) Example of a contour plot (A) and a dot plot (B) of a sample of 
unactivated gel-filtered platelets in flow cytometry. Forward scatter (FSC-H) is 
shown on the x-axis, the intensity of which is representative of the particle size, in this 
instance the platelets. Side scatter is on the y-axis, the intensity of this scattering is 
indicative of the granularity of the particles. The location of the population in the bottom 
left hand corner of the plots indicates the small size of resting platelets (2 - 4 m) and 
also the relatively low granular content of platelets. A threshold has been set on the 
FSC-H axis to eliminate any events from particles or debris smaller than the platelets 
that may be present in the sample. (A) The lines, or contours, in the contour map 
connect fields with the same number of events. (B) Each dot on the density plot 
represents an individual platelet that has passed through the flow cytometer; the grey 
colour indicates large numbers of events at this particular point.  
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Figure 2.3 (a) A schematic illustrating the generation of fluorescence in flow 
cytometry. (A) The sample containing the cells to be analysed is injected into the flow 
cytometer and focussed into a stream of single cells in sheath fluid through a 
pressurised flow system. (B) The cells have been labelled with fluorescent compound, 
for example a specific cell surface marker can be probed with an antibody conjugated 
to a fluorophore. A laser beam is focussed across the path of the cells. When the 
fluorophore comes in contact with the laser, it absorbs light and moves into an excited 
state. However, this excited state is very unstable and the fluorophore quickly returns 
to the ground state. The excess energy is emitted in the form of a photon and is 
referred to as fluorescence. The fluorescence is detected by fluorescence detectors. 
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Figure 2.3 (b) Example of a histogram, demonstrating an increase in 
fluorescence is illustrated as a shift in the histogram from left to right. A cell 
surface marker can be specifically targeted with a probe such as an antibody 
conjugated to a fluorophore. When this fluorophore passes through the laser beam, it 
absorbs light energy causing its electrons to move to a higher energy state. The 
electrons are highly unstable in this excited state and quickly return to ground state, 
causing the release of excess energy as fluorescence. A change in fluorescence 
associated with a sample population is displayed in the form of a histogram. An 
increase or decrease in the level of fluorescence detected is illustrated as a shift in the 
histogram along the x-axis to the right or left, respectively. These histograms 
demonstrate an example of increased fluorescence detected in B, compared to that 
detected in A.  
 
 
PAC-1 antibody is used to examine the activation state of the platelet specific 
integrin IIb3. It is a monoclonal antibody which binds only to the activated 
conformation of integrin IIb3. In this case, it is conjugated to the fluorophore 
fluorescein isothiocyanate (FITC).  Therefore, the amount of fluorescence 
emitted from the fluorophore after its excitation by laser (488 nm argon-ion 
laser) is directly proportional to the quantity of activated integrin IIb3 on the 
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platelet surface. PAC-1 was originally developed by fusing a murine myeloma 
cell line with splenic lymphocytes from a mouse which had been immunised 
with platelets from a Glanzmann’s patient (Shattil et al, 1985).  
 
Gel-filtered platelets were prepared as described in section 2.2.1.1. The platelet 
count was adjusted to 2.5 - 3 X 108/ml. Platelets were activated with either 
1U/ml thrombin, 3 mM DTT or 3 mM MnCl2 for 10 minutes, with 10 µl of PAC-1 
antibody present. All incubations were carried out at 37 °C without stirring. 
These times for incubation were obtained from the analysis of the platelet 
aggregation studies described above.  
 
After the 10 minute incubation, samples were diluted in 2 ml platelet buffer 
(MHPB) in 5 ml Falcon™ tubes. Samples were analysed on a Becton Dickinson 
FACSCalibur™ flow cytometer using CellQuest Pro software. The platelet 
population was gated, and 10,000 events were analysed.  
 
2.2.4 Assessment of platelet degranulation 
Flow cytometry was also used to assess the level of platelet degranulation or 
secretion, a process associated with platelet activation. P-selectin is released 
from -granules upon platelet activation and is expressed on the platelet 
surface (Jurk & Kehrel, 2005). CD62P is a monoclonal antibody, which 
selectively binds P-selectin. In this case, the antibody is conjugated to the 
fluorophore phycoerythrin (PE). PE has a peak emission fluorescence at 
578 nm and is detected by the FL-2 detector in the flow cytometer. The amount 
of fluorescence is indicative of the quantity of P-selectin on the surface of the 
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platelets, and hence, an indicator of the platelet activation state induced by the 
various platelet activators. 
 
Gel-filtered platelets were prepared as described in section 2.2.1.1. The platelet 
count was adjusted to 2.5 - 3 X 108/ml. Platelets were activated with either 
1U/ml thrombin, 3 mM DTT or 3 mM MnCl2 for 10 minutes. All incubations were 
at 37 °C without stirring. 10µl CD62P antibody was present during the 
incubations.   
 
Samples were then diluted in 2 ml platelet buffer (MHPB) in 5 ml Falcon™ tubes 
and analysed on a Becton Dickinson FACSCalibur™ flow cytometer using 
CellQuest Pro software. The platelet population was gated, and 10,000 events 
were analysed. 
 
2.2.5 Raman Spectroscopy: Analysis of intact platelets  
Raman spectroscopy (RS) is an optical technique used in the determination of 
molecular structure. Monochromatic light, usually a laser, is focussed onto a 
sample and interacts with the bonds in the molecules of the sample. Upon 
interaction with the light or photons, the molecules are transformed into 
oscillating or induced dipoles. This occurs when a molecule is placed in an 
electric field (laser) causing a distortion, whereby the positively charged nuclei 
are attracted to the negative pole and the negatively charged electrons are 
attracted to the positive pole (Ferraro, 2003). The scattering of photons by a 
molecule is dependent on the molecules polarisability. The polarisability of a 
molecule is defined as the ability of an applied electric field to induce a dipole 
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moment in an atom or molecule (Ball, 2001). These induced dipoles have the 
potential to emit or scatter light at three different frequencies. The three types of 
scattering are known as Rayleigh, Stokes and anti-Stokes scattering.  
 
Rayleigh scattering is an elastic scattering which occurs in molecules which 
contain no Raman-active modes. When the molecule is excited, it returns back 
to the same vibrational state and emits photons at the same frequency as the 
excitation source, i.e. the light does not gain or lose energy during the scattering 
(Figure 2.4). 
 
If there are Raman-active modes present in the molecules, the frequency of the 
photons emitted from the molecules is shifted up or down compared to the 
frequency of the original monochromatic light. It is this molecular inelastic 
scattering of light upon which the principle of Raman spectroscopy is based. 
Stokes scattering is a Raman effect which occurs when a photon is absorbed by 
a Raman-active molecule which at the time of interaction is in the basic 
vibrational state. Part of the photon’s energy is transferred to the Raman-active 
mode and, therefore, the frequency of scattered photon is reduced. Anti-stokes 
scattering is essentially the opposite of Stokes scattering. It occurs when a 
photon interacts with a Raman-active molecule which is already in an excited 
state. The molecule releases this excess energy, which results in the molecule 
returning to a basic vibrational state while the frequency of the resulting 
scattered photons is increased (Figure 2.4). It is important to highlight that the 
energy difference is due to the energy difference in vibrational states of the 
molecule and is not related to the absolute energy of the photon. When 
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obtaining a Raman spectrum from a sample, approximately 99.999 % of 
incidence photons will undergo Rayleigh scattering with only about 0.001 % 
producing inelastic Raman signals. 
 
 
Figure 2.4 A diagram illustrating Rayleigh and Raman scattering. The blue arrows 
represent the excitation light, while the black arrows represent scattered light. Rayleigh 
scattering involves photons being absorbed by molecules and re-emitted at the same 
frequency as the excitation light; elastic scattering. Raman scattering, both Stokes and 
anti-Stokes, is inelastic scattering. Stokes scattering occurs when photons interact with 
molecules in a ground state which causes some of the photons energy to be 
transferred to the Raman-active mode in the molecule, thereby reducing the frequency 
of the scattered photons. Anti-stokes scattering occurs when the excitation photons 
interact with molecules already in an excited state, the molecule releases the excess 
energy causing an increase in the frequency of the resulting scattered photons. 
 
Due to the low levels of Raman scattering, all scattered light is collected by a 
lens and is filtered to separate the strong Rayleigh scattering from the weaker 
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Raman scattering. The Raman scattered light is then dispersed on to a detector 
by a diffraction grating and a spectrum is generated (Figure 2.5).  
 
 
 
Figure 2.5 A schematic illustrating the basic Raman spectroscopy set up. A laser 
is focussed on the sample of interest. The photons of the excitation laser interact with 
the molecules of the sample and scattering of the photons occurs. Strong Rayleigh 
scattering is separated from the weaker Raman scattering by a filter. The light is then 
dispersed onto a detector by diffraction grating. This detector in turn sends a signal to 
the connected computer and a Raman spectrum providing information about the 
molecular structure of the sample is generated by the Raman analysis software. 
 
 
Gel-filtered platelets were prepared as described in section 2.2.1.1. The platelet 
count was adjusted to approximately 1.0 × 109/ml. This higher platelet count 
ensured a high Raman signal. Platelets were incubated with 1U/ml thrombin, 
3 mM MnCl2 or 3 mM DTT for 10 minutes. All incubations were carried out at 
37 °C, without stirring. Platelets were then fixed in 1 % formaldehyde.  Initially, 
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1 µl of sample was pipetted on to a glass cover slip and allowed to dry for 
approximately 10 minutes. This method was changed after it was found that 
centrifuging the samples in a microcentrifuge for 2 minutes at 9,300 x g, 
removing the supernatant and placing the platelet pellet on the glass cover slip 
gave a much larger signal. Raman Spectra were recorded on a Horiba/Jobin 
Yvon LabRam HR spectrometer. The laser line of 473 nm was employed, 
focussed through a 200 µm hole with a 100X objective. A grating of 
600 grooves/nm was used. The instrument was calibrated using a silicon chip. 
Power at the sample level was 1 mW. All spectra were analysed using LabSpec 
software. 
 
Alternative substrates to glass cover slips were tested to minimise background 
signal. These were poly-L-lysine slides and quartz slides. Surface Enhanced 
Raman Spectroscopy (SERS) was also carried out. SERS is a technique which 
enhances the weak Raman scattering signal when substances are adsorbed 
onto roughened metal surfaces (nano scale: 10 - 100 nm), most commonly 
gold, silver or copper (Campion, 1998). SERS is expected to enhance Raman 
signal from molecules by a factor of 106 or more. The surfaces that we used for 
SERS were a glass slide coated with fluorine-doped tin oxide (FDTO) onto 
which gold nanoparticles were electrodeposited (Sheridan, 2007) and also an 
aluminium oxide plate coated with gold which contained nanocavities (3 - 4 µm 
diameter) (Jose et al, 2009). Other SERS substrates tested included aluminium 
oxide plates coated with gold or silver.  
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2.2.6 Principal component analysis (PCA) 
Principal component analysis (PCA) was carried out on the data collected from 
the whole platelet analysis by Raman spectroscopy as described in section 
2.2.5. PCA is a multivariate statistical analysis technique used for finding 
patterns in data of high dimension. It allows the data to be expressed in a way 
in which differences or similarities in the data are highlighted. Each Raman 
spectrum consists of 1681 channels, not all of which contain useful information. 
PCA defines a new dimensional space in which the major variance in the 
original data can be defined by a small number of principal components (PC). 
This allows the identification of the most important channels where the most 
differences are detected. The data was baseline subtracted and normalised with 
Origin® software. It was then imported into The Unscrambler® software where 
the data was transposed and PCA was performed.  
 
2.2.7 Preparation of redox reagents 
Reduced and oxidised species of glutathione, GSH and GSSG respectively, 
and reduced cysteine (Cys) and oxidised cystine (CySS) were combined in 
different ratios to generate various redox potentials using the Nernst equation 
(Schafer & Buettner, 2001). Redox potential is a measure of the reducing 
capacity of the redox couple and is expressed in terms of millivolts (mV). A very 
negative redox potential value indicates a highly reducing environment, while a 
less negative, or more positive, value indicates an oxidising environment. 
 
Nernst equation: Eh = E° - RT/nF log [Red]
2/[Ox] 
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where Eh is electromotive force, E° is standard electrode potential (-264 mV for 
GSH/GSSG, -250 mV for CyS/CySS), R is the ideal gas constant (8.314 J K-1 
mol -1), T is absolute temperature (K), n is the number of electrons transferred, 
F is the Faraday constant, [Red] and [Ox] are the molar concentrations of the 
reduced and oxidised species, respectively. Redox potentials were set at mean 
plasma values (-130 mV for GSH/GSSG and -82 mV for CyS/CySS) ± 6 
standard deviations. These mean plasma values were obtained from a study by 
Go and Jones (Go & Jones, 2005) in which the range of plasma redox 
potentials for both GSH/GSSG and Cys/CySS were determined from a group of 
over 700 randomly selected individuals. The mean plasma value plus 6 
standard deviations yields an oxidising redox environment, whereas the mean 
plasma value minus 6 standard deviations gives a reducing redox environment. 
The reducing, mean and oxidising redox potentials for the GSH/GSSG and 
Cys/CySS redox couples, as used here, were determined as shown in 
Table 2.1. The concentrations of redox reagents used to generate these redox 
potentials are shown in Table 2.2. 
 
 
Table 2.1 The reducing, mean and oxidising potentials generated by combining various 
ratios of GSH/GSSG and CyS/CySS using the Nernst equation. 
 
Redox Potential GSH/GSSG CyS/CySS 
Reducing -264 mV -148 mV 
Mean -130 mV -82 mV 
Oxidising -10 mV +4 mV 
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Table 2.2 The concentrations of GSH, GSSG, Cys and CySS used to generate the 
reducing, mean and oxidising redox potentials using the Nernst equation. 
 
Redox 
potential 
[GSH] [GSSG] [CyS] [CySS] 
-264 mV 45 M 2 nM - - 
-130 mV 3.02 M 0.302 M - - 
-10 mV 0.25 M 25 M - - 
-148 mV - - 60.44 M 9.8 M 
-82 mV - - 14.22 M 93.33 M 
+4 mV - - 0.5 M 100.44 M 
 
 
Redox reagents, GSH, GSSG, Cys and CySS, were prepared as stock 
solutions at a concentration of 200 mM in 0.1 M hydrochloric acid (HCl). The 
reduced form of the reagents, in particular, has a tendency to become oxidised, 
therefore preparation of the reagents in concentrated HCl ensures the reagents 
remain in their correct forms. Reagents were diluted to the required working 
stocks in platelet buffer and thus the concentration of HCl to which the platelets 
were exposed was minimal (M).  
 
2.2.8 Measuring the number of thiols (-SH) on platelet surface  
2.2.8.1 Measuring free thiols on platelet surface using DTNB (5,5'-
dithiobis-(2-nitrobenzoic acid) on platelets in solution 
The DTNB assay (also known as Ellman’s Test (Ellman, 1959)) is a standard 
test used for the quantification of thiols. DTNB is a water-soluble compound that 
reacts with a thiol group to form a mixed disulphide and 2-nitro-5-thiobenzoic 
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acid (NTB) (Figure 2.6). NTB has a yellow colour and has a relatively intense 
absorbance at 412 nm. The stoichiometry of NTB to free thiols is in a 1:1 ratio. 
Therefore, measuring NTB formation allows us to determine the number of 
thiols present. As DTNB is cell impermeable, it was used to assess the number 
of platelet surface thiols.  
 
 
Figure 2.6 The chemical reaction between a thiol containing compound and 
DTNB (5,5’-dithiobis(2-nitrobenzoic acid). The thiol group of the thiol containing 
compound (RSH) reacts with DTNB causing its cleavage to form a mixed disulphide 
and NTB (2-nitro-5-benzoic acid). NTB is a coloured species, the absorbance of which 
can be measured at 412 nm and used to calculate the number of thiol groups in the 
original compound. (This schematic is adapted from UCDAVIS BioWiki: Structure and 
Properties of Amino Acids) 
 
Gel-filtered platelets were prepared as described in section 2.2.1.1. Platelets 
were incubated with various GSH/GSSG or CyS/CySS redox conditions, as 
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described in section 2.2.7. Platelets were subsequently activated with either 
0.1U/ml thrombin, 50 ng/ml convulxin or 38 g/ml collagen for 10 minutes at 
37 °C, without stirring. 100 M DTNB (5,5'-dithiobis-(2-nitrobenzoic acid) was 
added to the samples and incubated for 1 minute at room temperature. 
Samples were centrifuged in a microcentrifuge for 30 seconds at 13,400 x g. 
The supernatant was removed and transferred to a clear, flat-bottom 96-well 
plate. Absorbance was measured, using a Wallac plate reader at 405 nm (as 
this was the closest filter to 412 nm available).  
 
A standard curve was generated using known concentrations of cysteine (Cys), 
a thiol containing compound. Cysteine, at concentrations ranging from 
0 - 15 M, was incubated with DTNB (100 M), in triplicate, for 1 minute at room 
temperature. The absorbance of the samples was read in a clear, flat bottom 
96-well plate at 405 nm in the Wallac plate reader. Results were plotted and the 
equation of the line was generated using GraphPad Prism® 5 software. Platelet 
surface thiol populations were estimated from this standard curve.  
2.2.8.2 Measuring free thiols on platelet surface using DTNB (5,5'-
dithiobis-(2-nitrobenzoic acid) on adhered platelets 
Clear, flat bottom, 96-well plates were coated with 100 l per well of either 1 % 
bovine serum albumin (BSA) in Tris buffered saline (TBS: 150 mM NaCl, 50 mM 
Tris (base), pH7.4), 20 g/ml fibrinogen in TBS or 1 g/ml CRP  in TBS 
overnight at 4 °C. Plates were coated with 10 g/ml collagen overnight at room 
temperature. Excess substrate was removed and plates were then blocked with 
5 % BSA in TBS for 1 hour at 37 °C. Excess BSA was removed and plates were 
washed once with TBS, once with 0.1 % BSA in TBS and once with 0.1 % BSA 
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in TBS supplemented with 1.8 mM CaCl2 (BSA, fibrinogen and CRP wells) or 
2 mM MgCl2 (collagen wells). Washed platelets (prepared as described in 
section 2.1.1.2) were incubated with GSH/GSSG redox potentials for 
10 minutes at 37 °C. 50 l of redox treated washed platelets were added per 
well and plates were incubated for 45 minutes at 37 °C. All experiments were 
carried out in triplicate. Following incubation, non-adhered platelets were 
removed. Plates were washed twice with platelet buffer (MHPB). 100 l of 
100 M DTNB (5,5'-dithiobis-(2-nitrobenzoic acid), was added to each well and 
incubated for 1 minute at room temperature. Absorbance was read on the 
Wallac plate reader at 405 nm. 
 
2.2.9 Platelet static adhesion assay 
Clear, flat bottom, 96-well plates were coated with 100 l  per well, of either 1 % 
bovine serum albumin (BSA) in Tris buffered saline (TBS: 150 mM NaCl, 50 mM 
Tris (base), pH7.4), 20 g/ml fibrinogen in  TBS or 1 g/ml CRP in  TBS 
overnight at 4 °C. Plates were coated with 10 g/ml collagen overnight at room 
temperature. Excess substrate was removed and plates were blocked with 5 % 
BSA in TBS for 1 hour at 37 °C. Excess BSA was removed and wells were 
washed once with TBS, once with 0.1 % BSA in TBS and once with 0.1 % BSA 
supplemented with 1.8 mM CaCl2 for those wells coated with either BSA, 
fibrinogen or CRP; or 0.1 % BSA in TBS supplemented with 2 mM MgCl2 for 
those wells coated with collagen. 50 l of washed platelets were added per well, 
and incubated for 45 minutes at 37 °C. Each condition was performed in 
triplicate. Following incubation, non-adhered platelets were removed. Plates 
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were washed twice with platelet buffer (MHPB). 100 l of lysis buffer (70 mM 
sodium citrate, 30 mM citric acid, 0.1% (v/v) Triton-X-100) containing 5 mM 
pNPP (para-nitrophenyl phosphate) was added to each well and incubated for 
1 hour at room temperature. The reaction was stopped by adding 100 l of 2 M 
NaOH, per well. pNPP is a chromogenic substrate for most phosphatases 
including alkaline, acid, protein tyrosine and serine/threonine. The reaction 
yields para-nitrophenol, which becomes an intense yellow soluble product under 
alkaline conditions, hence the addition of NaOH. The absorbance was read on 
the Wallac plate reader at 405 nm. The absorbance is directly proportional to 
the amount of phosphatases present and, therefore, is an indirect measure of 
the total number of adhered platelets. 
 
2.2.10 Purified integrin IIb3: Buffer exchange and concentration 
Purified integrin IIb3 was purchased from Merck Millipore and stored at -80 °C 
until ready for use in experiments. The concentration of the purified 
integrin IIb3 was approximately 1.3 mg/ml, according to the manufacturer. As 
the protein was required at a high concentration, the purified integrin was 
concentrated as follows: 0.5 ml purified integrin was centrifuged through 
centrifugal filters for 5 minutes at 14,000 x g at 4 °C in a microcentrifuge, as 
recommended in the manufacturer’s instructions. This step was repeated a 
number of times, checking the volume of integrin after each centrifugation step. 
After 40 minutes, the volume of integrin present had decreased. Therefore, the 
purified protein was now anticipated to be more concentrated than the original 
stock.   
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Upon purchase, the purified integrin is in the following buffer: 100 mM NaCl, 20 
mM Tris-HCl, 1 mM CaCl2, 50 % glycerol, 0.1 % (v/v) Triton-X-100 and ≤ 0.1 % 
sodium azide, pH 7.4). In order to ensure all glycerol was removed from the 
system, a buffer exchange step was required. A volume of buffer A (100 mM 
NaCl, 1 mM CaCl2, 20 mM Tris-HCl, 0.1 % (v/v) Triton-X-100, pH 7.4), was 
added to the centrifugal filter to make the volume back up the original stock 
volume before the integrin was concentrated. The integrin was then centrifuged 
for 10 minutes at 14,000 x g at 4 °C. The filtrate was discarded and the filter 
device was removed, inverted and placed in a new, clean tube. It was then 
centrifuged for 2 minutes at 1000 x g at 4 °C to recover all purified integrin 
IIb3. 
 
A protein quantitation assay (section 2.2.11) was performed to calculate the 
concentration of purified integrin IIb3. Note: the protein quantitation assay was 
not performed before the buffer exchange step as high concentrations of 
glycerol are known to interfere with this assay. The purified integrin IIb3 was 
subsequently found to be at a final concentration of 5 mg/ml. 
 
2.2.11 Protein quantitation assay 
The protein quantitation assay is a colorimetric assay used to determine protein 
concentration of a solution. It was carried out using the Bio-Rad DC (detergent 
compatible) Protein Assay kit. The principal of this particular assay is similar to 
that described by Lowry (Lowry et al, 1951). The concept on which it is based is 
a reaction of protein with an alkaline copper tartrate solution and Folin reagent. 
It is a two-step reaction where the protein initially reacts with copper in an 
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alkaline medium, and the Folin reagent is then reduced by the copper-treated 
protein resulting in a subsequent colour change. A standard curve is generated 
using concentrations of BSA (Bovine serum albumin prepared in the buffer in 
which the protein sample of interest is diluted) ranging from 0 – 1.5 mg/ml (0, 
0.2, 0.4, 0.6, 0.8, 1.0, and 1.5 mg/ml). The exact contents of the solutions are 
not specified by the manufacturer and are referred to as solution S and 
reagents A and B. Solution A’ was prepared by adding 20 l solution S to 1 ml 
reagent A. 20 l of solution A’ was added to each required well in a clear, 
96-well plate. Following this, 5 l of either BSA or the protein of interest was 
added to the wells. 200 l reagent B was then added and incubated for 15 
minutes at room temperature. The assay was carried out with each sample in 
triplicate. The absorbance of the samples was read on the Wallac plate reader 
at 690 nm. A standard curve was generated using GraphPad Prism® 5 software 
(Figure 2.7) and the concentration of the protein of interest was calculated from 
the equation of the line. Note the protein of interest may be diluted if it is thought 
to be very concentrated. If so, it was important to remember this dilution factor 
when calculating the final concentration of protein. 
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Figure 2.7 A representative BSA standard curve generated using the BioRad DC 
Protein assay. Known concentrations of BSA ranging from 0 – 1.5 mg/ml (5 l per 
sample, in triplicate) were incubated with 20 l Solution A’ and 200 l reagent B for 15 
minutes at room temperature. The absorbance was read on the Wallac plate reader at 
690 nm. A standard curve was generated by plotting the absorbance (at 690 nm) 
versus concentration of protein (mg/ml) using GraphPad Prism® 5 software. The 
concentration of unknown protein samples was calculated from the equation of the line: 
y = 0.1072x + 0.1033, r2 = 0.9367. 
 
 2.2.12 Determining the free thiol population of purified integrin IIb3 
The thiol population of purified integrin IIb3 was determined using a thiol 
detection reagent known as Thiostar®. This reagent was used as an alternative 
to DTNB, which was used in the platelet thiol population, due to its higher 
sensitivity and ability to measure low concentrations of thiols on proteins. 
Thiostar® is a commercial product, the exact chemical mechanism of which is 
not available. However, it is known to be converted to a brightly fluorescent 
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product upon reaction with thiols. This fluorescence can be measured at a 
wavelength between 475 nm and 570 nm, with an excitation wavelength of 
350 – 410 nm.  
 
Purified integrin IIb3 was incubated with GSH/GSSG redox potentials for 
10 minutes at 37 °C. The excess, unreacted redox reagents were then removed 
from the system using P6 Bio-Spin columns. This step was carried out in order 
to ensure the excess reduced glutathione (GSH) did not interfere with the 
assay. The P6 spin columns were prepacked with polyacrylamide size exclusion 
gel which allowed the integrin to pass through and left the contaminating redox 
reagents behind in the column. The columns were pre-hydrated with 10 mM Tris 
buffer which needed to be exchanged for buffer A (100 mM NaCl, 1 mM CaCl2, 
20 mM Tris-HCl, 0.1 % (v/v) Triton-X-100, pH 7.4). The original buffer was 
allowed to drain out by gravity initially, then 500 l buffer A was added to the 
column and centrifuged for 1 minute at 1000 x g at room temperature. This step 
was repeated four times ensuring ≥ 99.9 % buffer exchange according to the 
manufacturer’s instructions. 
 
Following incubation with the GSH/GSSG redox potentials, the integrin was 
centrifuged in the P6 spin columns, equilibrated with buffer A, for 4 minutes at 
1000 x g at room temperature. The integrin was recovered and incubated with 
1 mM, 3 mM or 5 mM manganese chloride (MnCl2) for 10 minutes at 37 °C. It 
was found that 3 mM MnCl2 caused a significant increase in integrin thiols and 
all subsequent experiments were carried out using 3 mM MnCl2 to activate 
integrin IIb3. The resting or activated integrin (10 g/ml), in the absence or 
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presence of GSH/GSSG redox potentials, was incubated with Thiostar® (2.5 
g/ml) for 5 minutes, at room temperature, in a black, clear bottom 96-well 
plate. The fluorescence was measured using the Wallac plate reader at 355/535 
nm. 
 
2.2.13 Chinese hamster ovarian-K1 (CHO-K1) cell culture 
Chinese hamster ovarian-K1 (CHO-K1) cells expressing platelet integrin IIb3, 
as previously described by Aylward et al (Aylward et al, 2006) were used in 
these studies. Two cell lines were employed: a mock transfected CHO-K1 cell 
line and a CHO-K1 cell line expressing integrin IIb3 with a KVGFFKR 
sequence in the IIb-subunit (referred to as FF cells). FF cells express integrin 
IIb3 in a native, resting conformation. All cell lines were grown in Nutrient 
Mixture F-12 (HAM) and Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10 % bovine calf serum, 375 g/ml Geneticin and 250 g/ml 
Zeocin. Cells were grown to 80 - 90 % confluency and either used in 
experiments or passaged (split), for further culturing. 0.025 % Accutase® 
solution was used during cell splitting as an alternative to trypsin in order to 
ensure the integrin expressed in the CHO-K1 cells remained intact.  
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2.2.14 Assessment of Chinese hamster ovarian-K1 (CHO-K1) cells by flow 
cytometry 
2.2.14.1 Assessment of levels of integrin IIb3 activation in Chinese 
hamster ovarian-K1 (CHO-K1) cells 
The Chinese hamster ovarian-K1 (CHO-K1) cells employed in this study were a 
mock transfected CHO-K1 cell line and a cell line expressing integrin IIb3 in a 
resting conformation (FF cells). When cells reached a confluency of 80 - 90 %, 
they were deemed suitable for use in experiments. Cells were removed from the 
cell culture flasks and transferred to a 50 ml plastic tube. Cells were centrifuged 
for 3 minutes at 1200 x g to pellet them. Cell culture media was removed and 
cells were resuspended in TBS (150 mM NaCl, 50 mM Tris (base), pH7.4).The 
cell count for all cell lines was adjusted, by addition of TBS, so that they were all 
at a similar concentration of approximately 3.0 X 106/ml. The levels of integrin 
expression in the CHO-K1 cells were checked using the monoclonal antibody 
CD41a, which binds to the IIb-subunit of integrin, conjugated to a FITC 
fluorophore. Cells were incubated with 10 l CD41a-FITC for 10 minutes at 
37 °C. The reaction was stopped by adding 1 ml TBS in 5 ml Falcon™ tubes. 
Samples were analysed on a Becton Dickinson FACSCalibur™ flow cytometer 
using CellQuest Pro software. The CHO-K1 cell population was gated, and 
3,000 events were analysed.  
 
The activation state of the integrin IIb3 expressed in the FF cells was 
assessed using the FITC-conjugated monoclonal antibody PAC-1. PAC-1 binds 
specifically to the active conformation of the integrin. FF cells were incubated 
with MnCl2 at final concentrations of 1 mM, 3 mM, and 5 mM for 10 minutes at 
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37 °C in the presence of 10 l PAC-1 antibody. The reaction was stopped by 
adding 1 ml TBS in 5 ml Falcon™ tubes. Samples were analysed on a Becton 
Dickinson FACSCalibur™ flow cytometer using CellQuest Pro software. The 
CHO-K1 cell population was gated, and 3,000 events were analysed.  
 
It was found 3 mM MnCl2 induced a significant increase in the level of PAC-1 
binding to FF cells, compared to untreated FF cells, therefore 3 mM MnCl2 was 
chosen as the optimal concentration and used in all subsequent experiments.  
 
2.2.14.2 Assessment of the effect of an altered external redox environment 
on integrin IIb3 activation in Chinese hamster ovarian-K1 (CHO-K1) cells 
 
CHO-K1 cells were prepared as described in section 2.2.14.1 and the cell count 
adjusted to 3 X 106/ml by addition of  TBS. FF cells were incubated with 
GSH/GSSG redox potentials (reducing (-264 mV), mean (-130 mV) and 
oxidising (-10 mV)) (section 2.2.7) for 10 minutes at 37 °C. FF cells were 
subsequently incubated with 3 mM MnCl2 for 10 minutes at 37 °C before 
stopping the reaction by adding 1 ml  TBS in 5 ml Falcon™ tubes. Samples 
were analysed on a Becton Dickinson FACSCalibur™ flow cytometer using 
CellQuest Pro software. The CHO-K1 cell population was gated, and 3,000 
events were analysed. 
 
 
 
 78 
2.2.15 Assessment of platelet adhesion and spreading using confocal 
microscopy 
Confocal microscopy is an imaging technique pioneered by Marvin Minsky in 
1955 (Minsky, 1988). The main principle upon which confocal microscopy is 
based, and what makes it superior to conventional microscopy, is that it focuses 
a point of light on a specimen and excludes most of the scattered light from the 
specimen that is not directly from the focal point. This ensures the majority of 
unwanted light is not collected, producing a sharper, better resolved image with 
enhanced contrast compared to that produced by conventional microscopy. The 
majority of modern confocal microscopy employs fluorescent imaging, whereby 
a specimen is stained or labelled with a fluorescent dye. The fluorescence 
emitted from the fluorophore when excited by a laser, at its specific wavelength, 
is filtered, collected and an image is generated (Figure 2.8). A pinhole is used to 
exclude the out of focus, unwanted light. The smaller the pin hole the more 
unwanted light is excluded. However, reducing the size of the pinhole too much 
can also limit the amount of light of interest from the sample. This problem may 
be addressed by increasing the excitation laser intensity, although this can, in 
turn, lead to problems, such as damage to the sample. Therefore, a balance 
needs to be struck between pinhole size and excitation laser intensity.  
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Figure 2.8 A schematic illustrating the basic set up of a confocal microscope. A 
specimen of interest is labelled, or stained, with a fluorescent dye. An excitatory laser 
light is focussed on the specimen through the microscopes objective lens. The 
fluorophore molecules absorb the light and its electrons are moved from ground state 
to a higher excited state. However, they are unstable in this excited state and quickly 
fall back to a ground state, releasing excess energy in the form of photons or 
fluorescence. This emitted light, or fluorescence, passes back through the objective 
lens, the dichroic mirror and the pinhole to the detector. The detector then sends the 
signal to a computer and an image, representing a thin cross-section of the specimen, 
is generated. (Image adapted from (Semwogerere, 2005)).  
 
Poly-L-lysine coated glass slides were cleaned with ethanol. The slides were 
coated with 1 % bovine serum albumin (BSA) in Tris buffered saline (TBS: 150 
mM NaCl, 50 mM Tris (base), pH7.4), 20 g/ml fibrinogen in TBS, or 1 g/ml 
collagen related peptide (CRP) in TBS, overnight at 4 °C. Slides were coated 
with 10 g/ml collagen overnight at room temperature. The slides were gently 
washed twice with TBS and then blocked with 1 % BSA in TBS for 1 hour at 
37 °C. Slides were washed gently with 0.1 % BSA in TBS, followed by another 
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wash with 0.1 % BSA supplemented with 1.8 mM CaCl2 for the BSA, fibrinogen 
and CRP coated slides or 2 mM MgCl2 for the collagen coated slides. The 
platelet count of washed platelets (prepared as described in section 2.1.1.2) 
was adjusted to 3.0 X 107/l. Washed platelets were incubated with GSH/GSSG 
redox potentials (reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV)) for 
10 minutes at 37 °C. Platelets were placed onto the slides and incubated for 45 
minutes at 37 °C. The slides were then gently washed twice with platelet buffer 
(MHPB) to remove non-adhered platelets. Samples were fixed with 1 % 
formaldehyde for 10 minutes at room temperature and gently washed twice with 
platelet buffer (MHPB). Platelets were permeabilised with 0.1 % (v/v) 
Triton-X-100 for 10 minutes at room temperature. Slides were washed gently 
three times with platelet buffer (MHPB). Platelets were then stained with Alexa 
Fluor® 488 phalloidin, in platelet buffer at a 1 in 100 dilution of the original stock, 
for 20 minutes at room temperature. Slides were gently washed three times with 
platelet buffer (MHPB). Glass cover slips were carefully cleaned and a drop of 
mounting media was placed onto a coverslip. The coverslip was carefully 
placed on the slide, at an angle in order to avoid any air bubbles being created. 
The slides were left at room temperature for 1 hour to allow the mounting media 
to dry, and then imaged immediately or stored at 4 °C for imaging at a later 
date. Confocal microscopy was carried out using a Zeiss LSM510 Meta 
confocal microscope. A 488 nm laser, at 1 % intensity was employed for the 
analysis of platelets stained with Alexa Fluor® 488 phalloidin. A 63X 
oil-immersion objective was used when obtaining confocal images. A bandpass 
(BP) 505-550 filter was used, along with a pinhole of 90m. 
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2.2.16 Examination of platelet thiol population by confocal microscopy 
Poly-L-lysine slides were coated as described in section 2.2.16. Washed 
platelets were prepared as outlined in section 2.2.1.2.  The platelet count was 
adjusted to 3.0 X 107/l. Platelets were placed onto the slides and incubated for 
45 minutes at 37 °C. The slides were gently washed twice with platelet buffer 
(MHPB) to remove non-adhered platelets. Samples were stained with 100 nM 
Atto 655 maleimide for 10 minutes at room temperature. Slides were washed 
gently three times with platelet buffer (MHPB). Samples were fixed with 1 % 
formaldehyde for 10 minutes at room temperature and then gently washed twice 
with platelet buffer. Glass cover slips were carefully cleaned and a drop of 
mounting media was placed onto a coverslip. The coverslip was then carefully 
placed on the slide, at an angle, in order to avoid any air bubbles being created. 
The slides were left at room temperature for 1 hour to allow the mounting media 
to dry, imaged immediately or stored at 4 °C for imaging at a later date. 
Confocal microscopy was carried out using a Zeiss LSM510 Meta confocal 
microscope. A 633 nm laser, at 30 % intensity was employed for the analysis of 
platelets stained with Atto 655 maleimide. A 63X oil-immersion objective was 
used when obtaining confocal images. A long pass (LP) 650 filter was used, 
with a pinhole of 122m. 
 
2.2.17 Analysis of platelet spreading by scanning electron microscopy 
(SEM) 
Scanning electron microscopy (SEM) is a powerful technique which uses 
electrons to generate an image of a specimen, in contrast to most imaging 
 82 
techniques that use light. SEM has a number of advantages over traditional light 
microscopy including having a greater depth of field, higher resolution and more 
control of the degree of magnification. The basic principle upon which SEM 
works is a beam of electrons, the incident beam, is focussed on a sample under 
high vacuum. When the beam hits the specimen electrons and x-rays are 
emitted, collected by a detector and an image is generated. The incident beam 
of electrons is produced by an electron gun, accelerated to a high voltage and 
focussed into a thin beam of electrons towards the specimen by 
electromagnetic lenses. Upon interaction with the specimen an energy 
exchange occurs between the incident electrons and the electrons of the 
specimen. This results in the release of elastically scattered high-energy 
electrons, secondary electrons by inelastic scattering and electromagnetic 
radiation. These signals can be amplified and collected by specialised 
detectors. These detectors transmit the signal to a computer where the image of 
the specimen is generated. The preparation of specimens, in particular 
biological samples, for SEM is very important. Since the chamber in the SEM is 
under high vacuum, samples should be fixed and all water must be removed. All 
non-metals also require coating with a conductive metal such as gold. This 
process is known as sputter coating. It involves placing the specimen in the 
vacuum chamber filled with argon gas and gold foil. An electric field causes an 
electron to be removed from the argon, leaving it with a positive charge which is 
attracted to the negatively charged gold. The argon ions then knock gold atoms 
from the surface of the gold foil which fall and settle on the specimen forming a 
thin gold coating on the surface. This advanced technology allows SEM to 
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generate clear, detailed and striking images superior to those produced by 
conventional microscopy.  
 
Round, glass coverslips (diameter (Ø) 16 mm) were pre-coated with 
poly-L-lysine. A 1 in 10 dilution of the original stock solution (in dH20) was 
placed on the cover slips for 5 minutes at room temperature, excess was 
removed and the cover slips were allowed to dry for 2 hours at 37 °C. Cover 
slips were coated with 1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen or 
1 g/ml CRP as described in section 2.2.16. Washed platelets were prepared 
as outlined in section 2.2.1.2. The platelet count was adjusted to 3.0 X 107/l. 
Platelets were placed onto the coverslips and incubated for 45 minutes at 
37 °C. The coverslips were gently washed twice with platelet buffer (MHPB) to 
remove non-adhered platelets. Samples were fixed with 1 % formaldehyde for 
10 minutes at room temperature. Samples were gently washed twice with 
platelet buffer and stored in platelet buffer until the dehydration process was 
carried out. Samples were dehydrated and washed in a series of acetone 
concentrations (30 %, 50 %, 75 %, 80 %, 85 %, 90 %, 95 % and 100 %) for 
15 minutes at room temperature. Samples were sputter coated with 
approximately 20 nm gold, using an Emitech sputter coater, and mounted for 
SEM imaging. Images were obtained using a Hitachi S3400n SEM operating at 
5 kV. 
 
2.2.18 Western blotting  
Western blotting is a technique widely used to identify proteins in a sample or 
identify post-translational modifications of a protein, such as phosphorylation. 
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Firstly, proteins are separated according to their apparent molecular weight by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Once separated the proteins are transferred from the polyacrylamide gel to a 
nitrocellulose or polyvinyl difluoride (PVDF) membrane, which is more stable 
and easier to handle for subsequent steps than the polyacrylamide gel. The 
membrane is blocked to ensure a uniform protein surface, preventing unwanted 
non-specific binding, and is subsequently probed with a specific antibody to the 
protein of interest. The membrane is then probed with a secondary antibody 
which binds specifically to the primary antibody. The secondary antibody is 
conjugated to a reporter enzyme, such as horse radish peroxidase (HRP), 
which plays a key role in the enhancement of the signal during the blot 
development through a chemiluminescence detection technique.  
2.2.18.1 Preparation of platelet lysates 
Gel-filtered platelets were prepared as outlined in section 2.2.1.1. The platelet 
count was adjusted to approximately 8 X 108/ml. This high platelet count was 
used to ensure a sufficient concentration of protein was generated for 
subsequent Western blotting. Platelets were unactivated or activated with either 
0.1U/ml thrombin, 50 ng/ml convulxin or 38 g/ml collagen, in the presence of 
GSH/GSSG redox potentials, prepared as outlined in section 2.2.7. The 
samples for gel electrophoresis were prepared using a platelet aggregation 
assay. The platelet aggregations were carried out in a Biodata Corporation 
PAP4 aggregometer at 37 °C with constant stirring at 1100 rpm and followed for 
10 minutes. At the 10 minute time point,  10X radioimmunoprecipitation assay 
(RIPA) platelet lysis buffer (0.5 M NaCl, 10 mM sodium orthovanadate 
(Na3VO4), 200 mM tetra sodium pyrophosphate (Na4P2O7.10H2O), 500 mM 
 85 
sodium fluoride (NaF), 10 % (v/v) Triton X-100, and 100 mM Tris pH 7.4) 
containing 10X protease inhibitor cocktail (100X protease inhibitor cocktail: 100 
mM AEBSF.HCl, 80 μM Aprotinin, 5 mM Bestatin, 1.5 mM E-64, 1 mM EDTA, 2 
mM Leupeptin, 1 mM Pepstatin A, in 95 % DMSO) was added to the 
aggregation tubes. RIPA lysis buffer was at a final concentration of 1X in the 
platelet lysate samples. Lysates were vortexed, and kept on ice for 1 hour with 
regular vortexing, approximately every 10 minutes. Platelet lysates were either 
used immediately or divided into aliquots and stored at -20 °C.  
2.2.18.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE)  
Sodium dodecyl sulphate polyacrilamide gel electrophoresis (SDS-PAGE) is a 
method used to separate proteins. SDS is an anionic detergent which means its 
molecules carry a net negative charge when dissolved in an aquatic solution. 
Polypeptide chains bind to SDS and the negative charge of the SDS, along with 
heating or reducing of the samples causes the denaturation of the proteins to 
their primary amino acid sequences. The SDS also negates any positive 
charges on the protein, thereby, rendering the protein completely negative in 
charge and linearised. These negatively charged proteins will all migrate 
towards a positive charge (anode) at the same rate when a constant electrical 
field is applied to the gel. However, in a polyacrylamide gel, large molecules will 
migrate at a slower rate than smaller molecules, due to the size of the pores in 
the gel. Smaller proteins pass through the pores with ease while the bigger 
proteins will experience some resistance and take longer for them to pass 
through. Therefore, combining SDS with a polyacrylamide gel, allows us so 
separate proteins according to their size, or relative molecular mass, only.  
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2.2.18.2.1 Preparation of SDS-PAGE gels 
SDS-PAGE mini gels, 10 %, were prepared in sealed 1.0 mm Bio-rad glass 
plates. The 10 % resolving gel solution was prepared, in a final volume of 14 ml 
(sufficient for two mini gels), by mixing 3.5 ml resolving buffer (1.5 M Tris, pH 
8.8, 0.4 % sodium dodecyl sulphate (SDS)), 5.8 ml 30 % acrylamide and 4.7 ml 
dH2O. This solution was incubated for 5 minutes at 37 °C. Immediately before 
pouring the gel, 82 l 10 % (w/v) ammonium persulfate (APS) and 7.8 l 
tetramethylethylenediamine (TEMED) were added to the solution. The resolving 
gel was poured to approximately 2.5 cm from the top of the glass plate. 
Approximately 3 ml dH2O was carefully placed on top of the gel. The gel was 
allowed to polymerise for 1 hour at room temperature. The stacking gel (4.5 %) 
was prepared by mixing 3.75 ml stacking buffer (0.5 M Tris, pH6.8, 0.4 % SDS), 
2.25 ml 30 % acrylamide and 9 ml dH2O. The gel solution was incubated for 5 
minutes at 37 °C. Immediately before pouring the stacking gel, 110 l 10 % 
(w/v) APS and 15 l TEMED were added to the solution. The dH2O was 
carefully removed from the top of the resolving gel. The stacking gel was gently 
poured on top of the resolving gel and a 10 lane (1.0 mm) comb was carefully 
inserted, at an angle in order to avoid forming air bubbles. The gel was left to 
polymerise for 1 hour at room temperature. 
2.2.18.2.2 Preparation of samples and SDS-PAGE 
A protein assay, as described in section 2.2.11, was performed to measure the 
protein concentration in the platelet lysates. The assay was carried out using 
the Bio-Rad DC Protein Assay kit. In brief, a stock solution of 15 mg/ml bovine 
serum albumin (BSA) was prepared in 1X RIPA lysis buffer. BSA at 
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concentrations ranging from 0 – 1.5 mg/ml (5 l per sample, in triplicate) were 
incubated with 20 l Solution A’ (1 ml reagent A + 20 l solution S) and 200 l 
reagent B for 15 minutes at room temperature. The absorbance was read on 
the Wallac plate reader at 690 nm. A standard curve was generated by plotting 
the absorbance (at 690 nm) versus concentration of protein (mg/ml) using 
GraphPad Prism® 5 software. The concentration of the unknown platelet lysates 
was calculated from the equation of the line.  
 
Having found the concentration of protein present in the platelet lysates, the 
volume required for an equal loading of 20 g of protein per lane was 
calculated. This volume of platelet lysate was incubated with 5X reducing 
sample buffer (312.5 mM Tris, 5 % (w/v) SDS, 20 % (v/v) glycerol, 0.25 % (w/v) 
bromophenol blue, 2 % (w/v) dithiothreitol (DTT)), such that the final 
concentration of sample buffer was 1X, for 5 minutes at 95 °C. Samples were 
loaded in their respective lanes, along with 10 l molecular weight marker in 
lane 1. Any empty lanes were loaded with sample buffer in order to keep the gel 
balanced while running. Gels were set up in the electrophoresis rig with running 
buffer (192 mM glycine, 25 mM Tris, 0.1 % (w/v) SDS) and run at a constant 
voltage of 100 V for approximately 1 hour.   
2.2.18.3 Coomassie Blue staining of SDS-PAGE gel 
Following electrophoresis, gels were stained to visualise the protein in the 
samples and examine them for any degradation or differences in protein loading 
between samples. Gels were stained with a sensitive Coomassie Blue solution 
(10 % (v/v) phosphoric acid, 10 % (w/v) ammonium sulphate, 0.12 % (w/v) 
Coomassie Blue Brilliant, 20 % (v/v) methanol) overnight at room temperature 
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with gentle rocking (Candiano et al, 2004). A destain step was subsequently 
carried out to remove the stain from the gel so the blue stained protein bands 
could be visualised more clearly. This was carried out by placing the stained gel 
into a destain solution A (40 % (v/v) methanol, 7 % (v/v) acetic acid) overnight 
at room temperature with gentle rocking. The gel was then placed in a destain 
solution B (5 % (v/v) methanol, 7 % (v/v) acetic acid) for three hours at room 
temperature with gentle rocking. The gel was stored in dH2O and imaged. 
2.2.18.4 Protein transfer 
Following SDS-PAGE, the gel, containing the now separated protein bands was 
equilibrated in transfer buffer (192 mM glycine, 25 mM Tris, 20 % (v/v) 
methanol). The equilibrated gel was next placed in a cassette in a ‘sandwich’ as 
illustrated in Figure 2.9. The sponges, filter paper and membrane were all 
equilibrated in transfer buffer. The polyvinyl difluoride (PVDF) membrane was 
pre-activated for 1 minute in 100 % methanol before equilibration in transfer 
buffer. The cassette was placed in the transfer rig in transfer buffer, with an ice 
pack to prevent the generation of Joule heating. The transfer was carried out for 
1 hour at a constant voltage of 100 V at room temperature. Alternatively, the 
transfer could be carried out overnight at 4 °C at a constant voltage of 30 V.  
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Figure 2.9 A schematic illustrating the set-up of the transfer cassette ‘sandwich’. 
A transfer cassette (BioRad) was opened and a sponge was placed on the black side 
(negative side), followed by two pieces of filter paper, all equilibrated in transfer buffer. 
The gel was carefully removed from the glass plates in which the SDS-PAGE was 
carried out, equilibrated in transfer buffer and then placed on top of the filter paper. A 
piece of PVDF membrane, activated for 1 minute in 100 % methanol and equilibrated in 
transfer buffer, was placed on top of the gel. Any air bubbles that may have been 
trapped between the gel and membrane were rolled out. Two more pieces of filter 
paper were placed on the membrane, followed by another sponge; again all were 
equilibrated in transfer buffer. The cassette was then closed and placed in the transfer 
rig, ensuring that the black side of the cassette was towards the black side of the rig, 
indicating the transfer of proteins in a negative to positive direction. 
 
2.2.18.5 Probing with vasodilator stimulated phosphoprotein (VASP) 
antibodies 
Following the protein transfer, the membrane (which now contains the 
immobilised proteins) can be stained with Ponceau S to check if the proteins 
transferred correctly from the SDS-PAGE gel. If this step was carried out, the 
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membrane was stained with Ponceau S solution (0.1 % (w/v) Ponceau S in 5 % 
(v/v) acetic acid) for 5 minutes at room temperature with gentle rocking. The 
protein bands were stained a red colour if the transfer worked correctly. The 
membrane was then washed with TBS for 10 minutes at room temperature. 
This step was repeated with fresh TBS until all red staining was removed.  
 
The membrane was then blocked in 3 % BSA (in TBS-T: TBS with 0.1 % (v/v) 
Tween-20) for 1 hour at room temperature with gentle rocking. The membrane 
was probed with the primary antibody (VASP A290 (total VASP), 
phospho-VASP (Ser157) or phospho-VASP (Ser239) antibody). All of the VASP 
antibodies were polyclonal antibodies produced by rabbits. In all cases, the 
primary antibody was made at a 1:1000 dilution in 3 % BSA (in TBS-T). The 
membrane was incubated with the primary antibody, in a sealed plastic bag, on 
a rotator, overnight at 4 °C. 
 
Following incubation with the primary antibody the membrane was washed 
three times for 5 minutes with TBS-T. The secondary anti-rabbit antibody 
(conjugated to horse radish peroxidase (HRP)) was prepared at a dilution of 
1:10,000 in 3 % BSA (in TBS-T). The membrane was then incubated with the 
secondary antibody for 2 hours at room temperature, with gentle rocking. After 
two hours the membrane was washed for 3 X 5 minutes with TBS-T. This was 
followed by washing by 3 X 5 minutes with dH2O.  
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2.2.18.6 Developing the Western blots 
The blot was developed using SuperSignal West Pico Chemiluminescent 
Substrate. This is a luminol based substrate which emits light in the form of 
luminescence in the presence of the HRP conjugated to the secondary 
antibody. There are also chemical enhancers present in this particular substrate 
which intensify the light emission. This is referred to as enhanced 
chemiluminescence (ECL). There are two reagents present in the kit, a 
luminol/enhancer and a stable peroxide buffer. 1 ml of each reagent was mixed 
together and incubated with the membrane for 2 – 5 minutes. The excess 
solution was removed from the membrane and the membrane was placed in the 
AutoChemi™ UVP Bioimaging system. The system was set to take 30 images 
over a 40 minute period and a final image of all 30 combined was then 
generated.  
 
2.2.19 Statistics 
Statistical analyses were performed using GraphPad Prism® 5 software. One-
way Anova, repeated measures tests with a Bonferroni post-hoc analysis were 
performed on the data, unless otherwise stated. Data was expressed as the 
mean ± SEM and a value of p < 0.05 was considered statistically significant. 
Principal component analysis (PCA) was used for the analysis of the Raman 
spectroscopy data (as described in section 2.2.6). 
  
 
Chapter 3 
The role of thiols in integrin activation 
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3.1 Introduction 
Integrins are a family of adhesion molecules which comprise a large portion of 
platelet surface receptors and are available to mediate interactions between 
platelets and their extracellular environment. Platelets possess three families of 
integrins, with a total of six different integrins present in total, namely 21, 51, 
61, L2, V3 and IIb3. Integrin IIb3 is one of the major integrins present 
on platelets, with approximately 80,000 – 100,000 copies per platelet. As 
integrin IIb3 is the critical player in platelet aggregation, through its interaction 
with the plasma protein fibrinogen, extensive research has been conducted to 
reveal the intricacies of integrin activation. The vast number and highly 
conserved nature of cysteine residues present in integrins’ subunits structure is 
indicative of the significant role of thiol groups have in integrins’ function. 
Indeed, the pairing of these residues to form disulphide bonds has been shown 
to be essential for the structural integrity of the receptor (Calvete, 1999; Calvete 
et al, 1991; O'Neill et al, 2000). In a study in 2000, Yan and Smith investigated 
the on/off switch commonly associated with integrin IIb3 activation. They 
uncovered a redox site in a domain of approximately 200 residues that 
essentially encompassed the cysteine-rich domain of the 3-subunit. Free, 
unpaired cysteines were located within this region. They also showed there was 
an overall net reduction of one disulphide bond associated with a change in the 
activation state of the integrin (Yan & Smith, 2000). Furthermore, in 2001 they 
demonstrated that DTT reduces two disulphide bonds leading to global 
conformational changes in both integrin subunits. Selective mutation of critical 
cysteine residues within integrin IIb3 has been demonstrated to induce a 
 94 
constitutively active conformation of the integrin, particularly the long-range thiol 
bond between Cys5 and Cys435 (Sun et al, 2002). 
 
Previous studies in our laboratory used purified integrin IIb3, in a cell-free 
system, to investigate the relationship between thiol/disulphide groups and the 
activation state of integrin IIb3. It was demonstrated that both integrin IIb3 
and v3 have endogenous thiol isomerase activity, due to the presence of nine 
CXXC motifs within the -subunit. The function of this thiol isomerase activity is 
still not clear. However, inhibition of its activity with the pharmacological inhibitor 
bacitracin, led to disruption of both integrin activation and platelet aggregation 
(O'Neill et al, 2000). This endogenous thiol isomerase activity, and 
consequently integrin activation, could be induced by manganese chloride 
(MnCl2) and modulated by nitric oxide (NO) and glutathione (GSH) (Walsh et al, 
2004).  Subsequently, a direct interaction between thiols in integrin IIb3 and 
NO, termed S-nitrosylation, was revealed to induce thiol/disulphide shuffling. 
This reinforces the importance of thiol groups in the regulation of both the 
activation and deactivation of integrin IIb3  (Walsh et al, 2007).  
 
In this chapter, I will further investigate the role of thiol groups in purified 
integrin IIb3 in a cell-free system and explore the impact of an altered redox 
environment on this thiol population. I will use Chinese hamster ovarian-K1 
(CHO-K1) cells expressing integrin IIb3 as a model cell system to study the 
activation status of the integrin and the impact of the external redox 
environment in the regulation of integrin activation. The CHO-K1 cell line used 
in the study is as described previously by Aylward et al (Aylward et al, 2006). 
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Briefly, a mock transfected CHO-K1 cell line was used along with the CHO-K1 
cell line expressing integrin IIb3. These cells express integrin in a constitutively 
resting conformation, thereby making it possible to observe the effects of 
treatment with MnCl2 and the effect of the presence of redox potentials on the 
integrin activation state. Subsequently, I will examine the effects of MnCl2, 
dithiothreitol (DTT) and thrombin on platelet activity using platelet function tests. 
Additionally, I will investigate the impact of these activators on platelet structure 
at a molecular level using Raman spectroscopy. MnCl2 and DTT are both well 
established integrin IIb3 moderators, while thrombin is a potent platelet 
agonist. The potency of thrombin will be useful in this study, as platelet activity 
induced by MnCl2 and DTT can be measured relative to the level of platelet 
activity brought about by thrombin stimulation. 
 
()-thrombin, also known as coagulation factor II, is a coagulation protein. It is a 
trypsin-like serine protease that converts soluble fibrinogen into insoluble fibrin. 
It also catalyses and potentiates many other reactions in the coagulation 
cascade by activating Factors V, VIII, XI and XIII. Thrombin is formed through 
the cleavage of two sites on the vitamin K-dependent zymogen prothrombin. 
This cleavage is performed through the action of a prothrombinase complex, 
which is composed of activated Factor X bound to Factor V. Thrombin is 
composed of 2 chains, an A and a B chain. The A chain is composed of 36 
residues and is non-essential for proteolytic activities, while the three active site 
amino acids of thrombin are found amongst the 259 residues of the B chain. 
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Thrombin is a potent platelet activator and plays a critical role in promoting 
thrombus formation (McNicol & Gerrard, 1993). It initiates platelet 
degranulation, aggregation and indirectly activates the integrin IIb3 through the 
activation of a number of signalling cascades. Thrombin is also involved in the 
process of platelet shape change upon activation. Thrombin activates platelets 
predominantly through the G-protein-coupled protease-activated receptors 
(PARs) PAR-1 and PAR-4, and through the GPIb-IX-V complex. PARs are 
seven transmembrane domain receptors which are activated by a proteolytic 
cleavage at a specific site in the N-terminal extracellular domain.  
 
The GPIb-IX-V complex on the platelet surface also has a high affinity binding 
site for thrombin located at the N-terminal region of the GPIb subunit. It is well 
established that patients suffering from Bernard-Soulier syndrome, which lack 
GPIb-IX-V, have impaired responses to thrombin (Clemetson & Clemetson, 
1994). However, the involvement of the GPIb-IX-V complex in thrombin 
activation is controversial. While it has been found that GPIb has a key role in 
platelet activation by thrombin, particularly at low doses, the exact nature of the 
interaction remains unclear (Dormann et al, 2000). Elucidation of the crystal 
structure of the GPI-thrombin complex also further reconciles the important 
role of this interaction in platelet activation and in particular in the process of 
platelet aggregation (Dumas et al, 2003).  
 
Dithiothreitol (DTT), also known as Cleland’s reagent, is a strong reducing 
agent, due to its low redox potential of -330 mV at pH 7.0. It is a small, 
water-soluble molecule that readily crosses biological membranes. Due to its 
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potent reducing powers DTT is often used to reduce disulphide bonds in 
proteins or peptides. The reduction of a typical disulphide bond is shown in 
Figure 1.5. 
 
Although DTT induces platelet aggregation, little is known about the 
mechanisms involved in activation of platelets by DTT. It is hypothesised that 
DTT is not capable of initiating full integrin activation (Yan & Smith, 2000). 
However, it does induce conformational changes in integrin IIb3, and 
potentially other platelet receptors, resulting in platelet aggregation (MacIntyre, 
1974; Margaritis, 2011; Zucker & Masiello, 1984).  
 
Manganese chloride (MnCl2) is the universal integrin activator, the exact 
mechanism of which is yet to be fully elucidated. In general, integrins exhibit low 
ligand affinity and require activation in order to interact with their respective 
ligands (Hynes, 1992). It is believed conformational changes accompany 
integrins transition to a high affinity binding state. Studies indicate the I-domain 
of integrins is likely to be involved in the conformational changes observed in 
the activation of integrins (Landis et al, 1994; McDowall et al, 1998). The 
presence of a conserved divalent cation binding site in the I-domain suggests a 
role for divalent cations such as Mg2+ and Mn2+. The determination of the crystal 
structure of integrins led to major advances in understanding the mechanism of 
ligand binding to integrins and the role of the cation binding sites. These cation 
binding sites have been termed as metal ion-dependent adhesion sites or 
MIDAS (Humphries et al, 2003). However, the relationship between cation 
binding, integrin ligand binding and integrin conformation remains unclear. 
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Studies of integrin IIb3, specifically, have shown that Mn
2+ does indeed induce 
an active-like conformation, which in turn increases ligand binding.  Previous 
studies in our laboratory have found that Mn2+ induces key conformational 
changes in integrin IIb3 (Walsh et al, 2007). Raman spectroscopic analysis 
revealed that Mn2+ treatment of purified integrin IIb3 leads to a shift in the 
amide I feature to a lower frequency in the spectrum and also a shift in the 
disulphide stretch envelope to a higher frequency, indicating a reduction in 
strain in cysteine sites.  These findings confirm the importance of divalent 
cations in integrin activity. Mn2+ cations can also induce the endogenous thiol 
isomerase activity of integrin IIb3 (Walsh et al, 2004). 
 
Raman spectroscopy (RS) is one of few techniques that can unambiguously 
detect the presence of thiols and disulphide bonds in proteins (Pelton & 
McLean, 2000). This makes Raman an ideal tool to analyse thiol/disulphide 
events occurring on the surface of platelets in response to stimulation with 
platelet activators 
 
RS is an optical technique used in the determination of molecular structure. It 
was discovered in 1928 by Sir Chandrasekhra Venkata Raman (Raman, 1928). 
It is based on the analysis of the frequency of scattered light from the interaction 
of monochromatic light with a sample. The data generated yields vibrational 
information that is specific for each chemical bond within the molecule. 
 
A Raman spectrum is generated by plotting the intensity versus the frequency 
of the shifted light. The frequency shift is measured by wavenumber and is 
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expressed as an inverse unit of length, i.e. cm-1. The spectrum is usually plotted 
so that the Rayleigh scattering occurs at 0 cm-1. The Raman spectrum can then 
be analysed to determine the molecular composition in this case, of platelets. 
The energy required to excite the molecular vibrations depends on the 
molecular mass and the type of chemical bonds within the molecule (Krafft, 
2003). Therefore, the position and relative intensity of peaks in the spectra 
correspond to different chemical bonds (Table 3.1).  
 
Table 3.1 Peak position and assignment of main Raman vibrational modes (Lyng 
et al, 2007) 
 
Peak position (cm-1) Assignment 
622 C-C twisting 
724 CH2 deformation 
746 CH2 rocking 
754 Symmetric ring breathing 
779 Ring vibration 
832 CCH deformation aliphatic 
853 CCH deformation aromatic 
873 CC stretch 
922 C-C stretching 
1004 CC aromatic ring breathing 
1034 C-C stretching 
1065 C-N stretch 
1096 C-C chain stretching 
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1098 CC stretch 
1102 CC stretch 
1124 CC skeletal stretch trans 
1214 
CC stretch backbone carbon 
phenyl ring 
1236 
CN stretch, NH bending amide III 
band 
1240 
CN stretch, NH bending amide III 
band 
1314 CH deformation 
1337 CH2 deformation 
1335 CH2 deformation 
1366 CH2 bending 
1440 CH2 scissoring 
1484 CH2 deformation 
1548 
NH deformation; CN stretch amide 
II band 
1578 C=C olefinic stretch 
1585 C=C stretching 
1602 CO stretching 
1660-1665 C=O stretch amide I -helix 
2930 CH2 stretching 
2932 CH3 symmetric stretch 
 
 
RS has been traditionally used for the analysis of chemical samples and their 
composition. However, using RS as a tool to study biological and cellular 
samples is becoming increasingly popular. Platelet activation leads to structural 
modifications and, ultimately, conformational changes in platelet proteins. Along 
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with thiol/disulphide groups, other features of interest when analysing the 
Raman spectra of platelets include amide I (1630 -1700 cm-1) and amide III 
(1230 -1310 cm-1) (amide II has a very weak Raman signal). Additionally, the 
-helix and -sheet content of the proteins can be examined as changes in the 
relative abundance of each structure type may be detected by RS. Amide III is 
particularly sensitive to structural changes and is a promising region by which to 
estimate secondary structure. 
 
The objective of this aspect of the study is to obtain signature Raman spectra of 
unactivated platelets and platelets stimulated with various activators. Any 
changes that are observed in the spectra upon analysis may be attributed to a 
change in the molecular structure of the platelet membrane as a result of 
platelet activation. It is anticipated these studies will not only further our 
knowledge of key structural components of platelets but may also potentially 
uncover a platelet surface biomarker or a number of biomarkers associated with 
platelet activation that can be exploited in the development of Raman 
spectroscopy as a novel technique for the assessment of platelet activation 
states. 
3.2 Results 
3.2.1 The effects of protein concentration and buffer exchange on purified 
integrin IIb3  
Commercially available purified integrin IIb3 was used in these studies. 
Initially, the purified integrin was concentrated using micro-centrifugal filters and 
subsequently a buffer exchange step was carried out in order to remove 
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glycerol from the system. These manipulations of the integrin did not impact on 
the integrity of the protein. This was confirmed by running 20 g of purified 
integrin on a 7.5 % polyacrylamide gel and staining it with a sensitive 
Coomassie Blue stain. Bands corresponding to the IIb- and 3-subunits were 
stained and there was an absence of any other low-molecular weight bands 
which could be indicative of degradation of the protein (Figure 3.1 (a)). 
Additionally, a Western blot analysis of the integrin was also performed. The 
integrin was transferred from the polyacrylamide gel to a polyvinyl diflouride 
(PVDF) membrane and probed with SZ.22, an antibody specific for the IIb-
subunit of the integrin. It was demonstrated that the IIb-subunit was indeed 
present and intact (Figure 3.1 (b)).  
 
3.2.2 The effect of manganese chloride (MnCl2) on the thiol population of 
integrin IIb3 
The concentration of purified integrin was determined using a protein 
quantitation assay. The thiol population of the integrin was measured in an 
assay using the commercially available fluorescent thiol detection reagent 
Thiostar®. It was established that integrin at a concentration of 10 g/ml was the 
minimal concentration of integrin which contained a significant, detectable 
number of thiols in this particular assay (n=4, *p < 0.05, **p < 0.01) (Figure 3.2). 
Therefore, all subsequent purified integrin studies used an integrin 
concentration of 10 g/ml.  
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Manganese chloride (MnCl2), an established universal integrin activator, was 
used to examine the effects of integrin activation on the thiol population of 
integrin IIb3. Treatment with 3 mM MnCl2 induced a significant increase in the 
number of free thiols present in the integrin, compared to unactivated integrin 
(n=5, *p < 0.05) (Figure 3.3).  
 
3.2.3 The effect of GSH/GSSG redox potentials on the thiol population of 
integrin IIb3 
The redox environment of integrin IIb3 was altered by glutathione 
(GSH/GSSG) redox potentials. These redox potentials were generated by 
combining reduced (GSH) and oxidised (GSSG) in various ratios according to 
the Nernst equation and as outlined in Tables 2.1 and 2.2. The effects of a 
reducing (-264 mV), mean (-130 mV) and oxidising (-10 mV) redox environment 
were investigated. There was no significant effect of any of the redox potentials 
on the thiol population of unactivated integrin IIb3. Interestingly, the oxidising 
and mean redox potentials reduced the increase in the thiol population induced 
by treatment with 3 mM MnCl2 while the reducing redox potential completely 
abolished this increase (n=5) (Figure 3.4).  
 
3.2.4 The effect of manganese chloride (MnCl2) on integrin IIb3 expressed 
in Chinese hamster ovarian (CHO)-K1 cells 
Chinese hamster ovarian (CHO)-K1 cells expressing integrin IIb3 were used 
as a model cell system to further investigate the mechanisms of integrin 
activation. Two cell lines were employed in the study: a mock transfected 
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CHO-K1 cell line and CHO-K1 cells expressing native integrin IIb3, termed FF 
cells. The expression of integrin IIb3 in the FF cell line was confirmed by flow 
cytometry using CD41a, an antibody specific for the IIb-subunit of the integrin. 
There was a significant increase in integrin expression on FF CHO-K1 cells 
compared to mock CHO-K1 cells (n=3, **p < 0.01) (Figure 3.5). Furthermore, it 
was confirmed that the FF CHO-K1 cell line does indeed express integrin in an 
unactivated conformation using the monoclonal antibody PAC-1, which binds 
only to integrin IIb3 in an activated conformation (n=3) (Figure 3.6).  
 
A concentration-response study investigating the effect of MnCl2 on the 
activation status of integrin IIb3 in FF CHO-K1 cells was carried out. There 
was a significant increase in PAC-1 binding to FF cells upon stimulation with 
3 mM and 5 mM MnCl2 compared to untreated FF cells (n=3, **p < 0.01 and 
***p < 0.001 respectively) (Figure 3.7). Thereby, confirming MnCl2 as an integrin 
IIb3 activator.  
 
3.2.5 The effect of GSH/GSSG redox potentials on integrin IIb3 expressed 
in Chinese hamster ovarian (CHO)-K1 cells  
The external redox environment of FF CHO-K1 cells was altered by glutathione 
(GSH/GSSG) redox potentials. These redox potentials were generated by 
combining reduced (GSH) and oxidised (GSSG) in various ratios according to 
the Nernst equation and as outlined in Tables 2.1 and 2.2. The effects of a 
reducing (-264 mV), mean (-130 mV) and oxidising (-10 mV), environment on 
integrin IIb3 expressed in CHO-K1 cells were investigated. FF cells were 
incubated with the GSH/GSSG redox potentials, and subsequently treated with 
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3 mM MnCl2. The activation state of integrin IIb3 expressed by the FF cells 
was assessed with the monoclonal antibody PAC-1 using flow cytometry.  An 
oxidising redox environment had no significant effect on the level of PAC-1 
binding to FF cells activated by 3 mM MnCl2. A mean redox environment 
decreased PAC-1 binding, while a reducing redox environment almost 
completely inhibited PAC-1 binding induced by 3 mM MnCl2 (n=3, *p < 0.05, 
**p < 0.01 respectively) (Figure 3.8). 
 
3.2.6 The effects of manganese chloride (MnCl2), dithiothreitol (DTT) and 
thrombin on platelet function 
Platelet aggregation studies to generate concentration-response curves for 
manganese chloride (MnCl2) and dithiothreitol (DTT) were carried out with the 
following concentrations: 0 mM (unactivated platelets), 1 mM, 3 mM and 5 mM.  
Platelet aggregation of approximately 10 % and 40 % was induced by 
3 mM MnCl2 and 3 mM DTT, respectively. It indicated 3 mM was the lowest 
concentration of each activator to induce a significant level of platelet 
aggregation compared to unactivated platelets (n=4, **p < 0.01 and *p < 0.5 
respectively) (Figure 3.9). Therefore, 3 mM was the concentration of both MnCl2 
and DTT chosen for further studies. Platelets did not aggregate in the absence 
of an activator. In additional studies gel-filtered platelets activated with either 
1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT induced platelet aggregation to 
levels of approximately 80 %, 7 % and 40 % respectively (n=9) (Figure 3.10).  
Using flow cytometry, the levels of PAC-1 binding to unactivated gel-filtered 
platelets or platelets treated with either 1U/ml thrombin, 3 mM MnCl2 and 3 mM 
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DTT were assessed. Levels of binding were expressed as percentage gated 
relative to an arbitrary 2 % gate placed on unactivated platelets. Platelets 
activated with 1U/ml thrombin, 3 mM MnCl2 and 3 mM DTT resulted in 
activation of integrin IIb3 as indicated by PAC-1 binding at levels of 
approximately 70 %, 15 % and 30 % respectively (Figure 3.11).  
Platelet activation results in secretion of P-selectin from -granules, which is 
then expressed on the platelet surface, thereby acting as a surface marker for 
platelet activation.  Platelet secretion induced by 1U/ml thrombin, 3 mM MnCl2 
and 3 mM DTT was assessed by using the monoclonal antibody CD62P to 
measure the levels of P-selectin expressed on the surface of platelets. Levels of 
CD62P binding were expressed as percentage gated relative to an arbitrary 2 % 
gate placed on unactivated platelets. A significant level of CD62P binding was 
observed in platelets activated with thrombin, compared to unactivated platelets 
(n=4, ***p < 0.001). MnCl2 and DTT did not induce any P-selection secretion as 
there was no statistically significant difference in the levels of CD62P binding to 
platelets treated with MnCl2 and DTT compared to unactivated platelets (n=4) 
(Figure 3.12).  
The data for PAC-1 and CD62P binding to gel-filtered platelets treated with 
1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT is summarised in Table 3.1.  
3.2.7 The optimal conditions for obtaining Raman spectra of gel-filtered 
platelets  
Before the Raman spectroscopic analysis of platelets treated with various 
activators was carried out, a number of factors needed to be taken into 
consideration in order to ensure optimal conditions for the study. One such 
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condition was the acquisition time, i.e. the total time required to collect a Raman 
spectrum. Initially, I employed a relatively long acquisition time of 200 seconds 
which caused bleaching of major peaks, especially the carotenoid peaks. This 
implied that the platelet sample being exposed to the laser for long periods of 
time induced photochemical damage. To avoid this, a shorter acquisition time of 
25 seconds was employed for all subsequent experiments (Figure 3.13).  
A number of substrates on which to place the platelets when acquiring Raman 
spectra were tested. Glass coverslips were chosen as they do not have a large 
Raman signal and therefore, background signal was minimal. While glass is a 
known activator of platelets, this was not considered to be an issue due to the 
platelets being fixed before being placed on the glass. Other substrates which 
were considered included poly-L-lysine coated slides and Surface Enhanced 
Raman Spectroscopy (SERS) surfaces. SERS was carried out on flourine-
doped tin oxide (FDTO) coated glass slides upon which gold nanoparticles were 
immobilised (Sheridan, 2007), or on slides with gold nanocavities which were 
formed  by electrodepositing gold around polystyrene spheres, then removing 
the spheres (Jose et al, 2009). The nanocavities were approximately the same 
size as platelets, 3 - 4 µm in diameter (Figure 3.14), while the nanoparticles 
were smaller in size (< 100 nm). Neither of these surfaces gave a significant 
enhancement of the Raman signal of the platelets compared to platelets on 
glass cover slips and it was therefore decided to continue using glass cover 
slips (Figure 3.15).  
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3.2.8 The effects of thrombin, manganese chloride (MnCl2) and 
dithiothreitol (DTT) on platelet molecular structure assessed by Raman 
spectroscopy 
Platelets remained unactivated or activated with either 1U/ml thrombin, 3 mM 
MnCl2 or 3 mM DTT and Raman spectra were obtained. Upon inspection of the 
data, small spectral differences between the platelet samples can be observed. 
However, these differences are not clearly distinguishable from each other. This 
is an obstacle which is seen across the board with Raman analysis of biological 
samples due to their complexity. Therefore, principal component analysis (PCA) 
was carried out on the data in order to determine if unactivated platelets could 
be differentiated from activated platelets and also to analyse any molecular 
differences between platelets treated with the various activators. PCA is a 
multivariate statistical technique which employs mathematical formulae to 
describe major trends in data of high dimensions. The spectra were baseline 
subtracted and normalised using Origin® software before PCA analysis. All 
spectra were normalised to a lipid peak at approximately 3000 cm-1. This peak 
was chosen as there was very little variation in this peak regardless of the 
platelet activation state.  
A full signature, or ‘finger print’, Raman spectrum of platelets treated with each 
activator was obtained by averaging 3 - 5 spectra from each spectra sample 
from all donors together (n=4) (Figure 3.16 (a)).  
PCA was carried out on all of the spectra. There was clear separation of the 
platelets samples based on the platelet activator (Figure 3.16 (b)). The principal 
components used to construct this scatter plot are illustrated in Figure 3.16 (c). 
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The principal component loadings represent the correlation between the 
principal components and the original data. Plotting the loadings of the principal 
components as a function of the wave number gives an indication of the 
position at which the variation between samples arises within the original 
spectra. This analysis encompassed the full platelet spectrum. However, what 
this analysis does not tell us is where exactly, in terms of molecular structure, 
the differences between platelet samples arise. In an attempt to answer this 
question, the regions in which I anticipated molecular modifications to occur 
were examined in more detail. The regions focused on were: thiol 
(2550 - 2600 cm-1) (Figures 3.17 (a-c)); disulphide (470-530 cm-1) (Figures 3.18 
(a-c)); amide I (1630 - 1700 cm-1) (Figures 3.19 (a-c))) and amide III 
(1230 - 1310 cm-1) (Figures 3.20 (a-c)) stretches. The regions of interest were 
extracted from the full spectrum and PCA was performed specifically on these 
data.  
 
The thiol region of the platelet Raman spectrum stretches from approximately 
2550 - 2600 cm-1 (Figure 3.17 (a)). The PCA analysis of this region separated 
the platelet samples into well-defined clusters based on the platelet activation 
state (Figure 3.17 (b)). As shown in Figure 3.17 (a), there is a lot of background 
noise associated with this region. When the PCA results were examined, it was 
found that PC-1 accounted for a lot of this noise, therefore, the lower 
components PC-2 and PC-3 were used to generate the score plot. The loadings 
of PC-2 and PC-3 are shown in Figure 3.17 (c). 
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Based on the distinct clustering in the thiol region, I anticipated complementary 
results in the disulphide region because of the strong relationship between thiol 
and disulphide groups. The disulphide region is located at approximately 
470 - 530 cm-1 in the Raman spectrum. As this region is quite narrow, I 
therefore, chose a slightly larger region to analyse (Figure 3.18 (a)). The Raman 
signal in this region is relatively low while the noise in the region is quite high. 
Despite this and although the samples are all located close together, there is an 
obvious clustering of samples based on the platelet activation state 
(Figure 3.18 (b)). Figure 3.18 (c) demonstrates the loading of the principal 
components plotted in the score plot. 
 
The amide I and III regions were focussed on due to the potential protein 
structural information that may be found therein. The amide I region extends 
from 1630 - 1700 cm-1 in the Raman spectrum (Figure 3.19 (a)). Again, there is 
noticeable clustering of samples based on the activator used to activate the 
platelets (Figure 3.19 (b)). The loadings of PC-1 and PC-2 are shown in 
Figure 3.19 (c). 
 
Amide III is present in the Raman spectrum at 1230 – 1310 cm-1 
(Figure 3.20 (a)). Similar to the results of the PCA analysis of the amide I 
region, it was found that the samples clustered together based on the platelet 
activator (Figure 3.20 (b)). The loadings of the principal components PC-1 and 
PC-5 are shown in Figure 3.20 (c). 
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Furthermore, having examined the PCA of the regions in which structural 
differences between platelets in various states of activation were anticipated, 
the full platelet spectrum (200 – 3500 cm-1) was divided into regions to examine 
each in greater detail. This analysis was performed in order to ensure that we 
did not unintentionally overlook any area of the spectrum which may contain 
crucial information. The spectrum was divided into 6 regions, each 700 cm-1 in 
length except for the last region, region 6, which was 800 cm-1 in length. Each 
region overlapped the previous region by 200 cm-1 and they were designated as 
follows:  
 
 Region 1: 200 – 900 cm-1 
 Region 2: 700 – 1400 cm-1 
 Region 3: 1200 – 1900 cm-1 
 Region 4: 1700 – 2400 cm-1 
 Region 5: 2200 – 2900 cm-1 
 Region 6: 2700 – 3500 cm-1 
 
PCA was performed specifically on each of these regions. It was found the 
regions of greatest separation between the platelet samples were: 
700 - 1400 cm-1 (Figures 3.21 (a-c)); 1200 – 1900 cm-1 (Figures 3.22 (a-c)); 
2200 – 2900 cm-1 (Figures 3.23 (a-c)) and 2700 – 3500 cm-1 
(Figures 3.24 (a-c)).  
 
The region of the Raman spectra of all samples stretching from 700 – 1400 cm-1 
is shown in Figure 3.21 (a). PCA analysis of this region reveals the Raman 
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spectra separated into obvious clusters corresponding to the platelet activator 
(Figure 3.21 (b)). The loadings of the principal components PC-1 and PC-2 
which account for most of the variance within this data set are shown in Figure 
3.21 (c). 
 
The Raman spectra of each platelet sample in the region stretching from 
1200 - 1900 cm-1 is plotted in Figure 3.22 (a). The results of the PCA analysis 
are illustrated in Figure 3.22 (b), where clustering of the Raman spectra into 
groups corresponding to the same platelet activator is obvious. The loadings of 
the principal components used to plot the scores graph are shown in 
Figure 3.22 (c). 
 
The region of the Raman spectra stretching from 2200 – 2900 cm-1 is plotted in 
Figure 3.23 (a). The PCA results of the data from this region are in 
Figure 3.23 (b). The Raman spectra are clearly discriminated as a result of the 
platelet activator used to activate the platelets. The loadings of the first two 
principal components, PC-1 and PC-2, used to plot the scores scatter plot are 
illustrated in Figure 3.23 (c). 
 
Figure 3.24 (a) illustrates the Raman spectra in the region stretching from 
2700 - 3500 cm-1. A scatter plot of PC-1 versus PC-2 is shown in 
Figure 3.24 (b). The loading of these principal components as a function of 
wave number is plotted in Figure 3.24 (c).  
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Upon examination of these regions, namely 700 – 1400 cm-1, 1200 – 1900 cm-1, 
2200 – 2900 cm-1 and 2700 – 3500 cm-1, in which there is evident clustering of 
the Raman spectra corresponding to the platelet activator, it was found that 
each of these regions contain a peak or peaks associated with lipid structure. 
Further examination of the PCA results of the full spectrum (Figure 3.16) again 
demonstrate the significance of the carotenoid and lipid profile of the platelets 
as the higher principal components, PC-1 and PC-2, pick out the peaks 
associated with lipids as being the regions with the highest variability.  
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Figure 3.1 Concentration and buffer exchange of purified integrin IIb3 does not 
lead to degradation of the protein: (a) Coomassie Blue stain, (b) Western blot. 
20g of purified integrin IIb3 was run on a 7.5 % polyacrylamide gel. (a) Gel was 
stained with a sensitive Coomassie Blue solution overnight at room temperature with 
gentle rocking. Gels were destained and imaged. The purified integrin was found to be 
intact with prominent bands at ~120 kDa and ~90 kDa for both - and -subunits, 
respectively. (b) The protein was transferred from the gel to polyvinyl difluoride (PVDF) 
membrane, blocked and probed with SZ.22, an antibody that is specific for integrin IIb-
subunit. The -subunit was found to be intact with a strong band present at ~120 kDa. 
The band present at a higher molecular weight of ~240 kDa suggests the presence of a 
potential dimer of IIb-subunit.   
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Figure 3.2 Concentration curve demonstrating a measurable number of free 
thiols present in purified integrin IIb3. Purified integrin IIb3, at concentrations 
ranging from 0 – 100 g/ml was incubated with Thiostar® (2.5 g/ml) for 5 minutes at 
room temperature, in a black, clear bottom 96-well plate. The fluorescence was 
measured using a Wallac plate reader. Thiols were found to be detectable at a 
concentration of at least 10 g/ml. Data is presented as the mean ± SEM, n=4 
independent experiments, *p < 0.05, **p < 0.01. 
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Figure 3.3 Activation of purified integrin IIb3 by 3 mM MnCl2 causes a significant 
increase in the integrin free thiol population. Purified integrin IIb3 was activated 
with 1 mM, 3 mM or 5 mM MnCl2 for 10 minutes at 37 °C. It was then incubated with 
Thiostar® (2.5 g/ml) for 5 minutes at room temperature. The fluorescence was 
measured using a Wallac plate reader. Data is presented as the mean ± SEM, n=5 
independent experiments, *p < 0.05. 
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Figure 3.4 The significant increase in the free thiol population of activated 
integrin IIb3 is decreased in the presence of reducing GSH/GSSG redox 
potentials. Purified integrin IIb3 was incubated with GSH/GSSG redox potentials 
(-10mV, -130 mV or -264 mV) for 10 minutes at 37 °C. Excess, unreacted GSH/GSSG 
was removed from the system. Integrin was recovered and activated with 3 mM MnCl2 
for 10 minutes at 37 °C, then incubated with Thiostar® (2.5 g/ml) for 5 minutes at room 
temperature. The fluorescence was measured using a Wallac plate reader. Altering the 
redox environment had no impact on the thiol population of the unactivated integrin. 
Data is presented as the mean ± SEM, n=5 independent experiments, *p < 0.05. 
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Figure 3.5 The ‘FF’ Chinese hamster ovarian-K1 (CHO-K1) cell line expresses 
intact integrin IIb3. (a) The level of integrin IIb3 expression was significantly greater 
in the FF cells when compared to mock transfected CHO-K1 cells when measured by 
flow cytometry using the IIb-subunit specific monoclonal antibody, CD41a. Data is 
presented as the mean ± SEM, n=3 independent experiments, **p < 0.01. (b) A 
histogram illustrating the increase in integrin IIb3 expression levels in FF CHO-K1 
cells compared to mock transfected CHO-K1 cells, representative of n=3 independent 
experiments.   
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Figure 3.6 The ‘FF’ Chinese hamster ovarian-K1 (CHO-K1) cell line expresses 
integrin IIb3 in a resting conformation. (a) There was no significant difference 
between the levels of PAC-1 binding to mock transfected CHO-K1 cells and to FF cells, 
as measured by flow cytometry. Data is presented as the mean ± SEM, n=3 
independent experiments. (b) A histogram illustrating that there was no change in the 
level of PAC-1 binding between FF CHO-K1 cells and mock transfected CHO-K1 cells, 
representative of n=3 independent experiments.   
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Figure 3.7 Manganese chloride (MnCl2) treatment of FF CHO-K1 cells induces 
PAC-1 binding to integrin IIb3. (a) PAC-1 is a monoclonal antibody that binds only 
the activate conformation of integrin IIb3. The levels of PAC-1 binding to FF CHO-K1 
cells increased with increasing concentrations of MnCl2, thereby indicating MnCl2 
induced an active conformation of integrin IIb3, as measured by flow cytometry. Data 
is presented as the mean ± SEM, n=3 independent experiments, **p < 0.01, 
***p < 0.001. (b) A histogram illustrating the increase in PAC-1 binding to FF CHO-K1 
cells upon stimulation with increasing concentrations of MnCl2, representative of n=3 
independent experiments.   
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Figure 3.8 PAC-1 binding to FF CHO-K1 cells induced by 3 mM MnCl2 is inhibited 
by more reducing GSH/GSSG redox potentials. (a) FF cells were incubated with 
GSH/GSSG redox potentials (-10 mV, -130 mV and -264 mV) for 10 minutes at 37 °C 
and were subsequently stimulated with 3 mM MnCl2 for 10 minutes at 37 °C in the 
presence of PAC-1 antibody. PAC-1 binding to activated integrin IIb3 expressed on 
FF CHO-K1 cells was measured using flow cytometry. Data is presented as the mean 
± SEM, n=3 independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001.  (b) A 
histogram illustrating the inhibition of PAC-1 binding to CHO-K1 cells upon stimulation 
by 3 mM MnCl2 as the GSH/GSSG redox environment became more reducing, 
representative of n=3 independent experiments.  
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Figure 3.9 A significant level of platelet aggregation is induced by dithiothreitol 
(DTT) and manganese chloride (MnCl2).  Gel-filtered platelet were either unactivated 
or activated with 1 mM, 3 mM or 5 mM DTT or MnCl2 for 10 minutes at 37 °C with 
constant stirring at 1100 rpm. Data is presented as the mean ± SEM, n=4 independent 
experiments, *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3.10 Platelet aggregation is induced, at varying levels, by 1U/ml thrombin, 
3 mM MnCl2 and 3 mM DTT. (a) Gel-filtered platelets remained unactivated or were 
activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT for 10 minutes at 37 °C 
with constant stirring at 1100 rpm. Data is presented as the mean ± SEM, n=9 
independent experiments, ***p < 0.001. (b) A platelet aggregation tracing illustrating 
the levels of platelet aggregation of (1) unactivated gel-filtered platelets, (2) gel-filtered 
platelets activated with 1U/ml thrombin, (3) gel-filtered platelets activated with 3 mM 
MnCl2, (4) gel-filtered platelets activated with 3 mM DTT. Aggregation tracing is 
representative of n=9 independent experiments.  
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Figure 3.11 The level of PAC-1 binding to platelets varies between platelets 
activated by 1U/ml thrombin, 3 mM MnCl2 and 3 mM DTT (a) Gel-filtered platelets 
were activated with 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT, in the presence PAC-1 
antibody for 10 minutes at 37 °C. PAC-1 binding to platelets was measured by flow 
cytometry. Data is presented as the mean ± SEM, n=5 independent experiments, 
***p < 0.001. (b) A histogram illustrating the increase in PAC-1 binding to platelets 
following treatment with 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT compared to 
unactivated platelets, representative of n=5 independent experiments.  
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Figure 3.12 Platelet secretion is induced by 1U/ml thrombin but not 3 mM MnCl2 
or 3 mM DTT. (a) Gel-filtered platelets were unactivated or activated with either 1U/ml 
thrombin, 3 mM MnCl2 or 3 mM DTT in the presence of CD62P for 10 minutes at 37 °C. 
The level of CD62P binding indicating P-selectin expression on the surface of platelets 
as a result of platelet activation was measured by flow cytometry. Data is presented as 
the mean ± SEM, n=4 independent experiments, ***p < 0.001. (b) A histogram 
illustrating CD62P binding to platelets following activation with either 1U/ml thrombin, 
3 mM MnCl2 or 3 mM DTT. Data is representative of n=4 independent experiments.  
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Table 3.1 A summary of PAC-1 and CD62P binding to unactivated platelets or 
platelets activated with either 1U/ml thrombin, 3 mm MnCl2 or 3 mM DTT. 
Gel-filtered platelets were incubated with 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT in 
the presence of PAC-1 or CD62P antibodies for 10 minutes at 37 °C. The levels of 
antibody binding to platelets were measured using flow cytometry. The values are 
expressed as mean percentage gated ± SEM; PAC-1 n=5, CD62P n=4 independent 
experiments.  
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Figure 3.13 An increased acquisition time for platelet Raman spectra caused 
photo-bleaching of prominent peaks in the spectra. Unactivated gel-filtered 
platelets were fixed with 1 % formaldehyde, centrifuged, supernatant removed and the 
platelet pellet was used for Raman analysis. Raman spectra were recorded, with a 
laser line of 473 nm, on a Horiba/Jobin Yvon LabRam HR spectrometer. Spectra were 
acquired for 25 seconds (not bleached) or 200 seconds (bleached). Spectra were 
initially analysed using Lab Spec software; baseline subtraction and normalisation were 
then performed using Origin® software. 
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Figure 3.14 Gel filtered platelets on a gold nanocavity surface for Surface 
Enhanced Raman spectroscopy (SERS). Unactivated gel-filtered platelets were fixed 
in 1 % formaldehyde, centrifuged, supernatant removed. The resulting platelet pellet 
was placed on the gold nanocavity surface and images were obtained using the upright 
microscope attached to the Horiba/Jobin Yvon LabRam HR spectrometer, 
magnification X 100. 
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Figure 3.15 Surfaced enhanced Raman spectroscopy (SERS) on either gold 
nanocavity or gold nanoparticle covered surfaces did not enhance platelet 
Raman spectra. Fixed, unactivated, gel-filtered platelets were placed on glass 
coverslips for comparison with platelets placed on either (a) gold nanocavity or (b) gold 
nanoparticle covered surfaces. Raman spectra were obtained, with a laser line of 
473 nm, on a Horiba/Jobin Yvon LabRam spectrometer. Baseline subtraction and 
normalisation were performed using Origin® software.  
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Figure 3.16 (a) Signature Raman spectra of unactivated platelets and platelets 
activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. Gel-filtered 
platelets were fixed with 1 % formaldehyde, centrifuged and supernatant removed. 
Raman spectra were obtained from the resulting platelet pellet. Spectra were baseline 
subtracted and normalised to the lipid peak at approximately 3000 cm-1. Spectra shown 
are the average spectra of n=4 independent experiments with 3 - 5 spectra from each 
experiment.  
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Figure 3.16 (b) Principal component analysis (PCA) showing distinct clustering 
of each of the platelet activators (full spectrum). PCA analysis was performed on 
the Raman spectra of gel-filtered platelets which were unactivated or activated with 
either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The numbers on each sample refer 
to the donor number and spectrum number for that particular donor, for example 
unact1_2 refers to unactivated platelets, donor number 1 and spectrum number 2. The 
graph is a scatter plot of the first principal component (PC-1) versus the second 
principal component (PC-2). PCA analysis was carried out using The Unscrambler® 
software. Data shown is 3 - 5 spectra from n=4 independent experiments. 
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Figure 3.16 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the full spectrum of all 
samples: (i) Principal component-1 (PC-1) and (ii) Principal component-2 (PC-2). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 3.17 (a) The thiol region of the Raman spectra for all unactivated platelet 
samples or platelet samples activated with either 1U/ml thrombin, 3 mM MnCl2 or 
3 mM DTT. Gel-filtered platelets were fixed with 1 % formaldehyde, centrifuged and 
supernatant removed. Raman spectra were obtained from the resulting platelet pellet. 
Spectra were baseline subtracted and normalised to the lipid peak at approximately 
3000 cm-1. Data shown is 3 - 5 spectra from n=4 independent experiments.  
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Figure 3.17 (b) Principal component analysis (PCA) of the thiol region showing 
distinct clustering of samples based on the platelet activator. PCA analysis was 
performed on the Raman spectra of gel-filtered platelets which were unactivated or 
activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The numbers on each 
sample refer to the donor number and spectrum number for that particular donor, for 
example unact1_2 refers to unactivated platelets, donor number 1 and spectrum 
number 2. The graph is a scatter plot of the second principal component (PC-2) versus 
the third principal component (PC-3). PCA analysis was carried out using The 
Unscrambler® software. Data shown is 3 - 5 spectra from n=4 independent 
experiments. 
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Figure 3.17 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the thiol containing region 
only: (i) Principal component-2 (PC-2) and (ii) Principal component-3 (PC-3). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, in the thiol containing region 2400 – 2600 cm-1 only, using The Unscrambler® 
software.  
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Figure 3.18 (a) The disulphide region of the Raman spectra for unactivated 
platelet samples or platelet samples activated with either 1U/ml thrombin, 3 mM 
MnCl2 or 3 mM DTT. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. Data shown is 3 – 5 spectra from n=4 independent 
experiments. 
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Figure 3.18 (b) Principal component analysis (PCA) of the disulphide region 
showing distinct clustering of samples based on the platelet activator. PCA 
analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. This is a scatter plot of the first principal component (PC-1) 
versus the third principal component (PC-3). Data shown is 3 - 5 spectra from n=4 
independent experiments. 
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Figure 3.18 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the disulphide containing 
region only: (i) Principal component-1 (PC-1) and (ii) Principal component-3 (PC-
3). The components are numbered according to the amount of variance they account 
for. PCA analysis was carried out on the baseline subtracted and normalised Raman 
data of all samples, in the disulphide containing region 400 – 650 cm-1 only, using The 
Unscrambler® software. 
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Figure 3.19 (a) The amide I region of the Raman spectra for unactivated platelet 
samples or platelet samples activated with either 1U/ml thrombin, 3 mM MnCl2 or 
3 mM DTT. Gel-filtered platelets were fixed with 1 % formaldehyde, centrifuged and 
supernatant removed. Raman spectra were obtained from the resulting platelet pellet. 
Spectra were baseline subtracted and normalised to the lipid peak at approximately 
3000 cm-1. Data shown is 3 – 5 spectra from n=4 independent experiments. 
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Figure 3.19 (b) Principal component analysis (PCA) of the amide I region 
showing distinct clustering of samples based on the platelet activator. PCA 
analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the second principal component (PC-2). Data shown is 3 - 5 spectra 
from n=4 independent experiments. 
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Figure 3.19 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the amide I containing region 
only: (i) Principal component-1 (PC-1) and (ii) Principal component 2 (PC-2). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, in the amide I containing region 1600 – 1800 cm-1 only, using The 
Unscrambler® software. 
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Figure 3.20 (a) The amide III region of the Raman spectra for unactivated platelet 
samples or platelet samples activated with either 1U/ml thrombin, 3 mM MnCl2 or 
3 mM DTT. Gel-filtered platelets were fixed with 1 % formaldehyde, centrifuged and 
supernatant removed. Raman spectra were obtained from the resulting platelet pellet. 
Spectra were baseline subtracted and normalised to the lipid peak at approximately 
3000 cm-1. Data shown is 3 – 5 spectra from n=4 independent experiments. 
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Figure 3.20 (b) Principal component analysis (PCA) of the amide III region 
showing distinct clustering of samples based on the platelet treatment activator. 
PCA analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the fifth principal component (PC-5). Data shown is 3 - 5 spectra from 
n=4 independent experiments. 
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Figure 3.20 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the amide III containing 
region only: (i) Principal component-1 (PC-1) and (ii) Principal component-2 
(PC-2). The components are numbered according to the amount of variance they 
account for. PCA analysis was carried out on the baseline subtracted and normalised 
Raman data of all samples, in the amide III containing region 1200 – 1450 cm-1 only, 
using The Unscrambler® software. 
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Figure 3.21 (a) The 700 – 1400 cm-1 region of the Raman spectra for all 
unactivated platelet samples or platelet samples activated with either 1U/ml 
thrombin, 3 mM MnCl2 or 3 mM DTT. Gel-filtered platelets were fixed with 1 % 
formaldehyde, centrifuged and supernatant removed. Raman spectra were obtained 
from the resulting platelet pellet. Spectra were baseline subtracted and normalised to 
the lipid peak at approximately 3000 cm-1. Data shown is 3 – 5 spectra from n=4 
independent experiments. 
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Figure 3.21 (b) Principal component analysis (PCA) of the 700 – 1400 cm-1 region 
showing distinct clustering of samples based on the platelet treatment activator. 
PCA analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 and 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the second principal component (PC-2). Data shown is 3 - 5 spectra 
from n=4 independent experiments. 
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Figure 3.21 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the 700 – 1400 cm-1 region 
only: (i) Principal component-1 (PC-1) and (ii) Principal component-2 (PC-2). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, the 700 – 1400 cm-1 region only, using The Unscrambler® software. 
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Figure 3.22 (a) The 1200 – 1900 cm-1 region of the Raman spectra for all 
unactivated platelet samples or platelet samples activated with either 1U/ml 
thrombin, 3 mM MnCl2 or 3 mM DTT. Gel-filtered platelets were fixed with 1 % 
formaldehyde, centrifuged and supernatant removed. Raman spectra were obtained 
from the resulting platelet pellet. Spectra were baseline subtracted and normalised to 
the lipid peak at approximately 3000 cm-1. Data shown is 3 – 5 spectra from n=4 
independent experiments. 
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Figure 3.22 (b) Principal component analysis (PCA) of the 1200 – 1900 cm-1 
region showing distinct clustering of samples based on the platelet activator. 
PCA analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 and 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the second principal component (PC-2). Data shown is 3 - 5 spectra 
from n=4 independent experiments. 
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Figure 3.22 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the 1200 – 1900 cm-1 region 
only: (i) Principal component-1 (PC-1) and (ii) Principal component (PC-2). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, the 1200 – 1900 cm-1 region only, using The Unscrambler® software. 
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Figure 3.23 (a) The 2200 – 2900 cm-1 region of the Raman spectra for all 
unactivated platelet samples or platelet samples activated with either 1U/ml 
thrombin, 3 mM MnCl2 or 3 mM DTT. Gel-filtered platelets were fixed with 1 % 
formaldehyde, centrifuged and supernatant removed. Raman spectra were obtained 
from the resulting platelet pellet. Spectra were baseline subtracted and normalised to 
the lipid peak at approximately 3000 cm-1. Data shown is 3 – 5 spectra from n=4 
independent experiments. 
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Figure 3.23 (b) Principal component analysis (PCA) of the 2200 – 2900 cm-1 
region showing distinct clustering of samples based on the platelet activator. 
PCA analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 and 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the second principal component (PC-2). Data shown is 3 - 5 spectra 
from n=4 independent experiments. 
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Figure 3.23 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the 2200 – 2900 cm-1 region 
only: (i) Principal component-1 (PC-1) and (ii) Principal component (PC-2). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, the 2200 – 2900 cm-1 region only, using The Unscrambler® software. 
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Figure 3.24 (a) The 2700 – 3500 cm-1 region of the Raman spectra for all 
unactivated platelet samples or platelet samples activated with either 1U/ml 
thrombin, 3 mM MnCl2 or 3 mM DTT. Gel-filtered platelets were fixed with 1 % 
formaldehyde, centrifuged, supernatant removed. Raman spectra were obtained from 
the resulting platelet pellet. Spectra were baseline subtracted and normalised to the 
lipid peak at approximately 3000 cm-1. Data shown is 3 – 5 spectra from n=4 
independent experiments. 
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Figure 3.24 (b) Principal component analysis (PCA) of the 2700 – 3500 cm-1 
region showing distinct clustering of samples based on the platelet activator. 
PCA analysis was performed on the Raman spectra of gel-filtered platelets which were 
unactivated or activated with either 1U/ml thrombin, 3 mM MnCl2 or 3 mM DTT. The 
numbers on each sample refer to the donor number and spectrum number for that 
particular donor, for example unact1_2 refers to unactivated platelets, donor number 1 
and spectrum number 2. The graph is a scatter plot of the first principal component 
(PC-1) versus the second principal component (PC-2). Data shown is 3 - 5 spectra 
from n=4 independent experiments. 
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Figure 3.24 (c) The loadings of the two principal components used in the 
Principal component analysis (PCA) scatter plot of the 2700 – 3500 cm-1 region 
only: (i) Principal component-1 PC-1 and (ii) Principal component-2 (PC-2). The 
components are numbered according to the amount of variance they account for. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples, the 2700 – 3500 cm-1 region only, using The Unscrambler® software. 
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3.3 Discussion 
 
Extensive research investigating the significance of thiols in integrin IIb3 has 
been carried out. Platelet activation leads to reduction of disulphide bonds, with 
a concomitant increase in free thiols, within the cysteine rich repeats of integrin 
IIb3. This causes conformational changes of the integrin and exposure of 
ligand binding sites (Yan & Smith, 2000). In my studies, I have confirmed that in 
a purified, cell-free system MnCl2 does indeed cause an increase in the free 
thiol population of integrin IIb3 which is associated with an activated 
conformation of the integrin. Modification of thiol/disulphide groups in integrin 
IIb3 by thiol blockers or reducing reagents can impact on its function (Essex et 
al, 2001; Lahav et al, 2000; Manickam et al, 2008; Margaritis, 2011; Yan & 
Smith, 2001). However, the impact of an altered redox environment employing 
low-molecular-weight thiols, such as glutathione, at various redox potentials on 
the function of integrin IIb3 has yet to be explored in detail until now.  
 
Reduced (GSH) and oxidised glutathione (GSSG) were combined, in ratios 
determined by the Nernst equation and outlined in Tables 2.1 and 2.2, to 
generate reducing (-264 mV), mean (-130 mV) and oxidising (-10 mV) redox 
environments. The increase in free thiols in integrin upon activation by MnCl2 
persisted in an oxidising redox environment. This indicates the generation of 
this thiol population is a robust event. Interestingly, it was found that a reducing 
redox environment completely abolished the increase in the free thiol population 
induced by MnCl2 in purified integrin IIb3. An investigation into the impact of 
GSH/GSSG redox potentials on the activation state of integrin IIb3 expressed 
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on FF CHO-K1 cells demonstrated that a reducing redox environment inhibited 
activation of the integrin induced by MnCl2. It has been previously demonstrated 
in our laboratory that GSH (3 mM) could decrease MnCl2 induced integrin IIb3 
activation in platelets (Walsh et al, 2004). Of particular interest in this study 
here, however, is the concentration of GSH used to generate the redox potential 
of -264 mV, which was only 45 M, more than a 60 fold decrease in 
concentration. This demonstrates a sensitivity of the receptor to the external 
redox environment. This finding indicates a rearrangement or shuffling of 
thiol/disulphide groups rather than simply a reduction of disulphide bonds. It 
may also be potentially as a result of a direct modification of the thiol groups in 
a process known as S-glutathionylation. S-glutathionylation is a reversible 
process in which mixed disulphide bonds are formed between the thiol group of 
the protein itself and glutathione (Dalle-Donne et al, 2007). It is a potential 
mechanism for the post-translational regulation of proteins. This thiol 
modification is associated with the reactivity of the cysteine residues in the 
protein, integrin IIb3 in this case. Reactivity of a cysteine is determined by its 
pKa value which can be variable, depending on electrostatic interactions with 
adjacent amino acids. A reactive cysteine can form a thiolate in redox-sensitive 
proteins. A cysteine thiolate anion (S-) (i.e., an ‘active cysteine’), can react to 
form a mixed disulfide with GSH or a protein disulfide (Rhee et al, 2000). The 
formation of a thiolate anion is favoured by the presence of basic amino acids 
(histidine (H), lysine (K) or arginine (R)) in the vicinity of the cysteine. The 
3-subunit of integrin IIb3 contains 56 cysteine residues. An examination of the 
protein sequence and, specifically, cysteine residues of the -subunit by my 
colleague, Dr. Desmond Murphy (personal communication), found there are 10 
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cysteine residues adjacent to a single basic amino acid present. This gives rise 
to a redox sensitivity within the integrin, thus supporting the theory of 
S-glutathionylation of critical cysteine residues involved in the activation 
mechanism of integrin IIb3.  
 
The platelet aggregation and flow cytometry studies demonstrated thrombin, 
MnCl2 and DTT activate platelets to different extents. Thrombin is a potent 
physiological platelet agonist. Therefore, as anticipated, it activated platelets to 
a large extent as opposed to DTT and MnCl2 which are not physiological 
platelet agonists. The potency of thrombin as a platelet activator was confirmed 
with platelet aggregation levels of approximately 80 %, PAC-1 binding of 70 % 
and CD62P binding of 42 %. DTT is a strong reducing agent and induces 
platelet aggregation by reducing disulphide bonds on the platelets surface and 
causing the activation of integrins in particular. The reduction of disulphide 
bonds within the cysteine-rich domain in integrin IIb3 leads to an active 
conformation of the integrin (Walsh et al., 2004). This was confirmed in this 
study as platelets in the presence of DTT had approximately 40 % PAC-1 
binding, compared to 2 % with unactivated platelets. DTT also induced 
approximately 40 % platelet aggregation. From the CD62P data it can be seen 
that there is no platelet degranulation or secretion associated with DTT 
activation. MnCl2 is a known universal integrin activator. Integrins are known to 
bind their ligands in a divalent cation-dependent manner and manganese 
promotes this binding (Humphries et al, 2003). The flow cytometry studies show 
that MnCl2 increases PAC-1 binding (approximately 20 %), in comparison to 
unactivated platelets (approximately 2 %), therefore, indicating the presence of 
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an active conformation of integrin IIb3. MnCl2 also induces approximately 
10 % platelet aggregation. There is no CD62P binding associated with platelets 
activated by MnCl2 which indicates that no platelet degranulation has occurred. 
In the case of both DTT and MnCl2, the lack of platelet secretion implies that 
neither of these platelet activators is potent enough to induce further intra-
platelet signalling and, consequently, complete platelet activation. The results of 
the platelet aggregation studies, levels of PAC-1 binding and levels of secretion 
indicated by CD62P binding, confirm each of the platelet activators acts on the 
platelets in a different manner. It was anticipated that the differences observed 
in these platelet function assays between platelets activated with the various 
activators, would be reflected by differences in platelet membrane structure and 
revealed in the analysis of platelets by Raman spectroscopy (RS). 
 
A number of successful studies have been carried out using RS and the 
spectral analysis method of principal component analysis (PCA) in the 
evaluation of biological samples in recent years. Crow et al showed that Raman 
can be used as a method to distinguish between benign and malignant bladder 
and prostate cancers with an accuracy of 84 % and 86 % respectively (Crow et 
al, 2005). These numbers are compared to standard histological and 
classification by a uropathologist prior to Raman analysis. This study 
demonstrates the high level of accuracy of RS analysis in vitro and paves the 
way for the introduction of RS to a clinical in vivo setting. In a separate study of 
renal cancer, RS could differentiate normal and tumoural renal tissue, high and 
low-grade renal cell carcinoma (RCC) along with histological subtypes of RCC 
(Bensalah et al, 2010). This study highlights the sensitivity of RS, not only can it 
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distinguish between normal and tumoural tissue but it can be used to 
differentiate various grades of tumoural tissue. Similarly, a study investigating 
the potential of RS as a cervical cancer diagnosis tool found that RS was highly 
sensitive to biochemical changes in tissue allowing them to discriminate 
between normal cervical tissue, cervical intraepithelial neoplasia (CIN) and 
invasive carcinoma (Lyng et al, 2007). The results showed high sensitivity and 
specificity with accuracy between 98 – 100 %. These numbers were based on 
the comparison of Raman results to the prior classification of samples by a 
consultant pathologist. A very small number of samples were incorrectly 
classified but importantly no abnormal samples were classified as normal. 
 
All of these studies have focussed on the diagnosis of tissue states. It is 
important also to understand the spectral features of the tissue components, i.e. 
the individual cells and their subcellular components. There is a growing interest 
in the use of RS to study cells alone as opposed to studying tissue samples in 
which there are a variety of cells present. The morphology and biochemical 
composition of cells are commonly studied using electron microscopy or 
fluorescent spectroscopy. These methods require extensive preparation, which 
may compromise the integrity of the sample, and also staining or markers need 
to be decided on in advance.  Potentially, RS can overcome these limiting 
issues. While it may be advantageous in some cases, RS does not specifically 
require staining or labelling in general. The inelastic scattering of light by 
Raman-active vibrational modes, upon which the principle of RS is based, 
ensures the molecular specificity of RS. These properties, combined with 
immediate results, make RS a valuable analytical tool in the characterisation of 
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cellular processes. In a study examining the sensitivity of RS as a tool for 
studying single cells Krafft et al found that upon analysis of individual spectra 
combined with Raman mapping data of a variety of cells they could identify 
individual bands corresponding to proteins, lipids and nucleic acids. They also 
found that the relative intensities of these bands was dependent on the specific 
location of the components within the cells (Krafft, 2003). To date, Raman has 
not been used routinely as a tool to examine platelet activation processes. 
However, studies have been carried out using RS to investigate the effects of 
activation on the molecular structure of other cell types. One such study found 
clear differences in the spectra of eosinophils in an unactivated state compared 
to the spectra of those stimulated with interleukin-5 (IL-5) (Puppels, 1995). They 
found that activation of eosinophils leads to the secretion of granule contents so 
that little or no eosinophil peroxidase (EPO) remains in the cells. A decrease in 
the intensity of the EPO peak along with a shift in the mid peak value from 
1352 cm-1 in unactivated eosinophils to 1369 cm-1 in activated eosinophils 
illustrated this finding. This peak shift was also indicative of a change in the iron 
oxidation state of EPO from 3+ to 2+. These were significant observations with 
regard to elucidating the activation mechanism of eosinophils.  
 
Based on the interesting results from the purified integrin IIb3 assays, in 
addition to the flow cytometry and platelet aggregation studies in which the 
levels of PAC-1 binding to activated integrin and the levels of platelet 
aggregation varied depending on the platelet activator, it was anticipated 
changes in the spectra, particularly in the regions of thiols and disulphides, of 
platelets would be evident. Any change in the thiol region should correspond to 
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a similar, complementary shift in the disulphide region. PCA analysis of both the 
thiol and disulphide regions of the platelet Raman spectra show that these 
regions do, indeed, contribute to the separation of the platelet spectra into 
distinct clusters based on the platelet activator. In the thiol region, the score plot 
of PC-2 versus PC-3 shows the most obvious clustering of the platelet samples 
(Figure 3.17 (b)). When I examined the loadings of these principal components, 
the peaks present corresponded to the thiol (-SH) stretch. In the case of 
complex biological samples such as platelets, it can prove difficult to attribute 
differences in the region to specific events. However, any differences in this 
region can be indicative of not only a change in the absolute number of thiol 
groups present but may also indicate shuffling or rearrangement of the bonds or 
changes in the strain on the cysteine bonds. 
 
The score plot in the analysis of the disulphide stretch demonstrates that when 
PC-1 is plotted against PC-3, the Raman spectra can be discriminated from 
each other according to the platelet activator. The separation of the Raman 
spectra here is not as clean as in other regions as there tends to be higher 
noise levels in the region. However, there is a definite trend towards the 
clustering of the Raman spectra according to the platelet activator. Changes in 
this region may be due to shuffling or rearrangement, along with reduction of 
disulphide bonds, which would be consistent with the results we have found in 
the thiol region of the spectrum. This result also strengthens the model of 
thiol/disulphide exchange mechanisms involved in platelet activation (Essex & 
Li, 1999; Walsh et al, 2004).  
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It was also predicted there would be a change in the amide I (1630 – 1700 cm-1) 
and amide III (1230 – 1310 cm-1) regions, whereby platelet activation may 
cause a change in the secondary protein structure. Based on this prediction, 
these two regions were focussed on, in a similar manner to the thiol and 
disulphide stretches. As anticipated, in both amides I and III regions Raman 
spectra could be separated according to the platelet activator. The score plots 
for both cases do not show as good discrimination as expected but there is a 
clear trend present. Changes in these amide stretches indicate alterations in the 
-helix and -sheet content of proteins. The amide I mode is described as a CO 
stretching mode with some mixture of CCN deformation (Chen et al, 1994). 
Using the amide I band for structural analysis is known to be difficult, 
necessitating a combination of experiments with classical and quantum 
methods for advanced interpretation (Petersen & Nielsen, 2009). The amide III 
is a CN stretch and NH in-plane bending mode with C(C)H3 symmetric bending 
and CO in plane bending contributions  (Jordan & Spiro, 1994). From my 
current data, it is not possible to determine what exact modifications in protein 
secondary structure are occurring due to platelet activation or how each 
activator is actually inducing these modifications.  
 
The score plot is a projection of data onto subspace used to interpret relations 
amongst observations. PCA of each of the regions extracted from the full 
spectrum all platelet samples invariably demonstrated a visible trend in their 
location within the score scatter plots. The consistency in these results gave 
increased confidence in the data analysis. This ensured there was no bias when 
stating platelet activation states could be discriminated in a region of particular 
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interest such as the thiol/disulphide region. Clustering or grouping of samples 
within PCA score plots indicates similarities between the samples. Conversely, 
the platelet samples in this study were clearly distinct and separate from each 
other demonstrating obvious differences. In order to convey absolute 
confidence in the analysis, further multivariate analysis of the data such as 
linear discriminant analysis (LDA) or Fisher’s discriminant analysis (FDA) or the 
development of an appropriate mathematical algorithm would be required. In 
this case, PCA was a sufficient analysis indicating platelets do indeed express 
structural differences upon activation and these differences in fact are also 
dependent on the platelet activator in question.  
 
Following the analysis of specific regions within the platelet Raman spectrum in 
which we expected to find differences, a comprehensive analysis was 
performed in order to ensure important information was not overlooked. Further 
examination revealed the presence of a prominent carotenoid or lipid peak in 
each of these stretches in unactivated and activated platelets. The 
700 - 1400 cm-1 stretch contains very strong Raman peaks at 968 cm-1, 
1006 cm-1 and 1160 cm-1. The region from 1200 – 1900 cm-1 also contains a 
major peak at 1525 cm-1. All of these peaks are characteristic spectral features 
of carotenoids. Carotenoids are a group of organic pigments, lipid in nature, 
which are found in most cell membranes including platelets (Stefanini et al, 
1957). The exact role of carotenoids in cell membranes has yet to be fully 
elucidated but the antioxidant properties of carotenoids are particularly 
interesting with regard to their potential role in platelets (Di Mascio et al, 1989). 
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In summary, it has been found that Raman spectroscopy, combined with the 
multivariate statistical analysis technique PCA, may be employed as a novel 
tool to investigate the activation state of platelets. The structural components of 
platelets which have emerged as crucial in the discrimination of platelets in 
various states of activation are the lipids, carotenoids, thiols, disulphides, along 
with both amide I and III. The discovery that the thiol and disulphide regions of 
the platelet Raman spectrum contribute to the discrimination of platelet 
activation states is a particularly exciting result. These observations, combined 
with the potential antioxidant function of carotenoids further compound the 
importance of thiol populations, the redox environment and oxidative/reductive 
stress on platelet function. In Chapter 4, I will further investigate the role of 
thiols and redox in platelets. 
  
 
Chapter 4 
The external redox environment 
regulates platelet function through 
modulating the platelet surface thiol 
population 
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4.1 Introduction 
The redox environment of a cell, biological fluid or tissue is defined by the state 
of the low-molecular-weight redox couples present, along with reactive oxygen 
and nitrogen species (RONS) and their respective scavengers. Studies relating 
to redox environments have become increasingly popular in recent times due to 
the expanding number of disease states in which oxidative stress has been 
implicated. The redox homeostasis within biological systems is emerging as a 
critical regulatory factor as disturbances in this balance can have profound 
effects.  
RONS are readily generated during normal energy metabolism, and are 
typically scavenged and recycled. However, in the event of an imbalance in the 
system whereby there is an over-production of RONS or a depletion of 
scavengers or antioxidants, oxidative stress can arise. Furthermore, a disparity 
in the low-molecular-weight thiol couples, such as glutathione (GSH/GSSG) or 
cysteine (Cys/CySS), in which the concentration of the oxidising form of the 
couple becomes greater than that of the reducing form, can also lead to the 
development of oxidative stress. Oxidative stress can disrupt the fundamental 
structure of proteins and lipids, ultimately, resulting in alterations of their 
physical and chemical properties.  
Conversely, the phenomenon of reductive stress can also occur. Reductive 
stress arises upon a shift in the balance of the redox couple in favour of the 
reducing species. While it is less well known and researched, the implications of 
reductive stress may indeed be just as significant as those associated with 
oxidative stress. The modification of biological molecules during 
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oxidative/reductive stress is primarily due to the targeting of critical cysteine 
residues within their structure.  
It has been established that there are a number of cysteine, or thiol, containing 
proteins associated with platelets (Essex & Li, 2006). This makes platelets 
prime targets for modifications as a result of oxidative/reductive stress. It, 
therefore, emphasises the importance of the extracellular redox environment in 
the regulation of platelet function.  
Amongst these platelet thiol containing proteins are protein disulphide 
isomerase (PDI), glycoprotein Ib (GPIb)  (Burgess, 2000) and P2Y12, the 
ADP receptor (Ding, 2003). Thiol/disulphide groups have been shown to be 
intrinsic players in the regulation and modulation of the activity of platelet 
integrin IIb3 (Manickam et al, 2011; Manickam et al, 2008; O'Neill et al, 2000; 
Yan & Smith, 2000; Yan & Smith, 2001) and this has been substantiated by the 
findings in Chapter 3.  
Similarly, integrin 21 also exhibits functional properties related to the presence 
of thiol/disulphide groups within its structure (Gofer-Dadosh, 1997; Lahav et al, 
2000; Lahav et al, 2003). Integrin 21 is one of the major collagen receptors on 
platelets. The other main collagen receptor is glycoprotein VI (GPVI). While 
information about the exact role of the collagen receptors in haemostasis and 
thrombosis is crucial to the development of clinical therapies, the individual role 
of these two receptors in the adhesion of platelets to collagen is not well defined 
as of yet. It remains unclear if there is a physical interaction or signalling events 
which occur between the receptors, or indeed if there is any interaction at all. 
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Some argue that GPVI is the central collagen receptor and that platelet 
adhesion to collagen initially requires GPVI-collagen interactions to initiate 
platelet activation. It is suggested that collagen binding initiates signalling from 
GPVI, inducing a conformational change in integrin 21 allowing it to bind 
collagen, thereby increasing the strength of the adhesion.  
However, the role of integrin 21 may be underestimated, as the integrin itself 
can generate intracellular signals. Indeed, it has been demonstrated that 
patients deficient in integrin 21 have more severe bleeding disorders than 
those deficient in GPVI. Reduced expression of integrin 21 is associated with 
prolonged bleeding times, chronic mucocutaneous bleeding and reduced 
platelet adhesion to collagen (Nieuwenhuis et al, 1985). Additionally, over 
expression of integrin 21 has been linked to an increased risk for the 
development of cardiovascular disease (Carlsson et al, 1999; Moshfegh et al, 
1999; Samaha et al, 2005). On the other hand, mice deficient in the GPVI-FcR 
-chain have only minor effects with mildly increased bleeding times (Nieswandt 
et al, 2001b). Interestingly, a recent study suggests integrin 21 can bind 
collagen, under shear, without receptor pre-activation (Nissinen et al, 2012). 
This further supports integrin 21 as an independent collagen receptor capable 
of functioning without the need for inside-out signals. In the study, the authors 
suggest the initial low-affinity interaction between integrin 21 and collagen 
induces signals to promote integrin activation. This leads to a high-affinity 
conformation of the integrin for its ligand resulting in firm adhesion (Nissinen et 
al, 2012). Furthermore, it has been demonstrated that a thiol/disulphide 
exchange mechanism is required for platelet adhesion to collagen via integrin 
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21, which is independent of GPVI and may be enzymatically catalysed by PDI 
(Lahav et al, 2003).  
Previous work carried out in our laboratory has shown that altering the external 
redox environment impacts on platelets ability to function in response to 
collagen (Murphy et al, 2010). These findings, along with those of Lahav et al, 
are key to the studies carried out in this chapter.  
In Chapter 3, an examination of platelets by Raman spectroscopy, combined 
with the multivariate statistical analysis technique, principle component analysis 
(PCA), revealed the importance of thiols and disulphides in the structure of 
platelet membranes. PCA analysis revealed that both thiol and disulphide 
groups were modified upon stimulation with the platelet activators. These 
modifications were unique to the platelet activator, as an  analysis of the thiol 
(2550 – 2600 cm-1) and disulphide (470 – 530 cm-1) regions uncovered 
clustering of the Raman spectra based on the platelet activator (Figures 3.17 
(a-c) and 3.18 (a-c)). Interestingly, the characteristic carotenoid profile of 
platelets also appeared to play a significant role in the discrimination of platelet 
Raman spectra. Based on these findings, an assessment of platelets activated 
with more physiologically relevant agonists using Raman spectroscopy was 
carried out. Subsequently, the free thiol population on the surface of platelets 
was examined in greater detail and the impact of altering the external redox 
environment on this thiol population was investigated.  
A number of platelet agonists were used in the study, namely, thrombin, 
convulxin and collagen. As previously described, thrombin is a coagulation 
protein and a known potent physiological platelet activator. Collagen is the 
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major insoluble fibrous structural protein in the extracellular matrix and in 
connective tissue. It is the most thrombogenic component of the 
subendothelium (Baumgartner & Haudenschild, 1972). Upon vascular damage, 
collagen becomes exposed to circulating platelets. It acts as both a substrate 
for adhesion of platelets and also as a platelet activator through interactions 
with the receptors integrin 21 and GPVI. Twenty-eight types of collagen, 
composed of 46 distinct polypeptide chains have been identified (Brinckmann, 
2005). However, 80 – 90 % of all collagen in the body is either type I, II or III. 
Collagen has a triple helical structure formed by three parallel polypeptide 
strands in a left-handed, polyproline II-type (PPII) helical conformation. These 
polypeptides coil around each other with a one-residue stagger to form a right-
handed ‘coiled coil’ or triple helix. The tight packing of the PPII helices dictates 
that every third amino acid in the sequence is a glycine (Gly, G). This results in 
a repeated sequence of XYGly, where X and Y are any amino acid. The amino 
acids seen most frequently at the X and Y position are proline (Pro, P) and 
4-hydroxyproline (Hyp, O), with ProHypGly being the most abundant triplet in 
collagen (Ramshaw et al, 1998). Type I collagen is used in this study due to its 
tendency to favour binding to integrin 21. It possesses a high affinity binding 
motif, a hexapeptide GFOGER (glycine, phenylalanine, hydroxyproline, glycine, 
glutamic acid, arginine), in its triple helix which was found co-crystallised with 
the I-domain of the 2-subunit (Emsley et al, 2000; Knight et al, 1998; Knight et 
al, 2000).  
Convulxin is a snake venom protein from a tropical rattlesnake Crotalus 
durissus terrificus. It is a C-type lectin composed of two subunits,  and , 
which are cross-linked by disulphide bonds to form a hexamer: 33. Convulxin 
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is a well-known, potent platelet activator which acts through specific binding to 
the collagen receptor GPVI (Niedergang et al, 2000). Therefore, this makes 
convulxin a useful tool in studies examining the interaction between collagen 
and its receptors. Similarly, in the platelet adhesion studies, collagen related 
peptide (CRP) was used due to its specificity for the GPVI receptor. CRP 
consists of a backbone of GPO (GlyProHyp) sequences which has the ability to 
spontaneously form the helical structure of collagen. CRP is recognised by and 
is a potent platelet activator specifically through GPVI (Knight et al, 1999). (This 
peptide sequence is also recognised by integrin 21, however, there is no 
platelet reactivity associated with the interaction (Knight et al, 1999)).  
The effects of both the glutathione redox couple and the cysteine redox couple 
on platelets were examined, as Go and Jones have shown that the redox 
couples do not exert any effect on each other (Go & Jones, 2005; Jones et al, 
2004).  
Other reducing and oxidising agents are also used in order to determine if the 
effects on platelet function observed with the addition of GSH/GSSG and 
Cys/CySS redox potentials were unique to these physiological redox couples. 
These include dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine (TCEP), 
both of which are well-known reducing agents, and also reduced glutathione 
(GSH) alone. Oxidising environments are generated using DTNB (5,5'-dithiobis-
(2-nitrobenzoic acid)), a thiol blocker, and also using the oxidising component of 
the redox couples alone, i.e. GSSG or CySS. 
A number of assays will be performed in order to assess the thiol population on 
the surface of whole platelets under various redox conditions and activation 
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states. It is anticipated that changes in the surface thiol population will be 
detected, and any variations in this population may be attributed to a specific 
receptor or signalling pathway of platelets allowing us to further elucidate the 
role of thiols in platelet function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
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4.2 Results 
4.2.1 The effects of thrombin, collagen and convulxin on platelet 
molecular structure assessed by Raman spectroscopy 
Platelets were unactivated or activated with either 0.1U/ml thrombin, 38 g/ml 
collagen or 50 ng/ml convulxin and Raman spectra were obtained. Three to four 
spectra were obtained per platelet sample and an average spectrum for each 
condition per donor was generated (Figure 4.1 (a) (i)). Similarly, a signature or 
‘finger print’ Raman spectrum for unactivated platelets and platelets activated 
with each agonist was generated by averaging the spectra from all donors in 
each condition (Figure 4.1 (a) (ii)). 
 
Upon initial visual inspection of the Raman spectra in Figure 4.1 (a), any clear 
variation between unactivated and activated platelets was difficult to pinpoint. 
As mentioned in Chapter 3, to overcome this problem commonly experienced 
when analysing biological samples, principal component analysis (PCA) was 
performed on the platelet Raman data. Prior to carrying out PCA, all of the 
spectra were baseline subtracted and normalised to a peak at 3000 cm-1 using 
Origin® software. Normalisation of the data to one specific peak within the 
spectrum eliminates the differences in absolute signal intensity, which is 
influenced by environmental factors, and thereby ensures consistency across 
the data set. Initially, PCA was carried out on the full Raman spectra of all 10 
independent donors and it was found that the majority of samples clustered 
quite close together, while others were scattered randomly. This made it difficult 
to establish a clear pattern between unactivated and activated platelets 
(Figure 4.1 (b) (i)). PCA was then performed on the average or signature 
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platelet Raman spectra and the PCA scatter plot was plotted. Although the 
samples were located in close proximity, they could be distinguished from each 
other (Figure 4.1 (b) (ii)). Subsequently, when the PCA scatter plot was zoomed 
in on and graphed on a larger scale, it demonstrated that the samples could be 
easily discriminated from each other based on the platelet activator 
(Figure 4.1 (b) (iii)). The loadings of the principal components used to construct 
the PCA scatter plots for all the individual donors are illustrated in Figure 4.1 (c), 
while the principal components for the signature spectra are illustrated in Figure 
4.1 (d). The principal components highlight the areas which account for the 
most variance between samples. In order to further investigate the molecular 
differences between spectra, a number of important structural components were 
focussed on: thiol (2550 – 2600 cm-1), disulphide (470 – 530 cm-1), amide I 
(1630 – 1700 cm-1) and amide III (1230 – 1310 cm-1) regions. Due to the narrow 
spectral range of these structural components a slightly larger region was 
analysed.  
 
A region stretching from 2400 – 2600 cm-1 encompassing the thiol region was 
extracted from the full Raman spectra of platelets and analysed. An analysis of 
the data through PCA of the signature spectra showed the samples could be 
separated based on the platelet activator (Figure 4.2 (a-c)).  
 
Similarly, upon extraction of the disulphide containing region (400 – 650 cm-1), 
despite the poor signal to noise ratio in this stretch, the platelet samples could 
be clearly discriminated according to the platelet activator upon PCA of the 
signature Raman spectra (Figure 4.3 (a-c)). 
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To investigate the potential protein structural rearrangement as a result of 
platelet activation the amide I (1600 – 1700 cm-1) and amide III 
(1200 - 1400 cm-1) stretches of the platelet Raman spectra were examined. 
Again, it was demonstrated that PCA could discriminate the samples according 
to the platelet activator (Figures 4.4 and 4.5).  
 
For each of the thiol, disulphide and amide regions, the unactivated and the 
thrombin activated platelet sample were almost always found in close proximity 
to each other; whereas the collagen and convulxin activated platelet samples 
were almost frequently ‘far away’ from both the unactivated and thrombin 
samples and from each other. This was an interesting observation and due to 
the consistency of the trend from region to region it indicates a correlation 
between collagen and convulxin compared to either with unactivated or 
thrombin. 
 
Furthermore, the spectra were subsequently divided into a number of regions, 
each one encompassing 700 cm-1 of the spectrum, overlapping the previous by 
200 cm-1. This in depth and rigorous analysis of the data ensured no potentially 
valuable data went undetected. The regions examined were as follows: 
 
 Region 1: 200 – 900 cm-1 
 Region 2: 700 – 1400 cm-1 
 Region 3: 1200 – 1900 cm-1 
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 Region 4: 1700 – 2400 cm-1 
 Region 5: 2200 – 2900 cm-1 
 Region 6: 2700 – 3500 cm-1 
 
Regions 2, 3, 5 and 6 proved to be of most significance and interest. As was 
demonstrated previously in Chapter 3, these regions were found to contain at 
least one peak, corresponding to a carotenoid or lipid group, which accounted 
for the most variance across the data set (Figures 4.6 – 4.10). These findings 
suggested the carotenoid profile plays a significant role in the separation of the 
platelet Raman spectra. Therefore, further examination of the impact of these 
carotenoid peaks on platelet activation was necessitated. The characteristic 
carotenoid profile is labelled in the signature Raman spectra of unactivated and 
activated platelets (Figure 4.10 (a)). 
 
The intensity of characteristic carotenoid peaks at 968 cm-1, 1006 cm-1, 
1160 cm-1 and 1525 cm-1 in the Raman spectra of all platelet samples was 
measured. The fold increase in the peak intensity at each of the four carotenoid 
peaks was calculated relative to that of unactivated platelets. While statistically 
not significant, it was interesting to note a trend towards an increase in the 
intensity of all of the carotenoids peaks in platelets activated with either 
thrombin, collagen or convulxin when compared to unactivated platelets 
(Figure 4.10 (b)). 
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4.2.2 The effects of an altered external redox environment on platelet 
aggregation 
 
Thrombin, collagen and convulxin at concentrations of 0.1U/ml, 38 g/ml and 
50 ng/ml, respectively, induced comparable levels of platelet aggregation. 
Unactivated platelets did not aggregate while all activated platelets aggregated 
to levels of approximately 80 % (n=4, ***p < 0.001) (Figure 4.11).  
 
The redox reagents glutathione, both reduced (GSH) and oxidised (GSSG), and 
cysteine (Cys) and cystine (CySS) were prepared as stock solutions in 0.1 M 
hydrochloric acid (HCl) in order to reduce their tendency to convert to the 
alternative reduced or oxidised species of the redox couple. Prior to carrying out 
any experiments with the redox reagents, the impact of 1 mM HCl alone on 
platelet function was examined. It had no significant impact on the levels of 
platelet aggregation induced by 0.1U/ml thrombin, 38 g/ml collagen or 
50 ng/ml convulxin nor did it induce any platelet aggregation in unactivated 
platelets (n=4) (Figure 4.12). In fact, the maximum concentration of HCl to 
which the platelets were exposed was in the micromolar (M) range, and 
therefore any ‘interference’ from HCl on the activity of the platelets in these 
experiments was ruled out. 
 
In previous work carried out by my colleague, Dr. Desmond Murphy (Murphy et 
al, 2010), redox potentials were generated by combining reduced (GSH) and 
oxidised (GSSG) or cysteine (Cys) and cystine (CySS) in various ratios 
according to the Nernst equation and their impact on platelet aggregation was 
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examined. It was shown that neither the GSH/GSSG or Cys/CySS redox 
potentials (oxidising, mean or reducing) had any effect on the platelet 
aggregation response of unactivated platelets (n=6) (Figure 4.13). Additionally, 
it was demonstrated platelet aggregation to collagen was completely inhibited in 
the presence of a reducing external redox environment (GSH/GSSG: -264 mV 
and Cys/CySS: -148 mV). As the external redox environment was altered by 
mean (GSH/GSSG: -130 mV, Cys/CySS: -82 mV) and oxidising (GSH/GSSG: 
-10 mV, CyS/CySS: +4 mV) redox potentials, the platelet aggregation response 
to collagen was restored to levels observed in platelets in which the external 
redox environment was not altered. In contrast, platelet aggregation induced by 
thrombin or convulxin was not affected by either a reducing, mean or oxidising 
external environment generated by GSH/GSSG or Cys/CySS redox potentials 
(n=6, ***p < 0.001) (Figure 4.14).  
 
In order to further investigate this phenomenon, the effect of alternative 
reducing or oxidising agents on the levels of platelet aggregation of unactivated 
platelets and platelets activated with 0.1U/ml thrombin, 38 g/ml collagen and 
50 ng/ml convulxin were examined. The effects of the well-known reducing 
agents dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine (TCEP), along 
with reduced glutathione (GSH) alone, on platelet aggregation were 
investigated. Platelet aggregation induced by collagen was inhibited by 45 M 
DTT, 45 M TCEP and 45 M GSH. There was no effect on the level of platelet 
aggregation induced by thrombin or convulxin in the presence of any of the 
reducing agents (n=4, ***p < 0.001) (Figure 4.15 (a)). 
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The effects of oxidising agents on the platelet aggregation response to 0.1U/ml 
thrombin, 38 g/ml collagen and 50 ng/ml convulxin were also investigated. 
Oxidised glutathione (GSSG) alone, cystine, (CySS) alone and 5, 5’-Dithio-bis-
(2-nitrobenzoic acid) (DTNB), at a concentration of 45 M, were chosen as 
oxidising agents. It was found that none of these agents had any significant 
effect on platelet aggregation in unactivated platelets or platelets activated with 
thrombin, collagen or convulxin (n=4) (Figure 4.15 (b)). This was a result 
consistent to that seen with platelets in the presence of oxidising redox 
environments generated by GSH/GSSG and Cys/CySS redox potentials 
(Figure 4.14). 
 
4.2.3 Investigation into the signalling pathway of type I collagen  
Throughout this study, type I collagen was used based on the assumption that it 
was signalling primarily through integrin 21, as opposed to glycoprotein VI 
(GPVI). As a control, convulxin, a GPVI specific agonist was used. However, 
due to the interesting results observed thus far with altered redox environments 
and their impact specifically on the activation of platelets by collagen, it was 
deemed essential to clarify that the type I collagen used was indeed interacting 
with integrin 21. 
 
A broad Src family kinase inhibitor, PP2 (25 M), inhibited platelet aggregation 
to both 38 g/ml collagen and 50 ng/ml convulxin. PP2 had no effect on the 
platelet aggregation response of unactivated platelets or platelets activated with 
0.1U/ml thrombin. (n=4, ***p < 0.001) (Figure 4.16 (a)).  
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Bay 61-3606 (5 M), a specific Syk kinase inhibitor, inhibited platelet 
aggregation induced by 50 ng/ml convulxin. Bay 61-3606 had no significant 
impact on the level of platelet aggregation of unactivated platelets or platelets 
activated with 38 g/ml collagen or 0.1U/ml thrombin (n=4, ***p < 0.001) (Figure 
4.16 (b)).  
 
4.2.4 Examination of the surface thiol population of platelets in 
suspension 
The surface thiol population of platelets, in suspension, was examined using the 
well-known Ellman’s test (Ellman, 1959), a colourimetric assay which employs 
Ellman’s reagent, also known as 5, 5’-Dithio-bis-(2-nitrobenzoic acid) (DTNB). 
In the presence of a thiol group, DTNB is cleaved to form a mixed disulphide 
group and 2-nitro-5-benzoic acid (NTB). The ratio of thiol groups to NTB is 1:1. 
Therefore, measuring the concentration of NTB gives a direct measure of the 
numbers of free thiol groups present in a sample. NTB has an intense yellow 
colour, the absorbance of which was measured by a Wallac plate reader at a 
wave length of 405 nm. 
 
In order to calculate the concentration of thiol groups detected on the surface of 
platelets, a standard curve was first generated with the thiol containing 
compound: cysteine (0 - 15 M), in the presence of 100 M DTNB 
(Figure 4.17). The standard curve was found to have an r2 value of 0.989 and 
the equation of the line to determine the platelet thiol population (M) was 
calculated: y = 0.007x + 0.059. 
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The surface thiol population of unactivated platelets and platelets activated with 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin was measured. 
Activation of platelets by collagen was found to induce a significant increase in 
the platelet surface thiol population, compared to unactivated platelets and 
platelets activated with thrombin or convulxin. The surface thiol population of 
unactivated platelets and platelets activated with thrombin or convulxin was 
comparable (n=6, ***p < 0.001) (Figure 4.18 (a)).  
 
The external redox environment was altered by the introduction of glutathione or 
cysteine redox potentials. These redox potentials were generated by combining 
various ratios of the reduced (GSH, Cys) and oxidised (GSSG, CySS) forms of 
these low molecular weight thiols according to the Nernst equation and 
Tables 2.1 and 2.2.  
 
In the presence of an oxidising (GSH/GSSG: -10 mV, Cys/CySS: +4 mV) 
external redox environment, there was also a significant increase in the surface 
thiol population of platelets activated with collagen, compared to unactivated 
platelets. Again, the thiol population of unactivated platelets was similar to that 
of platelets activated with thrombin and those activated with convulxin (n=6, 
***p < 0.001) (Figure 4.18 (b)). There was a similar trend, though not statistically 
significant, of increased thiols on the surface of collagen activated platelets 
compared to unactivated platelets in the presence of a mean (GSH/GSSG: 
-130 mV, Cys/CySS: -82 mV) redox environment. There was no change in the 
thiol population of platelets activated by thrombin or convulxin (n=6) 
(Figure 4.18 (c)).  
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However, in the presence of a reducing (GSH/GSSG: -264 mV, Cys/CySS: 
-148 mV) external redox environment, the generation of free thiols on the 
surface of platelets activated with collagen was inhibited. There was also no 
effect on the surface thiol population of unactivated platelets or platelets 
activated with thrombin or convulxin (n=6) (Figure 4.18 (d)).  
 
The fold increase in the surface thiol population of platelets activated with either 
thrombin, collagen or convulxin compared to unactivated platelets in the 
presence of each external redox environment is shown in Figures 4.19 (a) and 
(b). These graphs illustrate very clearly the dramatic, (approximately 8-fold), 
increase in the thiol population of platelets activated with collagen, compared to 
unactivated platelets and platelets activated with thrombin or convulxin. This 
thiol population increase noticeably diminishes as the external redox 
environment becomes more reducing. Furthermore, there is no change in the 
thiol population of platelets activated with thrombin or convulxin, compared to 
unactivated platelets in the presence of any of the redox environments (n=6, 
*p < 0.05, **p < 0.01) (Figure 4.15). While the trend of the results is similar in 
the presence of both GSH/GSSG and Cys/CySS redox potentials; it is 
interesting to note the different kinetics between the two redox couples. This 
may be due to differing reactivity between the thiol groups of each redox couple, 
with Cys/CySS appearing the more reactive. The pKa ionisation constants for 
the thiol groups of GSH and Cys are 8.8 and 8.3, respectively (Winterbourn & 
Metodiewa, 1999). 
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From the graphs in Figure 4.19 (a) – (d), there is a considerable difference in 
the thiol concentrations of platelets in the absence of an altered external redox 
environment, compared to in the presence of a reducing external redox. This is 
due to the presence of excess thiol containing redox reagents themselves (GSH 
or Cys) reacting with DTNB and thus creating a background. Subtraction of this 
background was performed. However, subtraction of the background signal 
resulted in negative values. This may be due to platelet thiol/disulphide groups 
themselves reacting with the redox reagents.  
 
The average number of moles of thiol per platelet in each of the activation 
states and redox environments were calculated and are shown in Tables 4.1 (a) 
and (b). Again, these figures very clearly demonstrate the significant increase in 
the average number of moles of thiol found on the surface of collagen activated 
platelets. This diminishes as the redox environment becomes more reducing in 
nature. It is important to note the figures for the average number of moles of 
thiols in the presence of the redox environments, again, do not take the 
background of excess redox reagents into consideration. Nonetheless, it is fair 
to make a comparison of the platelets activated with each agonist in the same 
external redox environment, for example, the number of moles of thiol on 
unactivated platelets in the presence of an oxidising environment can be 
compared to that of platelets activated with collagen, convulxin or thrombin in 
an oxidising environment but not to platelets in a mean or reducing redox 
environment.  
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4.2.5 Examination of the surface thiol population of statically adhered 
platelets  
The levels of platelet adhesion to a number of substrates were investigated 
using the chromogenic substrate para-nitrophenyl phosphate (pNPP). pNPP 
reacts with phosphatases to form para-nitrophenol which has an intense yellow 
colour in the presence of alkaline conditions. The absorbance of para-
nitrophenol, read at 405 nm with a Wallac plate reader, is directly proportional to 
the quantity of phosphatases present and therefore an indirect measurement of 
the number of adhered platelets.  
Under static conditions, unactivated platelets adhered to 20 g/ml fibrinogen, 
10 g/ml collagen and 1 g/ml collagen related peptide (CRP) at comparable 
levels. Platelet adhesion to 1 % bovine serum albumin (BSA) was used as a 
negative control for the adhesion assay (n=6, ***p < 0.001) (Figure 4.20).  
 
The thiol population of platelets adhered to BSA (1 %), fibrinogen (20 g/ml), 
collagen (10 g/ml) and CRP (1 g/ml) was assessed using Ellman’s test with 
5, 5’-Dithio-bis-(2-nitrobenzoic acid) (DTNB). While not quite reaching statistical 
significance, there was an increase in the thiol population of platelets adhered 
to collagen compared to platelets adhered to fibrinogen or CRP. Interestingly, 
there was also a trend towards an increase in the thiol population of platelets 
adhered to fibrinogen, compared with platelets adhered to CRP (n=6) (Figure 
4.21).  
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The impact of an altered redox environment on the levels of platelet adhesion to 
1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen and 1 g/ml collagen related 
peptide (CRP) was also examined. This study was carried out by determining 
the numbers of platelets adhered to each substrate as observed by confocal 
microscopy. Adhered platelets were stained with Alex Fluor® 488 phalloidin, 
imaged and counted using ImageJ software.  
There was a significant decrease in the number of platelets adhered to collagen 
in the presence of a reducing (GSH/GSSG: -264 mV) external redox 
environment, compared to the level of platelet adhesion to collagen in the 
absence of an altered redox environment. In a mean (GSH/GSSG: -130 mV) or 
oxidising (GSH/GSSG: -10 mV) external redox environment no significant 
impact on platelet adhesion to collagen was observed. Platelets adhered to 
BSA, fibrinogen or CRP were not altered by an altered external redox 
environment (n=4, *p < 0.05) (Figures 4.22 (a - e)).  
The impact of an altered external redox environment on the thiol population of 
adhered platelets was also investigated. Platelets were incubated with 
GSH/GSSG redox potentials: oxidising (-10 mV), mean (-130 mV) and reducing 
(-264 mV) then adhered to 1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen 
and 1 g/ml CRP. The thiol population of adhered platelets was assessed using 
Ellman’s test with 5, 5’-Dithio-bis-(2-nitrobenzoic acid) (DTNB). 
There was an indication of a decrease in the thiol population of platelets 
adhered to collagen in the presence of a reducing external redox environment, 
compared to the thiol population of platelets adhered to collagen in the absence 
of an altered external redox environment. However, this did not reach statistical 
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significance. In an oxidising or mean external redox environment no impact on 
the thiol population of platelets adhered to collagen was observed. The surface 
thiol population of platelets adhered to BSA, fibrinogen or CRP remained 
unchanged regardless of the external redox environment (n=3) (Figure 4.23).  
The thiol population of platelets adhered to BSA, fibrinogen, collagen and CRP 
was also examined with confocal microscopy. Platelets adhered to each of the 
substrates were stained with a fluorescently labelled, thiol reactive probe: Atto 
655 maleimide. Similar to the results obtained from the DTNB adhesion studies, 
there was increased binding of Atto 655 maleimide to platelets adhered to 
collagen and fibrinogen compared to platelets adhered to BSA or CRP. This is 
indicative of an increased surface free thiol population on platelets adhered to 
collagen or fibrinogen. There was a degree of binding of Atto 655 maleimide to 
platelets adhered to CRP. However, the fluorescence was found to be 
associated with the outer regions and lamellipodia of the platelets, in contrast to 
platelets adhered to collagen and fibrinogen, whereby the fluorescence was 
concentrated in the centre region of the spread platelets (n=4) (Figure 4.24).   
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Figure 4.1 (a) Raman spectra of unactivated platelets and platelets activated with 
either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. Gel-filtered 
platelets were fixed with 1 % formaldehyde, centrifuged and supernatant removed. 
Raman spectra were obtained from the resulting platelet pellet. Spectra were baseline 
subtracted and normalised to the lipid peak at approximately 3000 cm-1. (i) Three or 
four spectra were taken for each platelet activator and averaged, to give one spectrum 
per activator per donor. (ii) Signature Raman spectra of platelets generated by 
averaging spectra for each platelet activator from all n=10 donors. 
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Figure 4.1 (b) Principal component analysis (PCA) of full Raman spectra of 
unactivated platelets and platelets activated with either 0.1U/ml thrombin, 38 
g/ml collagen or 50 ng/ml convulxin. (i) PCA of all spectra of all donors. (ii) PCA of  
average spectra, graphed on same scale as (i). (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. Data shown is from n=10 independent experiments. 
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Figure 4.1 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the full spectrum of all the platelet 
Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 (PC-
2) from the PCA of spectra from all donors (Figure 4.1 (b) (i)). The components are 
numbered according to the amount of variance they account for, i.e. PC-1 accounts for 
most of the variance found between the platelet samples. PCA analysis was carried out 
on the baseline subtracted and normalised Raman data of all samples using The 
Unscrambler® software. 
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Figure 4.1 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the full spectrum of the average or 
signature platelet Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature Raman spectra (Figure 4.1 (b) (ii) 
and (iii)). The components are numbered according to the amount of variance they 
account for, i.e. PC-1 accounts for most of the variance found between the platelet 
samples. PCA analysis was carried out on the baseline subtracted and normalised 
Raman data of all samples using The Unscrambler® software. 
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Figure 4.2 (a) The thiol region of the Raman spectra of unactivated platelets and 
platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml 
convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, centrifuged and 
supernatant removed. Raman spectra were obtained from the resulting platelet pellet. 
Spectra were baseline subtracted and normalised to the lipid peak at approximately 
3000 cm-1. (i) Three or four spectra were taken for each platelet activator and 
averaged, to give one spectrum per activator per donor. (ii) Signature Raman spectra 
of platelets generated by averaging spectra for each platelet activator from all n=10 
donors. 
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Figure 4.2 (b) Principal component analysis (PCA) of the thiol region of the 
Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 2400 – 2600 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments. (ii) PCA of  
average spectra, graphed on same scale as (i). (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.2 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the thiol region of all platelet Raman 
spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 (PC-2) from 
the PCA of the spectra from all donors (Figure 4.2 (b) (i)). The components are 
numbered according to the amount of variance they account for, i.e. PC-1 accounts for 
most of the variance found between the platelet samples. PCA analysis was carried out 
on the baseline subtracted and normalised Raman data of all samples using The 
Unscrambler® software. 
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Figure 4.2 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the thiol region of the signature platelet 
Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 
(PC-2) from the PCA of the signature spectra (Figure 4.2 (b) (ii) and (iii)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.3 (a) The disulphide region of the Raman spectra of unactivated 
platelets and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.3 (b) Principal component analysis (PCA) of the disulphide region of the 
Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 400 – 650 cm-1 region of the Raman spectra.  The graphs are scatter 
plots of the first principal component (PC-1) versus the second principal component 
(PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  average 
spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra on a 
smaller scale illustrating that the samples can be differentiated according to the platelet 
activator. 
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Figure 4.3 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the disulphide region of all platelet 
Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 
(PC-2) from the PCA of spectra from all donors (Figure 4.3 (b) (i)). The components are 
numbered according to the amount of variance they account for, i.e. PC-1 accounts for 
most of the variance found between the platelet samples. PCA analysis was carried out 
on the baseline subtracted and normalised Raman data of all samples using The 
Unscrambler® software. 
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Figure 4.3 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the disulphide region of the signature 
platelet Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature spectra (Figure 4.3 (b) (ii) and (iii)). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.4 (a) The amide I region of the Raman spectra of unactivated platelets 
and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen or 
50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.4 (b) Principal component analysis (PCA) of the amide I region of the 
Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 1600 – 1700 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  
average spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.4 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the amide I region of the spectrum of 
all samples. (i) Principal component-1 (PC-1) and (ii) Principal component-2 (PC-2) 
from the PCA of spectra from all donors (Figure 4.4 (b) (i)). The components are 
numbered according to the amount of variance they account for, i.e. PC-1 accounts for 
most of the variance found between the platelet samples. PCA analysis was carried out 
on the baseline subtracted and normalised Raman data of all samples using The 
Unscrambler® software. 
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Figure 4.4 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the amide I region of the signature 
Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 
(PC-2) from the PCA of the signature spectra (Figure 4.4 (b) (ii) and (iii)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.5 (a) The amide III region of the Raman spectra of unactivated platelets 
and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen or 
50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.5 (b) Principal component analysis (PCA) of the amide III region of the 
Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 1200 - 1400 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  
average spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.5 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the amide III region of all platelet 
Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal component-2 
(PC-2) from the PCA of all spectra (Figure 4.5 (b) (i)). The components are numbered 
according to the amount of variance they account for, i.e. PC-1 accounts for most of 
the variance found between the platelet samples. PCA analysis was carried out on the 
baseline subtracted and normalised Raman data of all samples using The 
Unscrambler® software. 
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Figure 4.5 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the amide III region of the signature 
platelet Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature Raman spectra (Figure 4.5 (b) (ii) 
and (iii)). The components are numbered according to the amount of variance they 
account for, i.e. PC-1 accounts for most of the variance found between the platelet 
samples. PCA analysis was carried out on the baseline subtracted and normalised 
Raman data of all samples using The Unscrambler® software. 
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Figure 4.6 (a) The 700 – 1400 cm-1 region of the Raman spectra of unactivated 
platelets and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.6 (b) Principal component analysis (PCA) of the 700 – 1400 cm-1 region 
of the Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 700 – 1400 cm-1 region of the Raman spectra. The graphs are scatter 
plots of the first principal component (PC-1) versus the second principal component 
(PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  average 
spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra on a 
smaller scale illustrating that the samples can be differentiated according to the platelet 
activator. 
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Figure 4.6 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 700 – 1400 cm-1 region of the 
spectrum of all samples. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of spectra from all donors (Figure 4.6 (b) (i)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.6 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 700 – 1400 cm-1 region of the 
signature Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature spectra (Figure 4.6 (b) (ii) and (iii)). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.7 (a) The 1200 – 1900 cm-1 region of the Raman spectra of unactivated 
platelets and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.7 (b) Principal component analysis (PCA) of the 1200 – 1900 cm-1 region 
of the Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 1200 – 1900 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  
average spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.7 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 1200 – 1900 cm-1 region of the 
spectrum of all samples. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of spectra from all donors (Figure 4.7 (b) (i)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.7 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 1200 – 1900 cm-1 region of the 
signature Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature spectra (Figure 4.7 (b) (ii) and (iii)). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.8 (a) The 2200 – 2900 cm-1 region of the Raman spectra of unactivated 
platelets and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.8 (b) Principal component analysis (PCA) of the 2200 – 2900 cm-1 region 
of the Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 2200 – 2900 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  
average spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.8 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 2200 – 2900 cm-1 region of the 
spectrum of all samples. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of spectra from all donors (Figure 4.8 (b) (i)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.8 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 2200 – 2900 cm-1 region of the 
signature Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature spectra (Figure 4.8 (b) (ii) and (iii)). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.9 (a) The 2700 – 3500 cm-1 region of the Raman spectra of unactivated 
platelets and platelets activated with either 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin. Gel-filtered platelets were fixed with 1 % formaldehyde, 
centrifuged and supernatant removed. Raman spectra were obtained from the resulting 
platelet pellet. Spectra were baseline subtracted and normalised to the lipid peak at 
approximately 3000 cm-1. (i) Three or four spectra were taken for each platelet activator 
and averaged, to give one spectrum per activator per donor. (ii) Signature Raman 
spectra of platelets generated by averaging spectra for each platelet activator from all 
n=10 donors. 
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Figure 4.9 (b) Principal component analysis (PCA) of the 2700 –3500 cm-1 region 
of the Raman spectra of unactivated platelets and platelets activated with either 
0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin. PCA analysis was 
performed on the 2700 – 3500 cm-1 region of the Raman spectra. The graphs are 
scatter plots of the first principal component (PC-1) versus the second principal 
component (PC-2). (i) PCA of all donors, n=10 independent experiments, (ii) PCA of  
average spectra, graphed on same scale as (i), (iii) PCA of signature, average spectra 
on a smaller scale illustrating that the samples can be differentiated according to the 
platelet activator. 
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Figure 4.9 (c) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 2700 – 3500 cm-1 region of the 
spectrum of all samples. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of spectra from all donors (Figure 4.9 (b) (i)). The 
components are numbered according to the amount of variance they account for, i.e. 
PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.9 (d) The loadings of the principal components used in the Principal 
component analysis (PCA) scatter plot of the 2700 – 3500 cm-1 region of the 
signature Raman spectra. (i) Principal component-1 (PC-1) and (ii) Principal 
component-2 (PC-2) from the PCA of the signature spectra (Figure 4.9 (b) (ii) and (iii)). 
The components are numbered according to the amount of variance they account for, 
i.e. PC-1 accounts for most of the variance found between the platelet samples. PCA 
analysis was carried out on the baseline subtracted and normalised Raman data of all 
samples using The Unscrambler® software. 
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Figure 4.10 (a) Signature carotenoid peaks observed in the Raman spectra of 
unactivated platelets and platelets activated with either 0.1U/ml thrombin, 
38 g/ml collagen or 50 ng/ml convulxin. Characteristic carotenoid peaks are 
labelled (i) 968 cm-1, (ii) 1006 cm-1, (iii) 1160 cm-1 and (iv) 1525 cm-1. Gel-filtered 
platelets were fixed with 1 % formaldehyde, centrifuged and supernatant removed. 
Raman spectra were obtained from the resulting platelet pellet. Spectra were baseline 
subtracted and normalised to the lipid peak at approximately 3000 cm-1. Spectra shown 
are the average spectra of n=10 independent experiments.   
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Figure 4.10 (b) There is a trend towards an increase in intensity of carotenoid 
peaks in the Raman spectrum of platelets activated with 0.1U/ml thrombin, 
38 g/ml collagen or 50 ng/ml convulxin to unactivated platelets. Characteristic 
carotenoid peaks in the Raman spectra of platelets were analysed: (i) 968 cm-1, (ii) 
1006 cm-1, (iii) 1160 cm-1 and (iv) 1525 cm-1. Gel-filtered platelets were fixed with 1 % 
formaldehyde, centrifuged and supernatant removed. Raman spectra were obtained 
from the resulting platelet pellet. Spectra were baseline subtracted and normalised to 
the lipid peak at approximately 3000 cm-1. The fold increase was determined by 
recording the intensity values for all conditions, assigning unactivated a value of one 
and calculating the increase in intensity of the activated platelets relative to this. Data is 
presented as the mean ± SEM, n=10 independent experiments. 
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Figure 4.11 Thrombin (0.1U/ml), collagen (38 g/ml) and convulxin (50 ng/ml) 
induce comparable levels of platelet aggregation. (a) Gel-filtered platelets were 
either unactivated or activated with 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml 
convulxin for 10 minutes at 37 °C with constant stirring at 1100 rpm. Each agonist was 
found to induce approximately 80 % platelet aggregation, with no statistically significant 
difference between each agonist. Data is presented as the mean ± SEM, n=4 
independent experiments, ***p < 0.001. (b) A platelet aggregation tracing illustrating 
the levels of platelet aggregation of (1) unactivated gel-filtered platelets; (2) gel-filtered 
platelets activated with 0.1U/ml thrombin; (3) 38 g/ml collagen; (4) 50 ng/ml convulxin. 
This tracing is representative of n=4 independent experiments.  
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Figure 4.12 Hydrochloric acid (HCl) does not affect unactivated platelets or 
platelets activated with either thrombin, collagen or convulxin. Gel-filtered 
platelets were incubated with 1 mM HCl for 10 minutes at 37 °C with constant stirring at 
1100 rpm. Platelets remained unactivated or were then activated with either 0.1U/ml 
thrombin, 38 g/ml collagen or 50 ng/ml convulxin for at least 10 minutes.  Data is 
presented as the mean ± SEM, n=4 independent experiments. 
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Figure 4.13 Altering the external redox environment has no impact on the 
activation status of unactivated platelets. The level of platelet aggregation of 
unactivated gel-filtered platelets in the presence of (i) GSH/GSSG redox potentials: 
oxidising (-10 mV), mean (-130 mV) or reducing (-264 mV) or (ii) Cys/CySS redox 
potentials: oxidising (+4 mV), mean (-82 mV) or reducing (-148 mV) was measured. 
Platelet aggregations were carried out for at least 10 minutes at 37 °C with constant 
stirring at 1100 rpm. Data is presented as the mean ± SEM, n=6 independent 
experiments.  
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Figure 4.14 A reducing external redox environment inhibits platelet aggregation 
to collagen but has no impact on unactivated platelets or platelet aggregation 
induced by thrombin or convulxin. The level of platelet aggregation of unactivated 
gel-filtered platelets or gel-filtered platelets activated with 0.1U/ml thrombin, 38 g/ml 
collagen or convulxin in the presence of (a) GSH/GSSG redox potentials (-10 mV, 
-130 mV or -264 mV) or (b) Cys/CySS redox potentials (+4 mV, -82 mV or -148 mV) 
was measured. Platelet aggregations were carried out for at least 10 minutes at 37 °C 
with constant stirring at 1100 rpm. Data is presented as the mean ± SEM, n=6 
independent experiments, ***p < 0.001. (As demonstrated by (Murphy et al, 2010). 
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Figure 4.15 (a) A reducing external redox environment generated by the reducing 
agents glutathione (GSH), tris(2-carboxyethyl)phosphine (TCEP) and 
dithiothreitol (DTT) inhibits platelet aggregation to collagen but has no 
significant impact on unactivated platelets or platelet aggregation induced by 
thrombin or convulxin. The level of platelet aggregation of unactivated gel-filtered 
platelets or gel-filtered platelets activated with 0.1U/ml thrombin, 38 g/ml collagen or 
convulxin in the presence of 45 M GSH, 45 M TCEP or 45 M DTT was measured. 
Platelet aggregations were carried out for at least 10 minutes at 37 °C with constant 
stirring at 1100 rpm. Data is presented as the mean ± SEM, n=4 independent 
experiments, ***p < 0.001. 
 
 
 
 
 251 
 
Figure 4.15 (b) An oxidising external redox environment generated by the 
oxidising agents glutathione (GSSG), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) 
and cystine (CySS) has no impact on unactivated platelets or platelet 
aggregation induced by thrombin, collagen or convulxin. The level of platelet 
aggregation of unactivated gel-filtered platelets or gel-filtered platelets activated with 
0.1U/ml thrombin, 38 g/ml collagen or convulxin in the presence of 45 M GSSG, 
45 M DTNB or 45 M CySS was measured. Platelet aggregations were carried out for 
at least 10 minutes at 37 °C with constant stirring at 1100 rpm. Data is presented as 
the mean ± SEM, n=4 independent experiments.  
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Figure 4.16 (a) The broad Src family kinase inhibitor, PP2, inhibits platelet 
aggregation induced by collagen and convulxin. There is no impact on the level of 
platelet aggregation induced by thrombin. Gel-filtered platelets were incubated with 
PP2 (25 M) for 15 minutes at 37 °C, with stirring (1100 rpm). Platelets remained 
unactivated or activated with either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml 
convulxin. Platelet aggregations were followed for at least 10 minutes at 37 °C, with 
constant stirring at 1100 rpm. Data is presented as the mean ± SEM, n=4 independent 
experiments, ***p < 0.001. 
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Figure 4.16 (b) The Syk kinase inhibitor, BAY 61-3606, inhibits convulxin induced 
platelet aggregation only. There is no impact on the level of platelet aggregation 
induced by thrombin or collagen. Gel-filtered platelets were incubated with BAY 
61-3606 (5 M) for 10 minutes at 37 °C, with stirring (1100 rpm). Platelets remained 
unactivated or activated with either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml 
convulxin. Platelet aggregations were followed for at least 10 minutes at 37 °C, with 
constant stirring at 1100 rpm. Data is presented as the mean ± SEM, n=4 independent 
experiments, ***p < 0.001. 
 
 
 
 
 
 254 
 
Figure 4.17 A standard curve generated with cysteine in the presence of 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB). Cysteine (Cys), a thiol containing compound, 
at a number of concentrations ranging from 0 - 15 M, was incubated with DTNB 
(100 M) for 1 minute at room temperature. The absorbance of the samples was read 
in a clear, flat bottom 96-well plate at 405 nm in the Wallac plate reader. Data is 
presented as the mean ± SEM, n=3 independent experiments, with each performed in 
triplicate. The concentration of thiols was calculated using the equation of the line: y = 
0.007x + 0.059, r2 = 0.9893. 
 
 
 
 
 
 255 
 
Figure 4.18 (a) There is a significant increase in the surface free thiol population 
of platelets activated with collagen compared to unactivated platelets and 
platelets activated by thrombin or convulxin. Gel-filtered platelets were either 
unactivated or activated with 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin 
for 10 minutes at 37 °C, in the absence of stirring. 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB) (100 M) was added and incubated for 1 minute at room temperature. 
Samples were centrifuged and the supernatant was removed and transferred to a 
clear, flat-bottom 96-well plate. Absorbance was measured at 405 nm, using a Wallac 
plate reader. The thiol concentration was calculated from the cysteine standard curve. 
Data is presented as the mean ± SEM, n=6 independent experiments, ***p < 0.001.  
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Figure 4.18 (b) In the presence of an oxidising external redox environment, there 
is a significant increase in the surface free thiol population of platelets activated 
with collagen compared to unactivated platelets and platelets activated with 
thrombin or convulxin. Gel-filtered platelets remained unactivated or activated with 
either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin in presence of (i) a 
GSH/GSSG oxidising redox potential (-10 mV) or (ii) a Cys/CySS oxidising redox 
potential (+4 mV). Gel-filtered platelets were incubated with agonists and redox for 10 
minutes at 37 °C, in the absence of stirring. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) 
(100 M) was added and incubated for 1 minute at room temperature. Samples were 
centrifuged and the supernatant was removed and transferred to a clear, flat-bottom 
96-well plate. Absorbance was measured at 405 nm, using a Wallac plate reader. The 
thiol concentration was calculated from the cysteine standard curve. Data is presented 
as the mean ± SEM, n=6 independent experiments, ***p < 0.001.  
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Figure 4.18 (c) In the presence of a mean external redox environment, there is a 
trend towards an increase in the surface free thiol population of platelets 
activated with collagen compared to unactivated platelets and platelets activated 
with thrombin or convulxin. Gel-filtered platelets were unactivated or activated with 
either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin in presence of (i) a 
GSH/GSSG mean redox potential (-130 mV) or (ii) a Cys/CySS mean redox potential 
(-82 mV). Gel-filtered platelets were incubated with agonists and redox for 10 minutes 
at 37 °C, in the absence of stirring. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (100 M) 
was added and incubated for 1 minute at room temperature. Samples were centrifuged 
and the supernatant was removed and transferred to a clear, flat-bottom 96-well plate. 
Absorbance was measured at 405 nm, using a Wallac plate reader. The thiol 
concentration was calculated from the cysteine standard curve. Data is presented as 
the mean ± SEM, n=6 independent experiments.  
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Figure 4.18 (d) In the presence of a reducing external redox environment, there is 
no difference between the surface thiol population of unactivated platelets and 
platelets activated with either thrombin, collagen or convulxin. Gel-filtered 
platelets were either unactivated or activated with 0.1U/ml thrombin, 38 g/ml collagen 
or 50 ng/ml convulxin in presence of (i) a GSH/GSSG reducing redox potential 
(-264 mV) or (ii) a Cys/CySS reducing redox potential (-148 mV). Gel-filtered platelets 
were incubated with agonists and redox for 10 minutes at 37 °C, in the absence of 
stirring. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (100 M) was added and incubated 
for 1 minute at room temperature. Samples were centrifuged and the supernatant was 
removed and transferred to a clear, flat-bottom 96-well plate. Absorbance was 
measured at 405 nm, using a Wallac plate reader. The thiol concentration was 
calculated from the cysteine standard curve. Data is presented as the mean ± SEM, 
n=6 independent experiments.  
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Figure 4.19 There is an approximately 8-fold increase in the surface thiol 
population of platelets activated with collagen compared to unactivated platelets 
and platelets activated with thrombin or convulxin. This increase diminishes as 
the external redox environment becomes more reducing in nature. There is no 
change in the surface thiol population of platelets activated with thrombin or collagen 
compared to unactivated platelets. Gel-filtered platelets were unactivated (no redox) or 
activated with either 0.1U/ml thrombin, 38 g/ml collagen or 50 ng/ml convulxin for 10 
minutes at 37 °C (without stirring) in the presence of (a) GSH/GSSG redox potentials or 
(b) Cys/CySS redox potentials. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (100 M) 
was added and incubated for 1 minute at room temperature. Samples were centrifuged 
and the supernatant was removed and transferred to a clear, flat-bottom 96-well plate. 
Absorbance was measured at 405 nm, using a Wallac plate reader. The thiol 
concentration was calculated from the cysteine standard curve. Fold increase was 
determined by assigning a value of 1 to unactivated platelets and calculating the 
change in platelet surface thiol population relative to this value. Data is presented as 
the mean ± SEM, n=6 independent experiments, *p < 0.05, **p < 0.01.  
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Table 4.1 The average number of moles of thiols present on the surface of 
unactivated platelets or platelets activated with either thrombin, collagen or 
convulxin in the presence of (a) GSH/GSSG redox potentials or (b) Cys/CySS 
redox potentials.  
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Figure 4.20 The extent of platelet adhesion to fibrinogen (20 g/ml), collagen (10 
g/ml) or collagen related peptide (CRP) (1 g/ml) is similar. (a) Washed platelets 
were allowed to adhere to clear, flat bottom 96-well plates coated with either BSA, 
fibrinogen, collagen or CRP. Adhered platelets were incubated with a lysis buffer 
containing para-nitrophenyl phosphate (pNPP) for 1 hour at room temperature. The 
reaction was stopped by the addition of 2 M NaOH. Absorbance was measured using a 
Wallac plate reader. Data is presented as the mean ± SEM, n=6 independent 
experiments, ***p < 0.001. (b) Washed platelets adhered to poly-L-lysine slides coated 
with (i) 1 % BSA, (ii) 20 g/ml fibrinogen, (iii) 10 g/ml collagen or (iv) 1 g/ml CRP for 
45 minutes at 37 °C. Samples were fixed with 1 % formaldehyde for 10 minutes at 
room temperature and permeabilised with 0.1 % Triton-X-100 for 10 minutes at room 
temperature. Platelets were stained with Alexa Fluor® 488 phalloidin. Samples were 
imaged using a Zeiss LSM510 Meta confocal microscope with a 63X oil-immersion 
lens. A laser wavelength of 488 nm, at an intensity of 1 % was employed. 
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Figure 4.21 While not statistically significant, there is an increase observed in the 
surface free thiol population of platelets adhered to collagen compared to that of 
platelets adhered to fibrinogen or collagen related peptide (CRP). Washed 
platelets were allowed to adhere to clear, flat bottom 96-well plates coated with either 
1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen or 1 g/ml CRP for 45 minutes at 
37 °C. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (100 M) was added and incubated 
for 1 minute at room temperature. The absorbance was measured at 405 nm using a 
Wallac plate reader. Data is presented as the mean ± SEM, n=6 independent 
experiments.  
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Figure 4.22 (a) Platelet adhesion to collagen is significantly decreased in a 
reducing external redox environment. Washed platelets were either untreated or 
incubated with GSH/GSSG redox potentials. Platelets were adhered to poly-L-lysine 
slides coated with (i) 1 % BSA, (ii) 20 g/ml fibrinogen, (iii) 10 g/ml collagen or (iv) 
1 g/ml CRP for 45 minutes at 37 °C. Samples were fixed with 1 % formaldehyde for 
10 minutes at room temperature and permeabilised with 0.1 % Triton-X-100 for 
10 minutes at room temperature. Platelets were stained with Alexa Fluor® 488 
phalloidin and imaged using a Zeiss LSM510 Meta confocal microscope with a 63X 
oil-immersion lens. A laser wavelength of 488 nm, at an intensity of 1 % was employed. 
Data was analysed using the ‘Cell Counter’ plugin in the ImageJ software package. 
Date is presented as the mean ± SEM, n=4 independent experiments, *p < 0.05. 
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Figure 4.22 (b) An altered external redox environment has no impact on platelets 
adhered to bovine serum albumin (BSA). Washed platelets were either untreated or 
incubated with GSH/GSSG redox potentials for 10 minutes at 37 °C: (i) no redox, (ii) 
oxidising (-10 mV), (iii) mean (-130 mV) and (iv) reducing (-264 mV). Platelets adhered 
to poly-L-lysine slides coated with 1 % BSA for 45 minutes at 37 °C. Samples were 
fixed with 1 % formaldehyde for 10 minutes at room temperature and permeabilised 
with 0.1 % Triton-X-100 for 10 minutes at room temperature. Platelets were stained 
with Alexa Fluor® 488 phalloidin and imaged using a Zeiss LSM510 Meta confocal 
microscope with a 63X oil-immersion lens. A laser wavelength of 488 nm, at an 
intensity of 1 % was employed. Images are representative of n=4 independent 
experiments. 
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Figure 4.22 (c) An altered external redox environment has no impact on platelets 
adhered to fibrinogen. Washed platelets were either untreated or incubated with 
GSH/GSSG redox potentials for 10 minutes at 37 °C: (i) no redox, (ii) oxidising 
(-10 mV), (iii) mean (-130 mV) and (iv) reducing (-264 mV).  Platelets adhered to 
poly-L-lysine slides coated with 20 g/ml fibrinogen for 45 minutes at 37 °C. Samples 
were fixed with 1 % formaldehyde for 10 minutes at room temperature and 
permeabilised with 0.1 % Triton-X-100 for 10 minutes at room temperature. Platelets 
were stained with Alexa Fluor® 488 phalloidin and imaged using a Zeiss LSM510 Meta 
confocal microscope with a 63X oil-immersion lens. A laser wavelength of 488 nm, at 
an intensity of 1 % was employed. Images are representative of n=4 independent 
experiments. 
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Figure 4.22 (d) Platelet adhesion to collagen is decreased in a reducing external 
redox environment. Washed platelets were either untreated or incubated with 
GSH/GSSG redox potentials for 10 minutes at 37 °C: (i) no redox, (ii) oxidising 
(-10 mV), (iii) mean (-130 mV) and (iv) reducing (-264 mV).  Platelets adhered to 
poly-L-lysine slides 10 g/ml collagen for 45 minutes at 37 °C. Samples were fixed with 
1 % formaldehyde for 10 minutes at room temperature and permeabilised with 0.1 % 
Triton-X-100 for 10 minutes at room temperature. Platelets were stained with Alexa 
Fluor® 488 phalloidin for 20 minutes at room temperature. Samples were imaged using 
a Zeiss LSM510 Meta confocal microscope with a 63X oil-immersion lens. A laser 
wavelength of 488 nm, at an intensity of 1 % was employed. Images are representative 
of n=4 independent experiments. 
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Figure 4.22 (e) An altered external redox environment has no significant impact 
on platelets adhered to collagen related peptide (CRP). Washed platelets were 
either untreated or incubated with GSH/GSSG redox potentials for 10 minutes at 37 °C: 
(i) no redox, (ii) oxidising (-10 mV), (iii) mean (-130 mV) and (iv) reducing (-264 mV). 
Platelets were adhered to poly-L-lysine slides coated with 1 g/ml CRP for 45 minutes 
at 37 °C. Samples were fixed with 1 % formaldehyde for 10 minutes at room 
temperature and permeabilised with 0.1 % Triton-X-100 for 10 minutes at room 
temperature. Platelets were stained with Alexa Fluor® 488 phalloidin for 20 minutes at 
room temperature. Samples were imaged using a Zeiss LSM510 Meta confocal 
microscope with a 63X oil-emersion lens. A laser wavelength of 488 nm, at an intensity 
of 1 % was employed. Images are representative of n=4 independent experiments. 
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Figure 4.23 In the presence of a reducing external redox environment, the thiol 
population of platelet adhered to collagen is decreased, though not significantly. 
This finding is consistent with a decreased level of platelet adhesion to collagen 
observed in a reducing environment. The external redox environment has no 
impact on the thiol population of platelets adhered to BSA, fibrinogen or 
collagen related peptide (CRP). Washed platelets were either untreated or incubated 
with GSH/GSSG redox potentials: oxidising (-10 mV), mean (-130 mV) and reducing 
(-264 mV) for 10 minutes at 37 °C. Platelets were then allowed to adhere to clear, flat 
bottom 96-well plates coated with 1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen or 
1 g/ml CRP for 45 minutes at 37 °C. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) 
(100 M) was added and incubated for 1 minute at room temperature. Absorbance was 
measured, using a Wallac plate reader, at 405 nm. Data is presented as the mean ± 
SEM, n=3 independent experiments.  
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Figure 4.24 The surface thiol population of platelets adhered to BSA, fibrinogen, 
collagen and collagen related peptide (CRP) labelled with the thiol probe Atto 655 
maleimide. Washed platelets adhered to poly-L-lysine slides coated with (a) 1 % BSA, 
(b) 20 g/ml fibrinogen, (c) 10 g/ml collagen or (d) 1 g/ml CRP for 45 minutes at 
37 °C. Platelets were stained with Atto 655 maleimide (100 nM) for 10 minutes at room 
temperature and fixed with 1 % formaldehyde for 10 minutes at room temperature 
Samples were imaged using a Zeiss LSM510 Meta confocal microscope with a 63X 
oil-immersion lens. A laser wavelength of 633 nm, at an intensity of 30 % was 
employed. (i) Back-scatter image (light reflected from the sample), (ii) fluorescent 
image (fluorescence from Atto 655 maleimide), (iii) backscatter and fluorescence 
images merged. Images are representative of n=4 independent experiments. 
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4.3 Discussion 
Raman spectroscopy is a powerful, non-invasive technique useful for the 
analysis of the structure and composition of chemical and, more recently, 
biological samples at a molecular level. In Chapter 3, it was demonstrated that 
Raman could be used as a novel method to examine platelet membrane 
structure and to differentiate platelets stimulated with various platelet activators. 
In light of these findings, it was decided to employ Raman to further investigate 
the impact of the activation of platelets with more physiologically relevant 
platelet agonists. This study aimed to reveal the structural subtleties brought 
about by platelet activation and confirm that platelets can be distinguished from 
each other irrespective of the nature or potency of the platelet activator. 
 
Raman spectroscopy has been successfully employed in a number of recent 
studies to analyse and distinguish biological samples based on characteristic 
properties which were examined at a molecular level (Bensalah et al, 2010; 
Crow et al, 2005; Lyng et al, 2007). Here, it was again demonstrated that a 
combination of Raman spectroscopy and PCA analysis could be used to 
separate platelet samples based on whether they are in an unactivated or 
activated state. Significantly, activated platelets could also be separated from 
each other based on whether they were activated with the platelet agonists: 
thrombin, collagen or convulxin.  
 
A more rigorous analysis of regions corresponding to different molecular 
structures, such as thiol, disulphide, amide I and amide III regions, revealed 
there were modifications in all of these regions which contributed to the 
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discrimination of platelet Raman spectra. It was also discovered during this 
analysis that lipid groups, and in particular carotenoids, appeared to play a key 
role in the separation of platelet Raman spectra by PCA.  
 
Carotenoids are a group of organic pigments, lipid in nature, which, unusually, 
are not produced by humans but are found in most cell membranes including 
platelets (Stefanini et al, 1957). Humans obtain carotenoids through their diet 
from foods such as fruit and vegetables which are rich in carotenoids. The exact 
role of carotenoids in cell membranes has yet to be fully elucidated but it is 
thought they act to minimise membrane damage and protect lipids. Carotenoids 
are tetraterpenoids, i.e. they contain 40 carbon atoms in their structure. Their 
basic structure consists of a long polyene hydrocarbon chain that can be 
modified, at one or both ends, by cyclisation, changes in hydrogenation level or 
by addition of oxygen-containing functional groups (Britton, 1995). Carotenoids 
can be divided into two classes: xanthophylls (oxygen containing) or carotenes 
(parent hydrocarbon). It is these variations in structure that give rise to more 
than 600 different carotenoids. The polyene chain which consists of a long 
system of alternating single and double carbon bonds is the main feature 
responsible for the chemical reactivity of carotenoids (Figure 4.21).  
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Figure 4.25 Basic structure of some common carotenoids. (a) Lycopene, an 
acyclic carotenoid; (b) -carotene, a dicyclic carotenoid, (c) lutein, a xanthophyll 
(oxygen containing carotenoid). Adapted from (Melendez-Martineza et al, 2007). 
 
In the characteristic Raman spectrum of carotenoids, the intense band at 
1160 cm-1 is usually attributed to the C-C stretching mode and the very strong 
band near 1520 cm-1 is assigned to the C=C stretching vibration (Merlin, 1985). 
In the Raman spectra of platelets (Figure 4.6 (a)), these peaks are very 
prominent. There is also an intense peak at approximately 1006 cm-1, which is 
assigned to the rocking motion of the molecules methyl components, and a 
peak at 968 cm-1 (Koyama et al, 1988). 
 
The antioxidant properties of carotenoids and the proposal that they are efficient 
scavengers of free radicals are particularly interesting with regard to their 
potential role in platelets (Di Mascio et al, 1989). The polyene chain in the basic 
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structure of carotenoid is highly reactive and rich in electrons. This forms the 
basis for carotenoids susceptibility to attack by electrophilic reagents and their 
instability towards oxidation (Britton, 1995). Carotenoids appear to have a direct 
effect on the structural and dynamic properties of lipid membranes, along with 
modulating the fluidity of the membrane, thereby, protecting the membrane from 
susceptibility to degradation as a result of oxidative stress (Gruszecki & 
Strzalka, 2005). Many human diseases, including cardiovascular disease, 
involve oxidation processes mediated by free radicals and it has been 
suggested in the literature that carotenoids may play a key role in the 
prevention of cardiovascular disease (Voutilainen et al, 2006). 
 
The absolute signal intensity of Raman spectra can be quite unreliable, as a 
result of variability from experiment to experiment due to environmental factors. 
However, normalisation of the spectra to the same peak across the board 
ensures the intensity (measured in arbitrary units) can be taken into 
consideration. Examination of the intensity of the carotenoid peaks present in 
the signature Raman spectra of unactivated platelets or platelets activated with 
thrombin, collagen or convulxin found that carotenoids may well play an 
important part in the reorganisation of the platelet membrane upon activation. 
The relative intensity of a Raman peak is a quantitative measure. Therefore, a 
trend towards an enhanced intensity of the carotenoid peaks in platelets as a 
result of activation is suggestive of an increase in the quantity of these particular 
carotenoids present in the platelet membrane.  
Similar to other biological membranes, platelets possess an asymmetrical 
phospholipid bilayer membrane. The lipid bilayer consists of an outer and an 
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inner leaf. The outer leaf is composed mainly of choline-phospholipids, while 
there is an abundance of amino-phospholipids in the inner layer. It is well 
established that upon activation there is a rearrangement of the platelet 
membrane lipid bilayer, whereby some phospholipids from the inner membrane 
become translocated to the outer surface. This phenomenon leads to the 
exposure of phospholipids such as phosphatidylserine (PS) on the outer surface 
of platelets (Bevers et al, 1983; Heemskerk et al, 2002).  
 
It is known that due to their hydrophobic nature carotenoids are generally 
localised to inner membranes (Britton, 1995). Consequently, it is quite plausible 
that the increase in the carotenoid peak intensity observed in the Raman 
spectra of activated platelets compared to unactivated platelets may be due to 
the exposure of additional carotenoid groups on the platelet membrane upon 
platelet activation. Prominent peaks in the platelet Raman spectra, at 
approximately 2670 cm-1 and 3040 cm-1, also indicate that the platelet lipid 
profile is an important factor in PCA distinguishing platelets stimulated with 
various activators. Lipid features at this higher end of the spectrum are 
generally thought to be less useful for identifying lipids and their conformation. 
This is due to the CH bond being highly localised and, therefore, rather 
insensitive to chain configuration or environment (Wallach et al, 1979). 
Nonetheless, the finding that these peaks are involved in the discrimination of 
platelet samples into distinct clusters associated with activation state indicates 
that these lipids are more important than previously thought. Studies have 
shown the presence of cholesterol-rich lipid islands in the resting platelet 
surface membrane. Following platelet activation, these lipid islands become 
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associated with the outer layer of the membrane (Del Conde et al, 2005). 
Additionally, the rearrangement of the platelet membrane and the subsequent 
exposure of PS on the surface of platelets is associated with the formation of 
membrane blebs which are eventually shed as pro-coagulant platelet-derived 
microparticles (Heemskerk et al, 2002). This phenomenon may be the link to 
the variances we observed in the lipid profile in the Raman spectra of 
unactivated and activated platelets. More in depth analysis may be required 
before any definitive conclusions relating to the role of lipids and carotenoids in 
platelet membrane can be reached.  
 
Similarly, PCA analysis of the thiol and disulphide containing regions of the 
Raman spectra of platelets revealed that there were differences in these 
regions that could potentially be associated with thiol/disulphide modifications 
as a result of platelet activation. As discussed in Chapter 3, the exact nature of 
these modifications is difficult to pinpoint due to the complex composition of 
platelets. However, differences in this region can be attributed to a change in 
the absolute number of thiol groups present or may also be indicative of 
shuffling or rearrangement of the bonds or changes in the strain on the cysteine 
bonds. 
 
Based on these interesting findings, further examination of the role of thiol 
populations in platelet function was performed. Previous studies in our 
laboratory, found the external redox environment impacted significantly on 
platelet activity, in particular in response to platelet stimulation by collagen. A 
reducing redox environment generated by glutathione (GSH/GSSG) and 
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cysteine (Cys/CySS) redox potentials inhibits platelet aggregation to collagen 
only (Murphy et al, 2010). Similarly, in my study reducing environments 
generated using the reducing agents, DTT, TCEP and GSH also inhibited 
platelet aggregation to collagen. A reducing environment has no effect on 
platelet aggregation to thrombin or convulxin. Oxidising redox potentials and 
other oxidising conditions have no effect on collagen, thrombin or convulxin 
induced aggregation. While others have found that reducing conditions can 
inhibit platelet activation, using concentrations of the reducing agents in 
millimolar (mM) concentrations, I show here that lower, physiologically relevant 
concentrations, in the micromolar range (M), have significant effects on 
platelet function (Pacchiarini et al, 1996). The results obtained from these 
combined studies point specifically to the collagen receptor, integrin 21, as a 
redox sensitive receptor. This is corroborated from the fact that neither thrombin 
nor convulxin induced platelet aggregation is affected by changing the external 
redox environment. The finding that platelet aggregation induced by convulxin, 
a GPVI specific agonist, implies this receptor is not implicated in the redox 
sensitive collagen pathway. In order to categorically confirm that type I collagen 
and convulxin in these studies were signalling through different receptors and 
intracellular pathways, two established tyrosine kinase inhibitors were 
employed. PP2 is a broad Src family kinase inhibitor, while BAY 61-3606 is a 
Syk specific inhibitor. Protein-tyrosine phosphorylation is a key signalling event 
associated with platelet activation (Clark et al, 1994). Platelet activation through 
collagen is known to stimulate activation of a number of protein-tyrosine 
kinases, including Src family kinases and Syk, which is downstream of Src 
kinases, and promote the rapid phosphorylation of a number of proteins. It was 
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found that PP2 inhibited platelet aggregation to both collagen and convulxin, 
implicating Src family kinases in the signalling cascade of both platelet agonists. 
However, BAY 61-3606 inhibited convulxin induced platelet aggregation only. 
BAY 61-3606 had no impact on the platelet aggregation response to collagen, 
indicating a divergence in the signalling pathways of the two agonists. These 
results confirmed the type I collagen was targeting integrin 21, and not GPVI. 
These findings are consistent with previous findings, whereby Src family 
kinases have been shown to be implicated in signalling through both GPVI and 
integrin 21, whereas collagen induced activation of Syk is specific to GPVI 
(Asselin et al, 1997; Dangelmaier et al, 2005; Ichinohe et al, 1997; Inoue et al, 
2003).  
The membrane-impermeable thiol blocker 5, 5’-Dithio-bis-(2-nitrobenzoic acid) 
(DTNB) was used to detect platelet surface thiols through Ellman’s test, a well 
established thiol detection assay. It was found that there are, on average, 
approximately 3.78 X 10-18 moles of thiols present on the surface of an 
unactivated platelet. Although it is well known that thiols are present on the 
surface of platelets, the actual number of free thiols present has not been well 
documented. One of few studies found 3.1 X 10-18 moles of thiol per platelet, a 
finding similar to ours (Harbury & Schrier, 1974). However, the study by Harbury 
and Schrier looked solely at the thiol population of unactivated platelets, while 
this study examined the thiol population of unactivated platelets along with the 
effects of platelet activation with a number of activators on this population. 
The surface thiol population of platelets activated by collagen in suspension 
was found to be significantly increased compared to unactivated platelets, from 
3.78 X 10-18 to 19.62 X 10-18 moles of thiol per platelet. Platelet activation by 
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thrombin or convulxin had no impact on the thiol population. In a parallel study 
examining the thiol population of adhered platelets, it was again observed that 
there was a trend towards an increase in the surface thiol population of platelets 
adhered to collagen, compared to those adhered to BSA, fibrinogen or CRP. 
This increase in the thiol population induced by collagen was abolished as the 
external redox environment became more reducing. All of the findings thus far 
highlight the importance of thiols in the collagen activation pathway of platelets, 
specifically suggesting a particular significance of the thiol groups in 
integrin 21. The presence of a reducing redox environment inhibited platelet 
aggregation to collagen only. This is suggestive of an integrin IIb3 independent 
effect, due to the final common pathway in platelet aggregation to thrombin or 
convulxin being integrin IIb3 mediated. These findings were unexpected as it 
was demonstrated in Chapter 3 that an altered redox environment impacts on 
integrin IIb3 in a purified system and in a CHO-K1 cell model. However, this 
finding therefore highlights the sensitivity of integrin 21 even compared to 
other integrins such as integrin IIb3. This increased sensitivity may be due to a 
greater number of reactive cysteine residues present in the 1-subunit in 
comparison to that of the 3-subunit. In an analysis of the cysteine rich region of 
these two -subunits, it was found there are almost twice as many potentially 
reactive cysteines in the 1-subunit as there are in the 3-subunit (personal 
communication, Dr. Desmond Murphy, RCSI). The reactivity of a cysteine 
residue is defined by its pKa value, which is inversely related to reactivity, i.e. a 
cysteine with a low pKa value is more reactive. The reactivity of a cysteine 
residue is influenced by the amino acid surrounding it. In particular, the pKa 
values of cysteine thiols may be decreased by charge interactions with 
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positively charged, basic amino acids adjacent to the cysteine thiol (Vukelić et 
al, 2012; Wakabayashi et al, 2004). There are 18 cysteines with at least one 
adjacent basic amino acid in the 1-subunit while there are only 10 in the 
3-subunit. The reactivity of the thiols in the cysteines of integrin 21 makes 
them prime targets for thiol modifications such as S-glutathionylation or 
S-cysteinylation. S-glutathionylation is a reversible process in which mixed 
disulphide bonds are formed between the thiol group of the protein itself and 
glutathione (Dalle-Donne et al, 2007). S-cysteinylation is a similar process and 
both are potential mechanisms for the post-translational regulation of proteins. 
The inhibition of the collagen activation pathway of platelets by reducing redox 
environments is suggestive of some such external modification of the receptor, 
whereby it may become locked into a particular conformation thereby unable to 
induce further intra-platelet signals which usually culminate in full platelet 
activation.  
The generation of thiols on the surface of platelets activated with collagen only 
is a very interesting observation. It is established that conversion of integrin 
IIb3 to an activated, ligand-binding conformation is associated with 
conformational changes and a subsequent increase in the free thiol population 
(Yan & Smith, 2000). It is somewhat surprising that there was such a significant 
increase in the thiol population of platelets activated by collagen, especially due 
to the smaller copy number of integrin 21 compared to integrin IIb3, the most 
abundant protein on platelets. However, the persistence of this new thiol 
population even in the presence of an oxidising environment, confirms the 
generation of these thiols in the collagen activation pathway is a robust and real 
event. These results suggest that activation of platelets by collagen induces a 
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reduction of disulphide bonds within the integrin or a thiol/disulphide exchange 
mechanism exists whereby thiols that were previously buried within the integrin 
become exposed upon stimulation with collagen. A reducing redox environment 
prevents the generation of this new thiol population on the surface of platelets 
activated with collagen, by potentially modifying or locking the integrin into a 
particular conformation. 
When the values corresponding to the redox background were subtracted from 
the values of platelets in the presence of redox, a negative value was found, 
indicating the thiols from the reduced form of the redox couples (GSH and Cys) 
were reacting with the thiols on the surface of platelets. Therefore, the absolute 
number of thiols in the system available for detection in the Ellman’s test is 
decreased. This is further evidence supporting the interaction of the external 
redox environment with the thiol population of integrin and thus demonstrates 
that S-glutathionylation or S-cysteinylation of thiols in a reducing redox 
environment is a plausible hypothesis.  
 
It is clear that we have uncovered a redox sensitive element of the collagen 
activation pathway in platelets and further elucidated a role for thiols in integrin 
activation. Further investigation of the collagen signalling pathway and 
downstream events is warranted and outlined in Chapter 5. 
  
 
Chapter 5 
External modification of the platelet 
surface thiol population impacts on 
intra-platelet signalling events 
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5.1 Introduction 
Platelet activation leads to a series of morphological and biochemical changes 
to the platelet. Upon activation, the platelet membrane undergoes a substantial 
transformation with the expression of a number of proteins which are not found 
on the surface of unactivated platelets. The characteristic discoid shape of 
unactivated platelets is maintained by a main microtubule arranged in a coil. 
This is associated with multiple short, highly dynamic microtubules, located 
beneath the plasma membrane (Patel-Hett et al, 2008). In addition to major 
membrane changes, platelets also undergo dramatic shape change as a result 
of activation. The underlying cause of this shape change is platelet cytoskeleton 
rearrangement. The platelet cytoskeleton contains two main actin filament-
based components. They are the actin filament network of the cytoplasm and 
the membrane skeleton, which is composed of a latticework of short cross-
linked actin filaments (Fox, 1993a). Actin is the most abundant protein present 
in platelets and is estimated to make up approximately 15 - 20 % of the total 
platelet protein content. The role of the cytoplasmic cytoskeleton is to mediate 
contractile events and to direct rapid platelet shape change upon activation. The 
platelet membrane cytoskeleton, which coats the plasma membrane, regulates 
membrane contours and stability along with the lateral distribution of membrane 
glycoproteins (Fox, 1993b). Reorganisation of the actin cytoskeleton is an 
essential part of platelet morphological modifications and functions (Hartwig, 
2006).  
 
In unactivated platelets, 30 - 40 % of actin is polymerised into filaments and is 
termed F-actin. The remaining actin is thought to be prevented from 
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polymerisation by the association of thymosin-4 with monomeric actin and by 
the association of gelsolin with the barbed ends of pre-existing actin filaments. 
Activation of platelets greatly increases the percentage of F-actin (Hartwig & 
DeSisto, 1991). New filaments form to fill extended filopodia and an actin 
network is formed at the periphery of the platelet. In addition to controlling 
shape changing events, the platelet cytoskeleton is also involved in the 
regulation of spatial organisations and, thus, in the integration of platelet 
activities. The cytoskeleton binds signalling molecules resulting in their 
localisation to specific regions, along with binding the plasma membrane and 
modulating membrane proteins (Fox, 2001). 
 
Proteins involved in signalling may become associated with actin in a direct 
interaction whereby the proteins specifically bind to actin or actin may be the 
link to other signalling proteins. Heat shock protein 27 (HSP27) is an example of 
a signalling protein that upon platelet activation becomes phosphorylated and 
bound to assembling actin (Zhu et al, 1994). HSP27 has been shown to not only 
interact with actin but also to regulate the actin cytoskeleton of platelets (Butt et 
al, 2001). The redox environment has been shown to play a significant role in 
the regulation of the actin cytoskeleton of cells. HSP27 is one of the proteins 
implicated in this process. In endothelial cells, hydrogen peroxide (H2O2), a 
critical player in the initiation of oxidative stress, potentiates activation of p38 
mitogen-activated protein kinase (p38 MAP kinase), which leads to the 
activation of MAP kinase-activated protein kinase-2/3 and the phosphorylation 
of HSP27 (Huot et al, 1997). In these cells, H2O2 also caused major 
reorganisation of the actin cytoskeleton (Huot et al, 1998). A similar signalling 
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pathway exists in platelets suggesting the role of intra-platelet redox 
environment may be just as significant. 
 
Membrane glycoproteins such as integrin IIb3 are also strongly associated 
with the actin cytoskeleton of platelets. Integrin activating inside-out signals are 
mediated by actin filament turnover, rearrangement of the platelet cytoskeleton 
and integrin regulatory proteins. A number of regulatory proteins involved with 
the linkage between integrins and the actin cytoskeleton have been identified 
and include talin-1, kindlin-2 and kindlin-3 (Montanez et al, 2008; Moser et al, 
2008). Talin-1 binds the cytoplasmic tails of the -subunits of integrins thereby 
connecting the actin cytoskeleton through its actin binding site. This links the 
cytoskeletal network to the extra-cellular matrix (ECM) (Tadokoro et al, 2003; 
Wegener et al, 2007). Indeed, a mutation of the 3-subunit (3(L746A)) of 
integrin IIb3 specifically abolishes talin-1 binding and impairs inside-out 
signalling associated with the integrin (Petrich et al, 2007). In a separate study, 
the platelets of talin-1 deficient mice displayed an inability to activate integrin 
IIb3 in response to platelet agonists. Furthermore, integrin 21 was also found 
to be impaired due to a defective response in adhesion of these platelets to 
collagen (Nieswandt et al, 2007).  
 
Vasodilator-stimulated phosphoprotein (VASP) is another protein capable of 
affecting and regulating actin polymerisation and filament bundling (Reinhard et 
al, 2001). VASP is a key regulatory protein found in platelets in particularly high 
concentrations (Eigenthaler et al, 1992). It is a substrate of both cAMP- and 
cGMP- dependent kinases (PKA and PKG) (Comerford et al, 2002). VASP 
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possesses three phosphorylation sites: Ser157, Ser239 and Thr278. Each of 
these sites is phosphorylated with different affinities by PKA or PKG. 
Approximately 90 % of VASP is present in the platelet membrane (Reinhard et 
al, 1992) and is also found in focal contacts (Jockusch et al, 1995). Focal 
contacts are protein rich structures which link the actin cytoskeleton to the ECM 
via integrins. These observations suggest a role for VASP in integrin activation 
and regulation. VASP plays a role in the binding of fibrinogen to integrin IIb3 
and the phosphorylation of VASP results in inhibition of platelet aggregation, 
thereby supporting an important role for VASP in the regulation of integrin 
function (Horstrup et al, 1994); (Aszodi et al, 1999). Additionally, previous work 
in our laboratory demonstrated integrin IIb3 exists in an activated conformation 
in the presence of increasing concentrations of homocysteine and similarly 
platelets obtained from patients presenting with clinical hyperhomocysteinemia 
displayed integrin IIb3 in a greater state of activation than healthy controls 
(McGarrigle et al, 2011). Subsequently, a link between the presence of 
homocysteine and the phosphorylation state of VASP in platelets was also 
demonstrated (unpublished data).  
 
It is clear platelet spreading, membrane alterations and the reorganisation of the 
cytoskeleton are critical events associated with the activation of platelets. A 
number of signalling molecules and regulatory proteins are involved in the 
process. The aim of this chapter is to examine receptor-ligand interactions and 
their impact on the dynamics of platelet shape change. Furthermore, the impact 
of an altered external redox environment on platelet spreading and actin 
cytoskeleton rearrangement in response to adhesion to a number of surfaces 
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will also be investigated. In order to further elucidate the critical role of thiols in 
the regulation of platelet function and specifically platelet intracellular signalling 
pathways and based on previous work carried out in our laboratory in relation to 
VASP, the effects of platelet activation and an altered external redox 
environment on the expression of VASP and its phosphorylation state will be 
explored.   
 
5.2 Results  
5.2.1 The effects of platelet adhesion on platelet morphology and actin 
cytoskeleton rearrangement  
5.2.1.1 Platelet imaging by scanning electron microscopy 
 
Scanning electron microscopy (SEM) was employed to investigate the 
morphology of platelets adhered to various substrates (with the assistance of 
Dr. Úna Prendergast (DCU)). SEM is a powerful imaging method superior to 
other imaging techniques due to its high resolution and degree of magnification 
control, which is independent of the power of an objective lens. The depth of 
field of SEM also produces high quality images displaying features on 
specimens that may not be visible with alternatives such as light microscopy.  
 
Unactivated platelets adhered to 1 % BSA, 20 g/ml fibrinogen, 10 g/ml 
collagen or 1 g/ml collagen related peptide (CRP) were prepared for SEM and 
imaged. The resulting SEM images revealed distinct and separate 
morphological changes of platelets adhered to these substrates (Figure 5.1). As 
expected, few platelets adhered to BSA. In general, those present were in a 
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typical unactivated state, with a round, discoid shape. Some platelets had a 
small number of tiny filopodia emerging from them indicating that these platelets 
may not be in a fully resting state. This may have resulted from the length of 
time the platelets were in contact with the BSA surface. Platelets adhered to 
fibrinogen displayed the distinct characteristic ‘fried-egg-like’ appearance 
associated with activated, spread platelets. The platelets became flattened with 
the organelles forced into the centre and the cytoplasm spread out to fill all 
spaces created by original filopodia. The ruffling of the membrane around the 
edges and the lack of interaction between individual platelets is interesting to 
note. In contrast, while many of the platelets adhered to collagen became 
flattened and spread, there appeared to be a clear interaction between 
platelets. The platelets adhered to CRP were most definitely interacting with 
each other although not quite to the same extent as those adhered to collagen. 
However, their appearance was strikingly dissimilar to platelets adhered to the 
other substrates. They formed a unique web-like pattern, created by numerous 
filopodia extensions from the platelets.  
5.2.1.2 Platelet imaging by confocal microscopy 
The major morphological differences in platelets observed by SEM suggested 
there may be a variation in the rearrangement of the cytoskeleton of platelets 
based on the substrate they are adhered to. Therefore, further examination of 
the actin cytoskeleton of adhered platelets was carried out.  
 
Unactivated platelets adhered to 1 % BSA, 20 g/ml fibrinogen, 10 g/ml 
collagen or 1 g/ml collagen related peptide (CRP) were permeabilised and 
stained with Alexa Fluor® 488 phalloidin and imaged using confocal microscopy. 
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Phalloidin is a high-affinity probe that specifically binds to filamentous actin (F-
actin). 
 
Analysis of the samples, at a high magnification (63X objective, ScanZoom 5.0), 
revealed the actin cytoskeleton rearrangement was primarily dictated by the 
surface to which the platelets had adhered (Figure 5.2). Platelets adhered to 
BSA were small and mostly in a discoid shape. Platelets adhered to fibrinogen 
were large in terms of diameter, and spread with the actin mainly around the 
perimeter of the platelets, with very little, if any, present in the centre of the 
platelets. Platelets adhered to collagen were slightly similar in appearance than 
those adhered to fibrinogen with the actin mainly localised around the outer 
surface of the platelets adhered to collagen. However, in contrast to platelets 
adhered to fibrinogen, collagen adhered platelets were found to be interacting 
and linking each other through their actin cytoskeletons. Platelets adhered to 
CRP displayed a ‘spindly’ appearance, whereby the platelets had formed a 
number of actin containing filopodia reaching out in all directions. Full spreading 
of the membrane and redistribution of all actin to the outer regions had not 
occurred within these platelets adhered to CRP.  
 
5.2.2 Examination of the surface coverage and spreading of platelets 
adhered to various surfaces 
Platelet spreading is an essential element of platelet plug formation and, 
ultimately, blood clot development. Following the observations of the 
morphological changes in platelets as a result of adhesion platelet spreading 
and actin cytoskeleton rearrangement was further investigated.  
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Unactivated platelets were allowed to adhere to 1 % BSA, 20 g/ml fibrinogen, 
10 g/ml collagen or 1 g/ml collagen related peptide (CRP), stained with Alexa 
Fluor® 488 phalloidin and examined by confocal microscopy. The percentage 
surface coverage was calculated based on a total surface area of 20408.98 m2 
(based on an image size: 142.86 m X 142.86 m). 
 
The percentage surface coverage of platelets adhered to fibrinogen was 
significantly higher than platelets adhered to BSA, collagen or CRP, in the 
absence of a redox environment (n=4, *p < 0.05, **p < 0.01) (Figure 5.3 (a) (i)). 
In reducing (-264 mV) and mean (-130 mV) GSH/GSSG redox environments, 
the percentage surface coverage by platelets adhered to fibrinogen was 
significantly greater than platelets adhered to BSA, collagen, or CRP. There 
was no significant difference observed between the level of platelet adhesion to 
their substrates in an oxidising environment (n=4, **p < 0.01, ***p < 0.001) 
(Figure 5.3 (a) (ii-iv)).  
 
Platelets adhered to fibrinogen were found to have a significantly larger area 
than platelets adhered to BSA, collagen or CRP. This was observed in the 
absence of an altered redox environment and in the presence of reducing 
(-264 mV) and mean (-130 mV) GSH/GSSG redox environments (n=4, 
**p < 0.01, ***p < 0.001) (Figure 5.3 (b) (i-iii)). In the presence of an oxidising 
environment, platelets adhered to fibrinogen were significantly larger than 
platelets adhered to BSA. There was no significant difference between platelets 
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adhered to fibrinogen and those adhered to collagen or CRP (n=4, *p < 0.05) 
(Figure 5.3 (b) (iv)).  
 
5.2.3 The effects of an altered external redox environment on surface 
coverage and spreading of statically adhered platelets 
It was found that a reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV) 
redox environment had no significant effect on the percentage surface coverage 
by platelets adhered to BSA, fibrinogen or CRP, compared to platelets adhered 
to their respective surfaces in the absence of an altered external redox 
environment (n=4) (Figure 5.4).  However, the percentage surface coverage by 
platelets adhered to collagen was significantly decreased in an external 
reducing environment, compared to platelets adhered to collagen in the 
absence of an altered redox environment (n=4, *p < 0.05) (Figure 5.4 (a)).  
Furthermore, the impact of an altered external redox environment on the 
average size of a platelet adhered to each of the surfaces was investigated. 
There was no significant effect of any of the altered redox environments on the 
average size of platelets adhered to BSA, fibrinogen or CRP compared to in the 
absence of an altered external redox environment (n=4) (Figure 5.4 (b)). 
Interestingly though, while it did not quite reach statistical significance, there 
was an obvious trend towards a decreased average area of platelets adhered to 
collagen in the presence of a reducing environment compared to platelets 
adhered to collagen in the absence of an altered redox environment (n=4) 
(Figure 5.4 (b)).  
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5.2.4 Examination of an intra-platelet signalling molecule: vasodilator-
stimulated phosphoprotein (VASP) 
5.2.4.1 Measuring total vasodilator-stimulated phosphoprotein (VASP) 
expression in platelets 
The levels of vasodilator-stimulated phosphoprotein (VASP) expression and 
phosphorylation in platelets were examined through Western blot analysis in 
order to investigate the effects of changing redox external environment on intra-
platelet signalling events. 
Platelets were unactivated or activated with either 0.1U/ml thrombin, 38 g/ml 
collagen or 50 ng/ml convulxin in the absence of an altered redox environment 
or in the presence of reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV) 
GSH/GSSG redox potentials. Platelet aggregations were performed and 
subsequently the samples were lysed. Initially, platelet lysates were separated 
on 10 % polyacrylamide gels and stained with Coomassie Blue in order to 
confirm the platelets had been lysed correctly and the platelet protein profile 
was found to be intact (Figure 5.5).  
For Western blot analysis platelet lysates were separated on 10 % 
polyacrylamide gels, transferred to polyvinyl difluoride (PVDF) membrane and 
probed with a rabbit polyclonal anti-VASP (A290) antibody, which detects total 
VASP expression. The levels of total VASP in platelets regardless of whether 
the platelets were unactivated or activated, in the presence or absence of an 
altered redox environment were similar as assessed by densitometry analysis 
using ImageJ software. Additionally, membranes were probed with an anti--
actinin antibody in order to assess sample loading. There was no significant 
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difference between the -actinin content across all conditions indicating equal 
loading of all samples (n=4) (Figure 5.6 (a) and (b)). 
5.2.4.2 The impact of platelet activation and altering the external redox 
environment on the phosphorylation status of vasodilator-stimulated 
phosphoprotein (VASP) at Serine 157 (Ser157) 
One of the sites at which vasodilator-stimulated phosphoprotein (VASP) can be 
phosphorylated is Serine 157 (Ser157). In order to investigate the impact of 
platelet activation and an altered external redox environment on the 
phosphorylation status of VASP an antibody to detect VASP phosphorylation at 
Ser157 through Western blotting was employed.  
Platelets were unactivated or activated with either 0.1U/ml thrombin, 38 g/ml 
collagen or 50 ng/ml convulxin in the absence of an altered redox environment 
or in the presence of reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV) 
GSH/GSSG redox potentials. Platelet aggregations were performed and 
subsequently the samples were lysed. Platelet lysates were run on 10 % 
polyacrylamide gels, transferred to polyvinyl difluoride (PVDF) membrane and 
probed with a rabbit polyclonal anti-VASP-P (Ser157) antibody. 
 
Analysis of the Western blots was carried out through densitometry. VASP 
phosphorylation at Ser157 was minimal in unactivated platelets in the presence 
of all redox environments. VASP was found to be phosphorylated at Ser157 in 
platelets activated with thrombin, convulxin and collagen, which was 
significantly greater than unactivated platelets. An altered redox environment 
had no significant impact on VASP phosphorylation at Ser157 in platelets 
activated with thrombin or convulxin, when compared to that of platelets 
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activated in the absence of an external redox environment. Activation of 
platelets with collagen, in the absence of an altered redox environment and in 
the presence of a mean or oxidising environment, led to the phosphorylation of 
VASP at Ser157. However, interestingly, in the presence of a reducing external 
redox environment there was a significant decrease in the level of VASP 
phosphorylation at Ser157 to a level comparable to that observed in unactivated 
platelets (n=4, *p < 0.05) (Figure 5.7 (a) and (b) (i)). Sample loading was also 
examined to ensure confirm there was equal loading in all lanes. This was 
carried out by reprobing the blots with anti--actinin antibody. Statistical 
analysis of the densitometry data associated with the -actinin bands found no 
significant difference between the loading of the platelet samples (n=4) (Figure 
5.7 (b) (ii)).  
5.2.4.3 The impact of platelet activation and altering the external redox 
environment on the phosphorylation status of vasodilator-stimulated 
phosphoprotein (VASP) at Serine 239 (Ser239) 
In addition to vasodilator-stimulated phosphoprotein (VASP) being 
phosphorylated at Ser157, it can also be phosphorylated at Serine 239 
(Ser239). The effects of platelet activation and GSH/GSSG redox potentials on 
VASP phosphorylation at Ser239 were investigated by Western blotting.  
Platelets were either unactivated or activated with either 0.1U/ml thrombin, 
38 g/ml collagen or 50 ng/ml convulxin in the absence of an altered redox 
environment or in the presence of reducing (-264 mV), mean (-130 mV) or 
oxidising (-10 mV) GSH/GSSG redox potentials. Platelet aggregations were 
performed and subsequently the samples were lysed. Platelet lysates were 
separated on 10 % polyacrylamide gels, transferred to polyvinyl difluoride 
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(PVDF) membrane and probed with a rabbit polyclonal anti-VASP-P (Ser239) 
antibody.  
Densitometry was employed to analyse the resulting Western blots. VASP 
phosphorylation was found to occur at Ser239 in unactivated platelets and 
platelets activated with thrombin in the absence and presence of all redox 
environments, with the redox environment having no significant impact on the 
phosphorylated VASP expression. There was a similar finding in platelets 
activated with convulxin. Although the overall levels appeared to be lower than 
that observed in unactivated or thrombin activated platelets, the redox 
environment did not impact on the level of VASP phosphorylation at Ser239. 
The level of VASP phosphorylation at Ser239 in platelets activated with 
collagen in the absence of an altered redox environment, or in the presence of a 
mean or oxidising environment, was comparable to that observed in unactivated 
and thrombin activated platelets. However, there was a significant increase in 
VASP phosphorylation at Ser239 in platelets activated with collagen in the 
presence of a reducing external environment (n=4, *p < 0.05) (Figure 5.8 (a) 
and (b) (i)). The loading of platelet lysate samples was found to be consistent by 
reprobing the blots with an anti--actinin antibody and carrying out densitometry 
on the resulting -actinin bands (n=4) (Figure 5.8 (b) (ii)).  
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Figure 5.1 The morphology of adhered platelets varies greatly depending on the 
nature of the substrate to which they are adhered. Washed platelets adhered to 
round, glass cover slips pre-coated with poly-L-lysine, then coated with (a) 1 % BSA, 
(b) 20 g/ml fibrinogen, (c) 10 g/ml collagen or (d) 1 g/ml CRP, for 45 minutes at 
37 °C. Samples were fixed with 1 % formaldehyde for 10 minutes at room temperature 
with subsequent dehydration through a series of acetone concentrations. Samples 
were sputter coated with approximately 20 nm gold and mounted for SEM imaging. 
Images were obtained using a Hitachi S3400n SEM operating at 5 kV. Images are 
representative of n=2 independent experiments.  
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Figure 5.2 The actin cytoskeleton rearrangement of adhered platelets is 
dependent on the substrate to which the platelets are adhered. Washed platelets 
were allowed to adhere to poly-L-lysine slides coated with (a) 1 % BSA, (b) 20 g/ml 
fibrinogen, (c) 10 g/ml collagen or (d) 1 g/ml collagen related peptide (CRP) for 
45 minutes at 37 °C. Samples were fixed with 1 % formaldehyde for 10 minutes at 
room temperature and permeabilised with 0.1 % Triton-X-100 for 10 minutes at room 
temperature. Platelets were then stained with Alexa Fluor® 488 phalloidin for 
20 minutes at room temperature. Samples were imaged using a Zeiss LSM510 Meta 
confocal microscope with a 63X oil-immersion lens. A laser wavelength of 488 nm, at 
an intensity of 1 % was employed. Images are representative of n=4 independent 
experiments. 
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Figure 5.3 (a) Percentage surface coverage by platelets adhered to fibrinogen is 
significantly higher than the percentage coverage by platelets adhered to BSA, 
collagen or collagen related peptide (CRP) in all external redox environments. 
Washed platelets were either (i) untreated (no redox) or incubated with the following 
GSH/GSSG redox potentials: (ii) reducing (-264 mV), (iii) mean (-130 mV) or (iv) 
oxidising (-10 mV) for 10 minutes at 37 °C. Platelets adhered to poly-L-lysine slides 
coated with 1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen or 1 g/ml CRP for 45 
minutes at 37 °C. Samples were fixed first with 1 % formaldehyde and then 
permeabilised with 0.1 % Triton-X-100 for 10 minutes at room temperature. Platelets 
were stained with Alexa Fluor® 488 phalloidin for 20 minutes at room temperature. 
Samples were imaged using a Zeiss LSM510 Meta confocal microscope with a 63X oil-
immersion lens. A laser wavelength of 488 nm, at an intensity of 1 % was employed. 
Data was analysed using the ImageJ software package. Percentage surface coverage 
was calculated based on a total surface area of 20408.98 m2. Date is presented as 
the mean ± SEM, n=4 independent experiments, **p < 0.01, *** p < 0.001. 
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Figure 5.3 (b) The average area of platelets adhered to fibrinogen is significantly 
greater than the average area of platelets adhered to BSA, collagen or collagen 
related peptide (CRP). Washed platelets were either (i) untreated (no redox) or 
incubated with the following GSH/GSSG redox potentials: (ii) reducing (-264 mV), (iii) 
mean (-130 mV) or (iv) oxidising (-10 mV) for 10 minutes at 37 °C. Platelets adhered to 
poly-L-lysine slides coated with either 1 % BSA, 20 g/ml fibrinogen, 10 g/ml collagen 
or 1 g/ml CRP for 45 minutes at 37 °C. Samples were fixed with 1 % formaldehyde 
and then permeabilised with 0.1 % Triton-X-100 for 10 minutes at room temperature. 
Platelets were stained with Alexa Fluor® 488 phalloidin for 20 minutes at room 
temperature. Samples were imaged using a Zeiss LSM510 Meta confocal microscope 
with a 63X oil-immersion lens. A laser wavelength of 488 nm, at an intensity of 1 % was 
employed. Data was analysed using the ImageJ software package. Date is presented 
as the mean ± SEM, n=4 independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 5.4 (a) The percentage surface coverage by platelets adhered to collagen 
in the presence of an external reducing redox environment is significantly 
decreased compared to the total surface coverage by platelets adhered to 
collagen in the absence of an altered external redox environment. There is no 
impact of an altered redox environment on the total surface coverage by platelets 
adhered to BSA, fibrinogen or collagen related peptide (CRP). Washed platelets were 
allowed to adhere to poly-L-lysine slides coated with (a) 1 % BSA, (b) 20 g/ml 
fibrinogen, (c) 10 g/ml collagen or (d) 1 g/ml CRP for 45 minutes at 37 °C. Samples 
were fixed with 1 % formaldehyde for 10 minutes at room temperature and 
permeabilised with 0.1 % Triton-X-100 for 10 minutes at room temperature. Platelets 
were then stained with Alexa Fluor® 488 phalloidin for 20 minutes at room temperature. 
Samples were imaged using a Zeiss LSM510 Meta confocal microscope with a 63X oil-
immersion lens. A laser wavelength of 488 nm, at an intensity of 1 % was employed. 
Total surface coverage was determined using ImageJ software. Data is presented as 
the mean ± SEM, n=4 independent experiments, *p < 0.05. 
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Figure 5.4 (b) The average area of platelets adhered to collagen decreases as the 
external redox environment becomes more reducing, while the average area of 
platelets adhered to BSA, fibrinogen or collagen related peptide (CRP) remains 
consistent irrespective of an altered external redox environment. Washed 
platelets were allowed to adhere to poly-L-lysine slides coated with (a) 1 % BSA, (b) 
20 g/ml fibrinogen, (c) 10 g/ml collagen or (d) 1 g/ml CRP for 45 minutes at 37 °C. 
Samples were fixed with 1 % formaldehyde for 10 minutes at room temperature and 
permeabilised with 0.1 % Triton-X-100 for 10 minutes at room temperature. Platelets 
were then stained with Alexa Fluor® 488 phalloidin for 20 minutes at room temperature. 
Samples were imaged using a Zeiss LSM510 Meta confocal microscope with a 63X 
oil-immersion lens. A laser wavelength of 488 nm, at an intensity of 1 % was employed. 
Total surface coverage was determined using ImageJ software. Data is presented as 
the mean ± SEM, n=4 independent experiments. 
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Figure 5.5 Coomassie Blue stained gels demonstrating the protein profile of 
unactivated and activated platelets in the absence and presence of an altered 
external redox environment. Gel filtered platelets were (i) unactivated or were 
activated with either  0.1U/ml thrombin (ii) 38 g/ml collagen  or 50 ng/ml convulxin in 
the absence or presence of an altered redox environment generated by GSH/GSSG 
redox potentials: reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV). Platelet 
lysates were run on 10 % polyacrylamide gels for 1 hour at a constant voltage of 100 V. 
Gels were then stained with a sensitive Coomassie Blue stain overnight at room 
temperature with gently rocking. In order to visualise the protein bands clearly, excess 
Coomassie Blue stain was removed in a destaining process. The gels were then stored 
in dH2O and imaged. 
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Figure 5.6 (a) Vasodilator-stimulated phosphoprotein (VASP) is present in equal 
quantities in all platelets, irrespective of the activation state of the platelets or 
their external redox environment. Gel filtered platelets remained unactivated or were 
activated with either 0.1U/ml thrombin, 38 g/ml collagen  or  50 ng/ml convulxin in the 
absence or presence of an altered redox environment generated by GSH/GSSG redox 
potentials: reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV). Platelet lysates 
were separated on 10 % polyacrylamide gels and proteins were transferred from the 
gel to PVDF membrane. Membrane was probed with rabbit polyclonal anti-VASP A290 
or monoclonal anti--actinin (loading control) antibodies. Blots are representative of 
n=4 independent experiments.  
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Figure 5.6 (b) Analysis by densitometry confirmed that vasodilator-stimulated 
phosphoprotein (VASP) is present at comparable levels in unactivated platelets 
and platelets activated with thrombin, collagen or convulxin in all external redox 
environments. Gel filtered platelets remained unactivated or were activated with either 
0.1U/ml thrombin, 38 g/ml collagen  or  50 ng/ml convulxin in the absence or presence 
of an altered redox environment generated by GSH/GSSG redox potentials: reducing 
(-264 mV), mean (-130 mV) or oxidising (-10 mV). Platelet lysates were separated on 
10 % polyacrylamide gels and proteins were transferred from the gel to PVDF 
membrane. Membrane was probed with (i) rabbit polyclonal anti-VASP A290 or (ii) 
monoclonal anti--actinin (loading control) antibodies. Densitometry analysis was 
performed using ImageJ software. Data is presented as the mean ± SEM, n=4 
independent experiments.  
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Figure 5.7 (a) Vasodilator-stimulated phosphoprotein (VASP) phosphorylation at 
Serine 157 (VASP-P (Ser157)) in platelets activated with collagen in the presence 
of a reducing environment is decreased to levels comparable to that of 
unactivated platelets. There is an increase in VASP phosphorylation at Ser157 in 
platelets activated with thrombin or convulxin compared to unactivated platelets, 
and the levels are not impacted on by an altered external redox environment. 
Gel-filtered platelets remained unactivated or were activated with either 0.1U/ml 
thrombin, 38 g/ml collagen  or  50 ng/ml convulxin in the absence or presence of an 
altered redox environment generated by GSH/GSSG redox potentials: reducing 
(-264 mV), mean (-130 mV) or oxidising (-10 mV. Platelet lysates were separated on 
10 % polyacrylamide and proteins were transferred from the gel to PVDF membrane. 
Membranes were probed with a rabbit polyclonal anti-VASP-P Ser157 or anti--actinin 
(loading control) antibody. Blots are representative of n=4 independent experiments. 
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Figure 5.7 (b) Analysis by densitometry confirmed that phosphorylation of 
vasodilator-stimulated phosphoprotein (VASP) at Serine 157 (Ser157) is 
significantly decreased in platelets activated with collagen in a reducing external 
redox environment, compared to platelets activated with collagen in the absence 
of an altered external redox environment. There was increased phosphorylation 
of VASP at Ser157 in platelets activated with thrombin or convulxin. An altered 
external redox environment had no significant effect on this level of VASP 
phosphorylation at Ser157 observed in platelets activated with thrombin or 
convulxin. Gel filtered platelets remained unactivated or were activated with either 
0.1U/ml thrombin, 38 g/ml collagen  or  50 ng/ml convulxin in the absence or presence 
of an altered redox environment generated by GSH/GSSG redox potentials: 
reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV). Platelet lysates were 
separated on 10 % polyacrylamide gels and proteins were transferred from the gel to 
PVDF membrane. Membrane was probed with (i) rabbit polyclonal anti-VASP-P Ser157 
or (ii) monoclonal anti--actinin (loading control) antibodies. Densitometry analysis was 
performed using ImageJ software. Data is presented as the mean ± SEM, n=4 
independent experiments, *p < 0.05.  
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Figure 5.8 (a) Vasodilator-stimulated phosphoprotein (VASP) phosphorylation at 
Serine 239 (VASP-P (Ser239)) is significantly increased in platelets activated with 
collagen in the presence of a reducing redox environment. Gel filtered platelets 
remained unactivated or were activated with 0.1U/ml thrombin, 38 g/ml collagen  or  
50 ng/ml convulxin in the absence or presence of an altered redox environment 
generated by GSH/GSSG redox potentials: reducing (-264 mV), mean (-130 mV) or 
oxidising (-10 mV). Platelet lysates were separated on 10 % polyacrylamide gels and 
proteins were transferred from the gel to PVDF membrane. The membranes were 
probed with a rabbit polyclonal anti-VASP-P Ser239 or a monoclonal anti--actinin 
(loading control) antibody. Blots are representative of n=4 independent experiments. 
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Figure 5.8 (b) Analysis by densitometry confirmed there was a significant 
increase in the level of vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation at Serine 239 (Ser239) in platelets activated with collagen in the 
presence of a reducing external redox environment. There is no significant 
change in the levels of VASP Ser239 phosphorylation of platelets activated with 
thrombin or convulxin compared to unactivated platelets, in the presence of any 
of the external redox environments. Gel filtered platelets remained unactivated or 
were activated with either 0.1U/ml thrombin, 38 g/ml collagen  or  50 ng/ml convulxin 
in the absence or presence of an altered redox environment generated by GSH/GSSG 
redox potentials: reducing (-264 mV), mean (-130 mV) or oxidising (-10 mV). Platelet 
lysates were separated on 10 % polyacrylamide gels and proteins were transferred 
from the gel to PVDF membrane. Membrane was probed with (i) rabbit polyclonal 
anti-VASP-P Ser239 or (ii) monoclonal anti--actinin (loading control) antibodies. 
Densitometry analysis was performed using ImageJ software. Data is presented as the 
mean ± SEM, n=4 independent experiments, *p < 0.05. 
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5.3 Discussion 
Platelet shape change, directed by membrane and cytoskeleton rearrangement, 
is a key event in the process of platelet activation. From my studies here it was 
revealed the substrate to which platelets adhere plays a significant role in 
determining not only the extent to which the platelets spread and the overall 
surface coverage but also the manner in which the actin cytoskeleton is 
rearranged, which leads to the a characteristic shape for platelets adhered to 
each substrate. These findings emphasise that the platelet response is directly 
linked to the activator and its specific signalling pathway. The platelet response 
is entirely dictated by the stimulus. The understanding of the impact of signalling 
pathways and regulatory proteins on changes in the cytoskeleton structure is 
still somewhat limited. While some signalling pathways overlap, such as the 
involvement of phospholipase C2 (PLC-2) 
integrin IIb3 and GPVI, there are also distinct differences between these 
signalling cascades (Wonerow et al, 2003).  
 
Having established the external redox environment plays a significant role in the 
response of platelets to various stimuli the impact of an altered redox 
environment on platelet spreading and actin cytoskeleton rearrangement was 
examined. Consistent with the findings so far, the platelet response to collagen 
exclusively was significantly affected. There was no impact on the degree of 
platelet spreading or the average size of platelets adhered to BSA, fibrinogen or 
collagen related peptide (CRP) in altered external redox environments. The 
average area of the platelets adhered to collagen in the presence of a reducing 
GSH/GSSG redox potential was less than that of platelets adhered to collagen 
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in the absence of any altered redox environment. This indicated that although 
these platelets were capable of binding to collagen, the signalling pathways 
leading to platelet spreading were disrupted. This finding is complementary to 
that shown in our laboratory previously (by Dr. Desmond Murphy, RCSI) where 
it was demonstrated, by flow cytometry, that a FITC-labelled collagen could still 
bind to platelets to some degree in the presence of a reducing redox 
environment though platelet activation could not be initiated.  
 
VASP is one of a number of proteins implicated in the regulation of actin 
rearrangement in platelets upon platelet activation (Reinhard et al, 2001). VASP 
and VASP-like proteins contain conserved N-terminal (EVH1) and C-terminal 
domains (EVH2). EVH2 is known to mediate tetramerisation of VASP (which 
enhances F-actin interactions), F-actin binding and bundle formation 
(Bachmann et al, 1999). The regions in which VASP proteins are found further 
support an important role for VASP in relation to actin remodelling and 
polymerisation. VASP is mainly localised to sites of actin assembly such as 
focal adhesions and membrane ruffles along with the tips of lamellipodia 
(Jockusch et al, 1995; Reinhard et al, 1992; Rottner et al, 1999). Focal 
adhesions are protein rich structures which link the actin cytoskeleton to the 
ECM via integrins, therefore also implicating VASP in integrin activation and 
regulation. Moreover, a link between integrin IIb3 has been suggested, in 
which VASP is a negative regulator of integrin IIb3 and consequently platelet 
aggregation (Horstrup et al, 1994). VASP null mice display increased agonist-
induced P-selectin expression along with enhanced fibrinogen binding to 
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integrin IIb3 (Aszodi et al, 1999; Hauser et al, 1999). To date there has yet to 
be any studies connecting VASP to integrin 21 activity. 
 
VASP is phosphorylated at three different sites: serine 157 (Ser157), serine 239 
(Ser239) and threonine 278 (Thr278) (Butt et al, 1994) (Figure 5.9). Ser239 is 
the VASP phosphorylation site preferred by cGMP-dependent protein kinase 
(PKG) (Smolenski et al, 1998), while Ser157 has a preference to be 
phosphorylated by cAMP-dependent protein kinase (PKA). Thr278 appears to 
come into play once the phosphorylation at the other two sites has essentially 
been completed (Butt et al, 1994). Along with visually analysing the Western 
blots illustrating VASP and its phosphorylation state in platelets, densitometry 
analysis was also employed. Densitometry provides a means of demonstrating 
the observations of a number of Western blots and summarising the findings in 
one graphical illustration. 
 
VASP is expressed at comparable levels in platelets, irrespective of the 
activation state or redox environment, as was expected. However, the 
phosphorylation of VASP at Ser157 was significantly decreased in collagen 
activated platelets in the presence of a reducing redox environment compared 
to collagen activated platelets in the absence of an altered external redox 
environment. A mean or oxidising external redox environment had no significant 
impact on this phosphorylation event. Ser157 was phosphorylated in platelets 
activated with thrombin and convulxin. The redox environment had no 
significant effect on the level of this phosphorylation event. There was no 
phosphorylation of VASP at Ser157 observed in unactivated platelets in any of 
 322 
the redox environments. This finding suggests, contrary to some reports in the 
literature, activation of platelets induces phosphorylation of VASP. The 
phosphorylation state of VASP in platelets activated with collagen in the 
presence of a reducing environment were comparable to unactivated platelets 
indicating that collagen was incapable of inducing any response in platelet 
under these conditions. 
 
Platelets are known to contain significant levels of PKA and PKG, which are 
regulated by cAMP and cGMP, respectively (Waldmann et al, 1986; Waldmann 
et al, 1987). cAMP elevation leads to PKA stimulation, while an increase in 
cGMP leads to stimulation of PKG. Regulation of protein kinases alters the 
phosphorylation state of specific key protein substrates associated with a 
biological function. Indeed, it is well established that cAMP elevating 
substances (PGE1, PGI2, forskolin) and cGMP elevating substances, such as 
the endothelium-derived relaxing factor, sodium nitroprusside, which releases 
nitric oxide (NO), inhibit the platelet aggregation (Waldmann et al, 1987; Walter, 
1989).   
 
The increase in VASP phosphorylation at Ser239 in platelets activated with 
collagen in the presence of a reducing environment is a particularly interesting 
revelation, especially as the levels were significantly higher than that observed 
in unactivated platelets. This result suggests that the reducing redox 
environment is not just preventing the activation of platelets by collagen but is in 
fact inducing an inhibitory response within the platelets. There is a significant 
difference between these states: unactivated implies that there has been no 
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stimulus applied to the platelets therefore they are in a resting state, whereas 
inhibited implies that a signalling pathway within the platelets has been initiated 
which prevents platelets becoming activated despite the presence of a platelet 
agonist. The findings suggest an external modification of the collagen receptor 
integrin 21 generates intra-platelet signals resulting in an increase in cGMP 
which leads to activation of PKG, ultimately, leading to phosphorylation of VASP 
at Ser239. The increase in Ser239 phosphorylation is a somewhat surprising as 
there is a high concentration of PKG found in platelets which would require 
significant increases in cGMP levels in order to activate PKG sufficiently to 
cause phosphorylation of VASP (Eigenthaler et al, 1992). However, the finding 
that the increase in phosphorylation at Ser239 correlates with a significant 
decrease in phosphorylation at Ser157 is also a fascinating discovery and 
demonstrates that the phosphorylation of VASP at different sites is related to 
distinct functions. Phosphorylation at one site may be associated with an initial 
stimulatory response which promotes platelet activation and aggregation by 
regulating integrin function and this may be followed by phosphorylation at the 
other site which induces an inhibitory response that may play a role in limiting 
the size of the thrombus formed and keeping the process under control. Such a 
mechanism has been alluded to in the literature for PKG implicating Ser239 (Li 
et al, 2003). Similarly, thrombin stimulation of platelets leads to phosphorylation 
of Ser157 in a PKC- and Rho-kinase-dependent mechanism (Wentworth et al, 
2006). However, our findings implicate both phosphorylation sites and are 
suggestive of synergy between these two molecules regulating VASP and its 
activities. 
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The differences that were observed in platelet morphology and cytoskeleton 
rearrangement in platelets which were dictated by the surface to which they 
were adhered may be related to variation in the levels of VASP phosphorylation. 
It would be interesting to further investigate this relationship by examining the 
expression and localisation of VASP within platelets adhered to different 
surfaces in the absence and presence of an altered external redox environment. 
Again, these findings imply that platelet activity and the activation end point 
reached is very much dependent on the stimulus and the signalling pathways 
activated thereafter. 
 
Future work on this study would entail measuring the levels of cAMP and cGMP 
in platelets following platelet activation with each of the platelet agonists and 
examining the impact of an altered external redox environment on these two 
cyclic nucleotides. Based on the findings to date, it is anticipated there would be 
elevated levels of one with a concomitant decrease in the other modulated by 
the platelet activator and external redox environment. Furthermore, an 
investigation into the exact location of VASP within the signalling pathway 
induced upon platelet activation by collagen could potentially further elucidate 
the role of VASP and its significance within this particular signalling cascade. An 
association between integrin IIb3 and VASP has been hypothesised, through a 
link with signalling proteins such as vinculin and zyxin providing a linkage to the 
actin and thereby controlling actin cytoskeleton rearrangement (Figure 5.9). The 
findings of my study suggest perhaps VASP may be found further upstream and 
closer to integrin 21 in terms of signalling events that previously thought. 
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Figure 5.9 The structure of vasodilator-stimulated phosphoprotein (VASP) and its 
direct interaction partners. VASP contains three phosphorylation sites: Serine 157 
(proline-rich domain) and Serine 239 and Threonine 278 (both located in the EVH2 
domain). The interaction partners of VASP and the domains through which they 
interact are shown in this schematic (adapted from (Dittrich et al, 2010)). 
 
Consistent with results in the previous chapter, these findings in relation to the 
collagen activation pathway again highlight integrin 21 as a particularly redox 
sensitive receptor. We have demonstrated that a reducing redox environment 
does not entirely inhibit the binding of collagen to the platelet. Therefore, it is 
hypothesised that the effects of a reducing redox environment on the collagen 
mediated signalling cascade are due to an external modification of the integrin 
21. This may in turn lead to disruption of signalling events involving intra-
platelet regulatory proteins thereby inhibiting normal platelet function.
  
 
Chapter 6 
The impact of bile acids on platelets: a 
novel insight into the role of platelets in 
inflammatory bowel disease 
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6.1 Introduction 
Although first proposed in 1936, a link between the two major biological 
processes, coagulation and inflammation, has only become a major focus of 
research in recent years (Bargen & Barker, 1936). Inflammatory bowel disease 
(IBD) is one such condition in which platelet activity may play a key role 
(Yoshida & Granger, 2009). IBD is the collective name for Crohn’s disease and 
ulcerative colitis, two pathologically different conditions but with similar 
symptoms. Crohn’s disease can affect the entire gastrointestinal tract while 
ulcerative colitis is limited to the colon region.  
There have been a number of discoveries in IBD which serve to enhance the 
proposed role of platelets in this debilitating, idiopathic disease. 
Thrombocytosis, characterised by a large number of smaller sized platelets, is 
known to be associated with IBD, although the underlying causes remain 
unknown (Harries et al, 1991). Additionally, platelets in IBD patients have been 
found to circulate in an active-like state which could be linked to the increased 
risk of thromboembolic events associated with IBD patients. Platelet 
hyperactivity and dysfunction in IBD is manifested as increased platelet surface 
expression of P-selectin, CD40-ligand (CD40L) and GP53 (Collins et al, 1994; 
Danese et al, 2003a; Danese et al, 2003b). Plasma levels of CD40L, 
-thromboglobulin and platelet factor-4 (PF4), released from the -granules of 
platelets upon activation, have also been found to be increased in IBD patients 
(Collins & Rampton, 1997; Danese et al, 2003b; Vrij et al, 2000). In vitro studies 
have demonstrated spontaneous platelet aggregation occurs in platelets from 
active IBD patients along with patients in remission. An increased sensitivity to 
platelet agonists such as ADP, arachidonic acid, ristocetin, collagen and 
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thrombin is also described (Collins et al, 1994; Mori et al, 1980; van Wersch et 
al, 1990). Platelet aggregates have been found circulating in vivo in venous 
blood of active IBD patients (Collins et al, 1994; Dhillon et al, 1992). 
Furthermore, higher numbers of platelet-leukocyte aggregates (PLA) mediated 
through the interaction of P-selectin on activated platelets with P-selectin 
glycoprotein ligand-1 (PSGL-1) expressed on leukocytes have been found in 
IBD patients compared to healthy controls and inflammatory controls 
(rheumatology patients) (Irving et al, 2004).  
Bile acids are commonly known for their role in facilitating the digestion and 
absorption of lipids. However, bile acids are becoming increasingly recognised 
as important signalling molecules regulating epithelial homeostasis, transport 
and barrier function, thereby modulating intestinal function (Keating & Keely, 
2009).  
Cholic acid (CA) and chenodeoxycholic acid (CDCA), the primary bile acids, are 
synthesised from cholesterol, conjugated to glycine and taurine in the 
hepatocytes and stored in the gallbladder. They are the primary constituents of 
bile which is secreted into the duodenum following ingestion of a meal. 
Approximately 95 % of bile acids are reabsorbed from the intestine and 
transported back to the liver while a small percentage (2 – 5 %) pass into the 
large intestine where they are converted to secondary bile acids (Figure 6.1).  
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Figure 6.1 The biosynthesis of bile acids from cholesterol. The biosynthesis of bile 
acids is a complex process involving at least 16 enzymes that catalyse as many as 17 
reactions (Russell, 2009). For purposes of clarity, this diagram only illustrates the 
synthesis of the bile acids used in this study – ursodeoxycholic acid (UDCA), 
deoxycholic acid (DCA) and taurodeoxycholic acid (TDCA). Cholesterol is hydroxylated 
at the 7 position, via the cytochrome P450 enzyme 7-hydrolase, to form 
7-hydroxycholesterol. 7-hydrolase is the rate limiting step in the biosynthesis of bile 
acids. The synthesis process is then divided into two branches, the ‘classic pathway’, 
which leads to the formation of the primary bile acid, cholic acid (CA), or the ‘acidic 
pathway’, which results in an alternative primary bile acid, chenodeoxycholic acid 
(CDCA). CA and CDCA, when secreted into the intestine, are converted to the 
secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. 
DCA may be conjugated to the amino acid taurine to form TDCA, while LCA can be 
further converted to UDCA. (The bile acid biosynthesis pathway is adapted from (Beilke 
et al, 2009)). 
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One of the main functions of the intestinal epithelium is fluid and electrolyte 
transport to and from the gut lumen. Fluid transport is dictated by secretion or 
absorption of ions, predominantly chloride (Cl-) controlled by an active ion 
transport mechanism (Barrett & Keely, 2000). Disruption of the balance 
between fluid absorption and secretion can lead to problems such as 
constipation or diarrhoea. An altered concentration of bile acids in the system 
can impact on this fluid balance. Indeed, bile acid malabsorption (BAM) has 
long been linked to the onset of diarrhoea. Bile acids have also been implicated 
in the regulation of the enteric nervous system and the mucosal immune 
systems, disruptions in which are linked to the development of IBD.  
The central role bile acids play in regulating intestinal function makes them a 
potentially significant player in the pathogenesis of IBD. Similarly, there is an 
ever growing body of evidence implicating platelet activity in IBD also. In this 
study the impact of bile acids on platelet function was investigated based on the 
hypothesis that there may be a link between these two key players in this 
chronic disease. 
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6.2 Results  
6.2.1 The effects of bile acids on platelet aggregation 
The impact of bile acids on platelet function was investigated by examining the 
effects of three commercially available bile acids, ursodeoxycholic acid (UDCA), 
deoxycholic acid (DCA) and taurodeoxycholic acid (TDCA), on platelet 
aggregation. 
An MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
colorimetric assay demonstrated that even the highest concentration (500 M) 
used of each of the bile acids had no significant effect on platelet viability 
(personal communication from Ms. Joanna Tan, RCSI).  
Gel filtered platelets were incubated with each bile acid at concentrations of 
10 M, 100 M or 500 M. The levels of platelet aggregation of unactivated 
platelets or platelets activated with 0.1U/ml thrombin, 50 ng/ml convulxin, 
38 g/ml collagen or 19 g/ml collagen following pre-treatment with the bile acid 
were measured.  
There was no significant difference between the levels of platelet aggregation of 
unactivated platelets treated with each of the bile acids compared to the level of 
platelet aggregation observed in unactivated platelets in the absence of any bile 
acid treatment (n=6) (Figure 6.2). 
UDCA was found only to impact on the levels of platelet aggregation in 
response to platelet activation by collagen. There was a trend towards a 
decrease in the level of platelet aggregation of platelets activated with 38 g/ml 
collagen following treatment with 500 M, while this decrease became 
 332 
statistically significant in platelets activated with 19 g/ml collagen. UDCA had 
no impact on platelet aggregation in response to thrombin or convulxin (n=6, 
(n=3 convulxin) **p < 0.01) (Figure 6.3). 
The bile acid, DCA, decreased platelet aggregation to thrombin, convulxin and 
collagen in a concentration dependent manner (n=5 (n=3 convulxin), **p < 0.01, 
***p < 0.001) (Figure 6.4). 
Likewise, TDCA impacted on the platelet aggregation response to all agonists. 
There was a significant decrease in platelet aggregation observed in platelets 
pre-treated with 500 M TDCA then activated with either 0.1U/ml thrombin or 
19 g/ml collagen. A similar trend was observed with platelets activated with 
38 g/ml collagen or 50 ng/ml convulxin, while not quite reaching statistical 
significance (n=3, *p < 0.05, **p < 0.01, ***p < 0.001) (Figure 6.5). 
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Figure 6.2 Bile acids alone do not induce platelet aggregation at any of the 
chosen concentrations. Gel filtered platelets were either untreated or incubated with 
bile acids: ursodeoxycholic acid (UDCA), deoxycholic acid (DCA) or taurodeoxycholic 
acid (TDCA) at concentrations of 10 M, 100 M or 500 M for 10 minutes at 37 °C 
with constant stirring at 1100 rpm. The levels of platelet aggregation were recorded. 
Data is presented as the mean ± SEM, n=6 independent experiments. 
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Figure 6.3 Ursodeoxycholic acid (UDCA) decreases platelet aggregation in 
response to collagen but has no impact on platelet aggregation induced by 
thrombin or convulxin. Gel filtered platelets were either untreated or incubated with 
10 M, 100 M or 500 M UDCA for 10 minutes at 37 °C with constant stirring at 
1100 rpm. Platelets were left unactivated or were activated with either 0.1U/ml 
thrombin, 50 ng/ml convulxin, 38 g/ml collagen or 19 g/ml collagen. Platelet 
aggregations were carried out for 10 minutes at 37 °C with constant stirring at 
1100 rpm. Data is presented as the mean ± SEM, n=6 (n=3 for convulxin) independent 
experiments, **p < 0.01. 
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Figure 6.4 Deoxycholic acid (DCA) affects platelet aggregation to thrombin, 
collagen and convulxin. Gel filtered platelets were either untreated or incubated with 
10 M, 100 M or 500 M DCA for 10 minutes at 37 °C with constant stirring at 
1100 rpm. Platelets were left unactivated or were activated with either 0.1U/ml 
thrombin, 50 ng/ml convulxin, 38 g/ml collagen or 19 g/ml collagen. Platelet 
aggregations were carried out for 10 minutes at 37 °C with constant stirring at 
1100 rpm. Data is presented as the mean ± SEM, n=5 (n=3 for convulxin) independent 
experiments, **p < 0.01, ***p < 0.001. 
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Figure 6.5 Taurodeoxycholic acid (TDCA) affects platelet aggregation to 
thrombin, collagen and convulxin. Gel filtered platelets were either untreated or 
incubated with 10 M, 100 M or 500 M TDCA for 10 minutes at 37 °C with constant 
stirring at 1100 rpm. Platelets were left unactivated or were activated with either 
0.1U/ml thrombin, 50 ng/ml convulxin, 38 g/ml collagen or 19 g/ml collagen. Platelet 
aggregations were carried out for 10 minutes at 37 °C with constant stirring at 
1100  rpm. Data is presented as the mean ± SEM, n=3 independent experiments, 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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6.3 Discussion 
Recent studies have suggested a role for platelets in a variety of clinical 
conditions such as atherosclerosis, sepsis, rheumatoid arthritis and IBD, thus 
linking the complex processes of inflammation and haemostasis. Inflammatory 
bowel disease (IBD) is a condition which affects approximately 15,000 people in 
Ireland and over 2 million across Europe. Subclinical thrombosis is common in 
IBD and is a major source of morbidity in approximately 25 % of IBD deaths 
(Tabibian & Roth, 2009). Therefore, a greater understanding of the underlying 
causes of IBD and the development of therapy for the condition is crucial.  
Platelet dysfunction in IBD patients has been demonstrated with the expression 
of activation surface markers (P-selectin, GP53 and CDL40) on platelets along 
with platelet secretory products (-thromboglobulin and PF4) in the plasma of 
IBD patients (Collins et al, 1994; Danese et al, 2003a). Furthermore, 
experimental IBD studies in which dextran sodium sulphate (DSS)-induced 
colitis mice were examined, showed a significant role for platelets interacting 
with leukocytes through the PSGL-1 receptor (Mori et al, 2005; Vowinkel et al, 
2007). Additional studies found antibody immuno-blockade of either P-selectin 
or PSGL-1 significantly attenuates the inflammatory response and histological 
tissue injury in a DSS-induced colitis mouse model, further evidence for the 
importance of platelets in IBD (Gironella et al, 2002; Rijcken et al, 2004).  
 
There is increased levels of circulating vWF in both active and inactive Crohn’s 
disease patients which is indicative of vascular cell damage (Stevens et al, 
1992). Platelets encounter inflamed or damaged endothelial cells in the vast 
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intestinal microvascular bed in IBD patients. Endothelial cell damage exposes 
basement membrane to which platelets are exquisitely sensitive. Exposure of 
substances such as collagen leads to platelet adhesion, activation and 
recruitment of further platelets. Additionally, platelet activation in IBD patients 
may be caused by virus-induced changes in the endothelium promoting platelet 
adhesion and activation prior to damage.  Similarly, platelets could be activated 
by platelet activating factors, such as TXA2 and PAF (platelet-activating factor), 
released from neutrophils into the mesenteric circulation at the site of intestinal 
disease (Eliakim et al, 1988; Visser et al, 1988; Webberley et al, 1993). Platelet 
activation in turn leads to the release of a number of pro-inflammatory 
cytokines, such as CD40L and interleukin-1 (IL-1), which can activate 
leukocytes and monocytes. Upon activation, these cells secrete more platelet 
activators such as ADP, arachidonic acid and PAF. All of these events, 
ultimately, demonstrate a vicious cycle wherein each activation process fuels 
and intensifies the other. It remains to be seen whether platelet activation is a 
cause or consequence of the inflammatory response.  
Bile acids, synthesised from cholesterol, are primarily involved in the digestion 
and absorption of dietary lipids. However, bile acids have been implicated in the 
pathogenesis of IBD due to their central role in the regulation of intestinal 
function. Bile acids contribute to the control of intestinal function by regulating a 
number of major functions of the intestine, namely epithelial proliferation and 
death, the epithelial barrier function and fluid and electrolyte transport. Bile 
acids also regulate the enteric nervous system, which innervates the mucosa, 
along with the mucosal immune systems (Keating & Keely, 2009).  Bile acids 
are known to interact with G-protein-coupled receptors (GPCR) (TGR5), 
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receptor tyrosine kinases (RTK), nuclear receptors (farnesoid X receptor – FXR) 
and membrane perturbations (Akare & Martinez, 2005; Cheng & Raufman, 
2005; Maruyama et al, 2002; Merchant et al, 2005; Schmidt & Mangelsdorf, 
2008). This vast number of interactions indicates that bile acids can potentially 
exert an effect on almost any cell they encounter. 
Preliminary findings from this study examining the effects of bile acids on 
platelet function proved interesting. It was demonstrated that deoxycholic acid 
(DCA) and taurodeoxycholic acid (TDCA) disrupted platelet aggregation 
responses to platelets activated with thrombin, convulxin and collagen. 
However, ursodeoxycholic acid (UDCA) displayed a specific inhibitory effect on 
the platelet collagen activation pathway only. Similar results were observed in a 
platelet secretion assay measuring the levels of ADP released from the dense 
granules of platelets upon activation. It was found that while DCA and TDCA 
significantly decreased the quantity of ADP released from platelets activated by 
all platelet agonists, UDCA again demonstrated an inhibitory effect on platelets 
activated by collagen only (personal communication from Ms. Joanna Tan, 
RCSI). The greater potency of DCA and TDCA may be due to their membrane 
permeability, whereas UDCA is known to have less affinity for membranes. 
These findings indicate that there may be a direct interaction between platelets 
and bile acids. As the inhibitory effects of the bile acids appear to be 
concentration dependent, the results suggest that higher concentrations of bile 
acids may have a protective function through maintaining platelets in an 
unactivated state, thereby disrupting or inhibiting the coagulation/inflammation 
cycle in IBD. The specificity of UDCA for the collagen activation pathway of 
platelets is a particularly interesting discovery. The observation that UDCA has 
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no impact on platelet activation induced by the GPVI specific agonist convulxin, 
suggests that UDCA is specifically targeting the collagen receptor integrin 21. 
In the previous chapters, a unique redox sensitivity of integrin 21 was 
revealed. These results provide further evidence to support a sensitivity of this 
particular platelet receptor to its external environment and indicate that it may 
play a significant role in the regulation of platelet activity in disease states where 
there is a major imbalance in the homeostasis of the platelet external 
environment.  
These findings, though preliminary, are quite promising with regard to novel 
insights into the interactions between platelets and bile acids. Further work in 
this study will entail examining the membrane permeability of the bile acids in 
greater detail, and the exact mechanisms involved in the interaction including 
investigating the presence of a bile acid receptor on the surface of platelets and 
examining the effects of bile acids on intra-platelet signalling cascades. 
Furthermore, the impact of bile acid supplements on the platelet function of 
DSS colitis-induced mice will be explored.  
These studies will lead to a greater understanding of the intimacies of platelet 
activity and inflammation. Improved knowledge of the exact mechanisms may 
lead to novel targeted therapies working at the interface of both processes, thus 
providing a new treatment for IBD which is currently without a medical cure. 
  
 
Chapter 7 
General Discussion 
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Platelets are small, versatile megakaryocyte-derived cell fragments that are 
primarily involved in haemostasis and thrombosis but have also been implicated 
in cancer progression and inflammatory conditions. The capabilities of platelets 
may have been underestimated in the past due to their ‘simple’ structure which 
lacks a nucleus and genetic material. However, the sheer volume of studies and 
literature relating to platelet activity and function demonstrates the significance 
and complex role of platelets in a variety of biological processes. Despite this 
ongoing research, the understanding of the fundamental mechanisms of platelet 
activity remains limited, thus restricting the development of advanced pro- and 
anti-platelet therapies. Further studies, such as this one, will enhance our 
understanding of platelet activation and the pathogenesis of platelet related 
diseases, potentially leading to the development of novel targeted therapies. 
 
Integrins, such as integrin IIb3 and integrin 21, are key players in stable 
platelet adhesion, aggregation and thrombus formation. Therefore, elucidation 
of the intricate mechanisms of integrin activation is essential to enhance 
knowledge of the processes of platelet activation. Integrins possess a cysteine-
rich structure which is critical in the regulation of integrin function and activity. It 
is well established the conformational rearrangement of integrins as they 
‘switch’ from an unactivated state to an activated state is mediated by a 
thiol/disulphide shuffling or exchange mechanism. In Chapter 3, purified integrin 
IIb3 and a CHO-K1 cell model, expressing integrin IIb3, were employed to 
examine the thiol population of integrin IIb3. It was demonstrated, consistent 
with reports in the literature, activation of integrin IIb3 by MnCl2, the universal 
integrin activator, leads to conformational changes in the integrin, resulting in an 
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increased thiol population. Furthermore, it was demonstrated that MnCl2 and 
dithiothreitol (DTT), a reducing agent, induced platelet aggregation and PAC-1 
binding to the activated conformation of integrin IIb3 on platelets. However, 
neither MnCl2 nor DTT induced platelet secretion. These findings indicate 
external modification of integrin IIb3 is insufficient to initiate outside-in 
signalling, leading to platelet secretion and, eventually, full platelet activation. 
Interestingly, Raman spectroscopy, in conjunction with principal component 
analysis (PCA), successfully separated platelet spectra into distinct clusters due 
to changes in the thiol/disulphide regions of the spectra, based on the platelet 
activator. These findings imply MnCl2, DTT and thrombin exert unique effects 
on the surface thiol population of platelets and suggest the thiol groups may 
play an important role not only in the regulation of integrin function but also the 
function of platelets as a whole. 
 
Based on the findings of Chapter 3, the remainder of this thesis was aimed at 
further investigating the role of thiols in platelet activity and examining the 
impact of modifying these thiol groups on platelet function. In contrast to the 
initial studies in Chapter 3, more physiologically relevant platelet agonists were 
used throughout the rest of the thesis. It was revealed the platelet surface thiol 
population was increased upon platelet activation by collagen only. 
Furthermore, this thiol increase was specifically associated with collagen 
activation through integrin 21 and not GPVI, the other collagen receptor. This 
is a novel and significant finding in relation to the mechanisms of integrin 21 
activation and, ultimately, the platelet activation pathways of collagen. 
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I hypothesise this new thiol population is as a result of conformational 
rearrangements of integrin 21, in which a shuffling of thiol/disulphide groups 
or a reduction in disulphide bonds results in the exposure of more external free 
thiols. Due to the relatively low copy number of integrin 21 expressed on 
platelets, compared to integrin IIb3, the significant increase in the surface thiol 
population of platelets activated with collagen is somewhat surprising. In 
Chapter 3, it was confirmed that activation of integrin IIb3 led to an increase in 
the thiol population, thus integrin IIb3 could potentially contribute to this 
elevated platelet surface thiol population in response to collagen activation. 
Thrombin and convulxin, two potent platelet agonists, both induced platelet 
aggregation similar to that induced by collagen, indicating these agonists 
converted platelet integrin IIb3 to an activated, ligand-binding conformation. 
However, the surface thiol population of platelets activated with thrombin or 
convulxin remained similar to that of unactivated platelets. Likewise, while the 
level of platelet adhesion to collagen, fibrinogen and collagen related peptide 
(CRP) was comparable, there was again an increase in the thiol population of 
platelets adhered to collagen only. Though, it was noted the thiol population of 
platelets adhered to fibrinogen was higher than that of platelets adhered to 
CRP. Nonetheless, this indicates integrin IIb3 is not the major source of the 
increased platelet surface thiol population and, therefore, hypothetically the 
thiols may originate from another source that is specifically associated with 
integrin 21 stimulation.  
 
Thiol isomerase enzymes have been implicated in receptor regulation, 
activation and substrate processing when expressed on the surface of cells. 
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Such enzymes, for example protein disulphide isomerase (PDI), have been 
found on the surface of platelets following activation. Modification of the activity 
of these enzymes impacts on platelet function, with a decrease in platelet 
aggregation, secretion and integrin IIb3 activation (Essex & Li, 1999). 
Additionally, it has been revealed that integrin IIb3 has an endogenous thiol 
isomerase activity (O'Neill et al, 2000). An attractive proposition is the increased 
surface thiol population of platelets activated with collagen may, therefore, be 
due to the translocation of one or more thiol isomerase enzymes to the surface 
of platelets upon stimulation of integrin 21 specifically. Indeed, PDI activity 
has been associated with integrin 21 whereby bacitracin, an inhibitor of 
disulphide exchange, abrogated platelet aggregation to collagen (Lahav et al, 
2003). Similarly, a monoclonal antibody raised against PDI inhibited platelet 
adhesion to the integrin 21 specific peptide GFOGER-GPP but not CRP.  
 
A parallel, novel, redox sensitivity, exclusive to the collagen activation pathway 
of platelets was also revealed in Chapter 5. This redox sensitivity was assigned 
specifically to the collagen receptor, integrin 21. An external reducing redox 
environment inhibited platelet aggregation and adhesion, along with affecting 
the phosphorylation state of an intra-cellular signalling protein, VASP, in 
response to stimulation by collagen only. Additionally, the increased surface 
thiol population associated with platelet activation by collagen was also 
abolished. This confirms the importance of thiols in integrin 21 function and 
demonstrates that, unlike integrin IIb3, external modification of these thiol 
groups can trigger downstream intra-platelet effects, ultimately, impacting on 
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the activation state of platelets through the modification of outside-in signalling 
mechanisms.  
 
As previously alluded to, the sensitivity of integrin 21 compared to that of 
integrin IIb3 may be due to the presence of a greater number of reactive 
cysteines in the -subunit of the integrin. This greater sensitivity of integrin 21 
is supported by the study of Lahav et al. In their study they demonstrate that 
bacitracin completely abolished platelet aggregation to collagen, while only 
decreasing the platelet aggregation response to CRP. Subsequently, higher 
concentrations of bacitracin were found to completely inhibit platelet 
aggregation to CRP (Lahav et al, 2003). This finding was attributed to the higher 
concentration of bacitracin blocking conformational changes and activation of 
integrin IIb3, thereby inhibiting platelet aggregation. The fact that this 
phenomenon was only observed with a high concentration of bactrican, while a 
low concentration of bactracin impeded integrin 21, again highlights a greater 
sensitivity of integrin 21 compared in integrin IIb3. 
 
Reactive cysteines, with a lower pKa value than others, are more likely to 
interact with other thiol containing agents. I hypothesise the inhibition of 
platelets response to collagen in the presence of a reducing external redox 
environment may be as a result of the modification of the reactive cysteines 
present in integrin 21. Such modifications, due to an interaction with 
glutathione or cysteine, could result in S-glutathionylation or S-cysteinylation of 
the thiol groups. These thiol modifications may potentially lock integrin 21 into 
a conformation, whereby the mechanism which results in the generation of an 
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increased thiol population is prevented from occurring and thus further 
signalling from integrin 21 is also altered.  
 
An alternative hypothesis is one based on the push-pull mechanism proposed 
for the regulation of integrin IIb3 function. Li et al suggest that a resting IIb/3 
transmembrane domain heterodimer may be destabilised and activated by 
stabilising the resulting IIb and 3 transmembrane domain homodimers (Li et al, 
2005). This push-pull mechanism is based on the concept of association and 
dissociation of receptor subunits. A heterodimeric association of subunits to 
form a receptor complex is also demonstrated in the GPIb-IX complex in which 
the GPIb and GPIb subunits are in fact linked via disulphide bridges between 
their respective Cys residues (Luo & Li, 2008; Luo et al, 2007; Mo et al, 2008). 
A similar mechanism may exist in integrin 21 whereby dissociation of the 
subunits upon activation leads to exposure of free thiols extracellularly. An 
altered external redox environment could potentially inhibit this mechanism from 
occurring, thereby inhibiting the exposure of the free thiol population and 
resulting in the integrin being fixed into a conformation that leads to altered 
downstream signalling. This modulation of integrin 21 by the external redox 
environment would impact on the interaction between the integrin and its ligand, 
collagen, ultimately, impacting on platelet activity induced by collagen. 
 
The significance of the balance of the components of the physiological redox 
environment is well established. However, the results observed in this thesis 
suggest the converse, lesser known condition, reductive stress, could be a real 
player in the regulation of platelet activity. It would be interesting to investigate 
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the redox potential of the plasma from patients with disease states associated 
with bleeding disorders and examine whether the balance of the redox 
environment is tipped in favour of a more reducing one, thereby, affecting 
integrin 21 function and impacting on platelet adhesion at sites of injury.  
 
Clinically, the implications of these findings may be significant. Alterations of the 
redox environment, to a more oxidising environment, are common in disease 
states such as in atherosclerosis, rheumatoid arthritis, IBD and diabetes. 
Likewise, thromboembolic events, linked to platelet hyperactivity, are frequent in 
patients suffering from these conditions. Antioxidant management is a potential 
therapy to alleviate such events. Reducing agents could be employed to 
specifically target the collagen receptor integrin 21, without completely 
shutting down platelet activity. Platelet adhesion to collagen is one of the 
primary events in platelet plug formation. By inhibiting this process, abnormal 
thrombus formation, potentially resulting in events such as heart attack or 
stroke, could be prevented. Altering the redox environment and quenching 
platelet activity will inevitably not cure the original disease but will work to the 
limit the complications that arise thereafter.  
 
The findings of this thesis suggest the redox environment is critical in the 
regulation of platelet activity and an imbalance in the system may have 
significant consequences. A noteworthy observation throughout the study was 
that platelet activity in the absence of an altered redox environment was 
comparable to that of platelets in the presence of an oxidising environment, 
while a mean redox potential was consistently lower. These findings highlight 
 350 
the importance of the redox environment of plasma in the regulation of platelet 
activity. Furthermore, normal platelet behaviour is more reminiscent of that 
observed in a mean redox environment. This, rather controversially, suggests 
that perhaps all platelet studies, across the board, should be carried out in the 
presence of a mean redox environment rather than an unaltered external redox 
environment. 
 
The final section of the study investigating a link between bile acids and 
platelets in IBD produced some interesting results. Preliminary findings suggest 
there is undoubtedly an interaction between bile acids and platelets, which may 
be significant in relation to these two key players in the pathogenesis of IBD. 
While, the nature of this interaction remains to be seen, the impact of UDCA 
specifically on the collagen activation pathway of platelets, calls for further 
investigation, particularly based on other findings of this thesis with regard to 
the collagen receptor, integrin 21.  
 
Additionally, not only has work in this thesis helped further elucidate the role of 
thiols in platelet function but also demonstrates Raman spectroscopy as a 
potentially novel technique for the analysis of platelets. Raman spectroscopy 
was successfully employed to discriminate platelet Raman spectra based on the 
platelet activation state and, even more significantly, on the platelet activator. 
The separation of platelet Raman spectra was due to molecular variances in the 
platelet membrane arising as a result of the treatment or activation of platelets. 
The sensitivity of the technique indicates it could be employed to predict the 
onset of platelet dysfunction leading to disease, by the identification of specific 
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platelet surface biomarkers. A study using Raman to examine platelets from 
patients suffering from cardiovascular disease (CVD), compared to healthy 
controls, could detect such biomarkers or biochemical changes associated with 
CVD onset. Patients presenting with IBD, in addition to a cardiovascular-related 
event, would be ideal candidates to take part in such a study. The significance 
of thiol/disulphide groups in platelet function has been demonstrated throughout 
this thesis, and based on the serious implications of modification of thiol groups, 
i.e. inhibition of the platelet response to collagen, I propose them as a platelet 
surface marker worthy of examination. The clinical potential of Raman 
spectroscopy as a novel non-invasive diagnostic tool could be assessed based 
on the findings of such a study. 
 
In conclusion, this thesis has not only highlighted the significant role of the 
external redox environment of platelets but has also succeeded in furthering our 
knowledge of the role of thiols in the regulation of platelet function. It has 
demonstrated the lesser recognised platelet integrin 21 displays a superior 
sensitivity to integrin IIb3 and furthermore, modification of its function can 
impact greatly on the platelet response to collagen, one of the primary 
physiological agonists of platelets. The exclusive redox sensitivity of this platelet 
receptor to its external environment signifies its potentially crucial role in 
dictating the platelet response to variations in external conditions. The impact of 
an altered redox environment on platelet aggregation and adhesion implies that 
integrin 21 could be a significant platelet regulator, whereby the platelet is 
switched ‘on’ or ‘off’ depending on the nature of the external redox imbalance. I 
propose integrin 21 as a novel target for improved pro- and anti-platelet 
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therapies, whereby redox reagents could be exploited to modify integrin 21 
and thereby regulate platelet activity. Administration of redox reagents could 
also work in a complimentary manner to combat the original imbalance in the 
redox environment which is ultimately responsible for the abnormal platelet 
activity. A therapeutic intervention such as this could alleviate the complication 
of thromboembolic events associated with a number of conditions including IBD, 
diabetes and rheumatoid arthritis.  
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